descriptor,terms
subgroup_name, age race family history smoking hypertension prior myocardial infarction aspirin use hdl cholesterol
subgroup_name, age sex diabetes clopidogrel given procedure location treatment center indication stent
subgroup_name, serum csf 005 001 r mmse minimental
subgroup_name, factor v leiden prothrombin mutation sex age previous venous thromboembolic events time since randomization time since cessation fulldose warfarin therapy
subgroup_name, entry criteria coronary vessels 50 diameter stenosis
subgroup_name, age sex race ethnicity us resident myocardial infarction left ventricular hypertrophy hypercholesterolemia congestive heart failure revascularization diabetes
subgroup_name, age sex diabetes angina class iii iv prior intervention complex lesions
subgroup_name, age smoking status bodymass indexf menopause hrt hypertension blood pressure
subgroup_name, age sex infarct location types fibrinolytic agent predominant type heparin
subgroup_name, treatment stratum age body mass index diabetes mellitus baseline ldlc
subgroup_name, previous disease age years sex treated hypertension history diabetes diastolic blood pressure mm hg total cholesterol mmol l ldl cholesterol mmol l hdl cholesterol mmol l triglycerides mmol l
subgroup_name, previous disease age years sex treated hypertension history diabetes diastolic blood pressure mm hg total cholesterol mmol l ldl cholesterol mmol l hdl cholesterol mmol l triglycerides mmol l
subgroup_name, troponin level clopidogrel pretreatment duration diabetes
subgroup_name, race age
subgroup_name, entire cohort race age chd status
subgroup_name, entire cohort gender race age baseline ldlc chd status
subgroup_name, sex age total cholesterol ldl cholesterol triglycerides hdlcholesterol diabetes hypertension bodymass index current past smoker
subgroup_name, baseline pasi score baseline bsa involvement dissatisfied stopped 1 prior systemic therapy side effects 2 prior systemic therapies side effects prior use 2 systemic therapies prior use biologic agents
subgroup_name, age sex diabetes established ascvd established ascvd 2 cv risk factors lowdose aspirin use baseline disease etoricoxib dose
subgroup_name, patients clinical event patients complicated events patients uncomplicated events
subgroup_name, age years sex bmi previous cad smoking diabetes total cholesterol mmol l triglyceride mm hdlcholesterol ldlcholesterol
subgroup_name, age years sex sbp mm hg history hypertension hba1c history macrovascular disease history microvascular disease treatment bp lowering drugs treatment openlabel perindopril treatment statins treatment antiplatelet drugs
subgroup_name, age bmi systolic blood pressure previous myocardial infarction previous hypertension cardiac rhythm anticoagulants
subgroup_name, stratified analyses
subgroup_name, lumbar spine total hip femoral neck trochanter onethird radius total body without head
subgroup_name, primary prevention subgroup secondary prevention subgroup
subgroup_name, sex race age body mass index+ smoking status
subgroup_name, sex race age body mass index smoking status diabetes status
subgroup_name, age sex systolic blood pressure glycated hemoglobin blood glucose bodymass index history macrovascular disease history microvascular disease lowering drugs treatment statins treatment antiplatelet drugs
subgroup_name, prespecified analysis medical history stroke risk score alcohol use age sex ethnic group obesity randomization placebo telmisartan statin use aceinhibitor use time onset qualifying stroke randomization toast classification qualifying stroke diabetes mellitus medical history hypertension baseline systolic blood pressure
subgroup_name, age bmi family history ol diabetes exercise weekly hyperlension hyperlipidemia menopause ht tolal choleslerol ldl choleslerol hdl choleslerol tolal choleslerollohdl choleslerol ralio nonhdl choleslerol a1c hscrp
subgroup_name, age years gender smoking status gold stage region race reversibility bmi
subgroup_name, age sex ejection fraction use ace inhibitor use betablocker diabetes hospitalization heart failure within 6 mo geographic region
subgroup_name, age sex diabetes history mi infarct localization interval pain onset admission interval study drug pci interval clopidogrel pci
subgroup_name, age hf lvd use ace inhibitor use antiarrhythmic agent use betablockers af alone
subgroup_name, type surgery baseline highsensitivity crp baseline ldl cholesterol baseline total cholesterol cardiac risk temporary discontinuation study drug
subgroup_name, gender age yrs baseline killip class history diabetes mellitus previous ml infarct location geographic location sites time symptom onset randomization hrs time qualifying ecg balloon inflation hrs time symptom onset balloon inflation hrs pci delay due low risk enrollment lmwh high risk
subgroup_name, gender age yrs history diabetes mellitus previous ml infarct location geographic location sites time symptom onset randomization hrs time qualifying ecg balloon inflation hrs time symptom onset balloon inflation hrs index pci performed pci delay due low risk enrollment lmwh high risk
subgroup_name, age years sex nihss baseline time treatment initiation min previous diabetes history stroke hypertension arial flutter fibrillation smoking history previous chronic use antiplatelet drugs
subgroup_name, bmi category
subgroup_name, age sex diabetes history mi infarct localization interval pain onset admission interval study drug pci interval clopidogrel pci
subgroup_name, age 75 age 75
subgroup_name, age sex smoking status baseline fev1 baseline cv treatment prior mi baseline shortacting anticholinergics
subgroup_name, age sex p blockers cause heart failure nyha class diabetes hypertension baseline heart rate
subgroup_name, age wegu sex renal fmclicn creatntoe clearance cardiac disease intended duratsm antccagubficn rarertd antocagibtcn andorrtzafon prertous eptscde dvt pe kheeatne index dvt known rciitoji cccndilon locafon index dvt mafcaiancy randorrtzaton modmy al randcnxzaton miami k antagonist received redon
subgroup_name, age weight renal function creatinine clearance intended duration anticoagulation parenteral anticoagulalion randomization malignancy randomization race
subgroup_name, country
subgroup_name, baseline corticosteroids baseline corticosteroids
subgroup_name, gender n race n fracture history predefined n history bone disease predefined n history medical conditions n risk factor predefined falling screening n maternal history n paternal history n tobacco use alcohol consumption
subgroup_name, acs type acs treatment apixaban dose matching placebo geographic region age sex race bmi level renal impairment diabetes mellitus heart failure history stroke
subgroup_name, age sex smoking history copd severity gold 20087 use ics albuterol reversibility bmi kg m2 waisthip ratio
subgroup_name, age years gender race use rescue medication investigatorreported hypoglycaemia framingham 10year cv risk score
subgroup_name, hba1c baseline age years gender bmi baseline kg m2 duration metformin therapy months duration diabetes months
subgroup_name, age sex body weight qualifying atherosclerosis history stroke aspirin enrollment thienopyridine enrollment diabetes current smoker egfr mumin 173 m2 region
subgroup_name, age sex body weight qualifying atherosclerosis history stroke aspirin enrollment thienopyridine enrollment diabetes current smoker estimated glomerular filtration region
subgroup_name, sex age weight prior stroke tia planned thienopyridine enrollment diabetes prior stent egfr ml min 173m2 qualifying myocardial infarction region
subgroup_name, diabetes ckd chronic cvd
subgroup_name, full po pulatio n age 75 age 75 women men bm 30 bmi 30 n diabetes diabetes smo king smoking acs acs number stent1 number stet 2
subgroup_name, full po pulatio n age 75 age 75 women men bm 30 bmi 30 n diabetes diabetes smo king smoking acs acs number stent1 number stet 2
subgroup_name, prior cardiac surgery n prior arrhythmias n congestive heart failure n nyha class n ejection fraction percent sd left atrial diameter mm sd prior implantable cardiodefibrillator n prior pacemaker n prior cardiac resynchronization therapy n prior af ablation n euroscore logistic median 25th 75th euroscore additive median 25th 75th beta blocker statin angiotension converting enzymeinhibitor angiotensin receptor blocker calcium channel blocker loop diuretics aldosterone antagonists digitalis antiplatelets anticoagulants antiplatelets anticoagulants amiodarone antiarrhythmics age years sd male sex n planned valve surgery n current smoking n body mass index kg m2 sd waist circumference cm sd hypertension n dyslipidemia n diabetes mellitus n chronic obstructive pulmonary disease n chronic renal failure n coronary heart disease n prior myocardial infarction n prior percutaneous coronary intervention n
subgroup_name, blood pressure mm geographic site
subgroup_name, weight creatinine clearance initial diagnosis clinical presentation vte initial diagnosis risk factors recurrent vte f age yr male sex
subgroup_name, overall uac 30 mg g uac 30300 mg g uac 300 mg g
subgroup_name, low feno subgroup 195 ppb n 193 high feno subgroup 195 ppb n 201 low eosinophil subgroup 260 ml n 383 high eosinophil subgroup 260 ml n 414 low periostin subgroup 50 ng ml n 279 high periostin subgroup 50 ng ml n 255
subgroup_name, low subgroup high subgroup
subgroup_name, age time randomization sex systolic blood pressure killip class infarct location hypertension diabetes weight place randomization timi risk score time randomization
subgroup_name, overall age65 ageadj male female diabetes diabetes previous cv event previous cv event maximum cimt median maximum cimt med hbalc medan hbalca median tnglycendes median tngtycendes median fastng plasma glucose median fascng plasma glucose medan statin stalin acei arb acei arb
subgroup_name, overall age65 age 265 male female diabetes dabetes previous cv event previous cv event maximum cimt median maximum cimt med hbalc median hbalca median tngtycerides median tngtycerides median fasting plasma glucose median fasting plasma glucose 2 medan ststm llv wlalil 1 statin acei arb acei arb
subgroup_name, age years hba1c levels frailty status
subgroup_name, sex smoking status treatment arm copd severity gold stage age bronchodilator response ml region
subgroup_name, ala carriers pro pro homozygotes
subgroup_name, ala carriers pro pro homozygotes
subgroup_name, age sex duration ulcerative colitis extent disease baseline composite mayo clinic score baseline fecal caicrctectin prior treatment history1 stratification variables
subgroup_name, stage 3b egfr 30 45 ml min per 173 m2 stage 3a egfr 45 60 ml min per 173 m2
subgroup_name, age sex diabetes mellitus baseline lvef baseline ecrcl pci high risk contrast volume ciaki risk score
subgroup_name, cohort time randomization age sex acute coronary syndrome diabetes ejection fraction bifurcation left main disease multivessel stenting type des
subgroup_name, race n smoking status n copd severity n lung function mean
subgroup_name, smoking history theophylline use screening ics use saba reversibility copd severity ethnicity
subgroup_name, age years interaction p055 time randomisation hours interaction p071 previous ml interaction p009 sex interaction p059 systolic blood pressure mmhg interaction p056 killip class interaction p062 infarct location interactsn p029 p lace randomization interaction p010 timi risk score interaction p049 time randomization interaction p004
subgroup_name, age sex diabetes previous ml pnorpci pnorcabg index event location ml tim 1 nsk score highest killip classiciation prepci prior asa use gpifeellla inhibitor use angography morphine use index event pci heparin ondaparinux brvalirudin use rxjex event
subgroup_name, angina class baseline betablocker use randomization heart rate age sex history diabetes previous myocardial infarction previous coronary revascularization
subgroup_name, sex age chads2 score af pattern history tia stroke prior years taking warfarin laa ostium laa length lv ejection fraction
subgroup_name, sex smoking status previous pneumonia bmi gold stage
subgroup_name, baseline hscrp tertiles mg
subgroup_name, ics usage
subgroup_name, age randomization sex qualifying myocardial infarction time qualifying myocardial infarction history diabetes aspirin dose history pci region race weight second prior mi multivessel disease nonendstage renal dysfunction
subgroup_name, sex age weight planned thienopyridine baseline diabetes prior stent egfr ml min 173m2 region
subgroup_name, race gender age ethnicity bmi statin treatment llt randomization history ml ischemic stroke moderate ckd randomization diabetes randomization
subgroup_name, age subgroups sex race region diabetes duration subgroups sulfonylurea metformin thiazolidinedione includes pioglitazone insulin prior congestive heart failure hba1c subgroups renal function subgroups history hypertension systolic blood pressure subgroups diastolic blood pressure subgroups cigarette smoking status medications taken time randomization statins ace inhibitors angiotensin receptor blockers diuretics calcium channel blockers beta blockers aspirin
subgroup_name, anticcp antibody u ml rf iu ml crp mg dl mmp3 ng ml haqdi das28 esr mtss concomitant mtx average dose mg week
subgroup_name, age sex bmi previous cancer pe associated dvt diagnosis time therapeutic range inclusion perfusion defectsatinclusion right ventriculardysfunction atinclusion ddimer levelsatinclusion thrombophilia accp score compression stockings
subgroup_name, initial timi flow final timi flow symptom onset diabetes hypertension dyslipidemia rentrop score killip baseline age ejection fraction lad thrombus aspiration
subgroup_name, bmi gender region age race ethnicity prior history ml ischemic stroke diabetes mellitus moderate ckd statin treatment dose atorvastatin dose rosuvastatin llt statin randomization
subgroup_name, age risk factors vascular history concomitant drugs
subgroup_name, age sex race ethnicity region glycated hemoglobin body mass index blood pressure control estimated glomerular filtration rate urine albumintocreatinine ratio cardiovascular risk metformin sulfonylurea insulin thiazolidinediones dpp4 inhibitor statins ezetimibe antihypertensives angiotensinconverting enzyme inhibitors angiotensin receptor blockers calcium channel blockers beta blockers diuretics acetylsalicylic acid
subgroup_name, age sex ethnicity region glycated hemoglobin body mass index blood pressure control estimated glomerular filtration rate urine albumintocreatinine ratio cardiovascular risk metformin sulfonylurea insulin statins ezetimibe antihypertensives angiotensinconverting enzyme inhibitors angiotensin receptor blockers calcium channel blockers beta blockers diuretics acetylsalicylic acid
subgroup_name, risk category points
subgroup_name, age race sex body mass index region indication pci aspirin dose randomization thienopyridine randomization stent type
subgroup_name, japan n 148 notjapan n 3 066 overall n3 214
subgroup_name, overall population # prior bdmards # prior tnfi among nontnfi naive # prior nontnfi bdmards
subgroup_name, qualifying diagnosis age sex diabetes mellitus chronic kidney disease prior mi prior pci cabg surgery prior heart failure planned treatment strategy actual treatment strategy time randomization pci stelevation mi min time randomization pci nonstelevation mi h predictors cardiovascular risk
subgroup_name, duration assigned regimen surgery postrandomisation characteristic age bodymass index ldl cholesterol previous ml lvef
subgroup_name, age sex previous statin use troponin 1 baseline duration assigned regimen surgery postrandomisation characteristic surgical technique postrandomisation characteristic procedure postoperative glucocorticoid use postrandomisation characteristic postoperative nsaid glucocorticoid use postrandomisation characteristic
subgroup_name, duration assigned regimen surgery postrandomisation characteristic age bodymass index ldl cholesterol previous ml lvef
subgroup_name, sex race smoking status screening severity airflow limitation severity copd copd exacerbations previous year inhaled glucocorticoid use screening laba use screening labainhaled glucocorticoid use screening lama use screening
subgroup_name, age years race severity airflow obstruction ics use baseline ccv history condition baseline history atrial fibrillation flutter history cardiac arrhythmia longacting bronchodilator use screening
subgroup_name, age sex history hypertension history diabetes history hypercholesterolemia history ischemic stroke lipidlowering agents time randomization
subgroup_name, age sex race hispanic ethnicity hypertension history coronary artery disease history aerobic activity body mass index abdominal obesity ada impaired fasting glucose idf impaired fasting glucose homa glycated hemoglobin hdl triglycerides metabolic syndrome medication adherence
subgroup_name, acr deciles
subgroup_name, age years bmi kg m2 creatinine clearance ml min race ethnicity
subgroup_name, stage 1 stage 2 stage 3a stage 3b
subgroup_name, stage 1 stage 2 stage 3a stage 3b treatment egfr stage
subgroup_name, sex age racea copd disease severity diabetes mellitus ics use baseline cardiac history cardiac rhythm disorders
subgroup_name, ss baseline race race ss baseline baseline body weight quartile steroid use baseline
subgroup_name, ra duration months baseline erosion das28 mtss haqdi rf iu ml crp mg dl mmp3 ng ml tnfalpha pg ml il6 pg ml baseline steroids mtx exposure mg week
subgroup_name, overall prior antitnf therapy prior biologic therapy including antitnfs
subgroup_name, age gender race body mass index ada impaired fasting glucose glycated hemoglobin homamedian triglycerides coronary artery disease history hypertension history atrial fibrillation statin arb ace aspirin
subgroup_name, group left ventricular ejection fraction total region interval clinical evaluation initiation oftreatment clinical history nyha class within past month total blood pressure mm hg laboratory values treatment randomization
subgroup_name, age screening gender race ejection fraction baseline systolic bp time first eval coronary artery disease diabetes gfr assessed mdrd history chronic hf region ntpro bnp troponin
subgroup_name, race cardiovascular inclusion criteriat high risk receiving treatment concomitant cardiovascular therapy taken 30 days
subgroup_name, smoking status age group cv entry criteria 6080 cv risk disease n2285 gender ethnicity race africanamerican african heritage n129 region ischemic heart disease indicator n650l vascular disease indicator n6650
subgroup_name, study age sex race region bmi blood pressure control duration diabetes glycated hemoglobin egfr history cardiovascular disease history peripheral vascular disease history heart failure history amputation insulin use statin use antithrombotic use raas inhibitor use betablocker use diuretic use
subgroup_name, age years sex smoking status exacerbations previous year fev5 baseline reversibility mmrc baseline baseline therapy
subgroup_name, age years sex smoking status exacerbations previous year fev baseline reversibility mmrc baseline baseline therapy
subgroup_name, blood pressure mm hg estimated gfr 51 race geographic region medication
subgroup_name, age sex geographic region race body weight estimated gfr baseline tobacco use baseline diabetes history hypertension baseline dyslipidemia coronary artery disease peripheral arterial disease
subgroup_name, time randomization sex systolic blood pressure killip class hypertension diabetes weight
subgroup_name, age randomization years gender prior disease time since qualifying event region atorvastatin dose systolic blood pressure mmhg diastolic blood pressure mmhg body mass index kg m1 waisthip ratio alcohol intake cigarette smoking medication ldl cholesterol mg dl nonhdl cholesterol mg dl hdl cholesterol mg dl total cholesterol mg dl triglycerides mg dl apolipoprotein a1 mg dl apolipoprotein b mg dl lipoprotein nmol l glomerular filtration rate ml min 173ma urinary albumimcreatinine ratio
subgroup_name, bmi gender race region age 3 classes age 2 classes duration diabetes tertiles ascvd per protocol ascvd including tia statin versus statin randomization statin vs statin alone vs statin plus llt highintensity statin vs medium lowintensity statin randomization prior history mi ischaemic stroke ckd egfr 3 classes baseline albumin creatinine ratio 3 classes diabetic kidney disease calculated ldlc 4 classes nonhdlc 4 classes baseline trlc 2 classes baseline trlc quintiles baseline hdlc 2 classes baseline triglycerides 3 classes baseline triglycerides 2 classes baseline triglycerides quintiles baseline lp 3 classes baseline lp 2 classes baseline total pcsk9 level median baseline free pcsk9 level median baseline hba1c 3 classes diabetes mellitus status baseline insulin daily dose kg
subgroup_name, demographics coexisting conditions index acs event index acs event labs index acs event
subgroup_name, index event subtype modified rankin scale score
subgroup_name, age current smoker prior stroke aphasia cad htn hx
subgroup_name, corticosteroid use baseline gender prior antitnf therapy
subgroup_name, age gender race prior stroke carotid stenosis atrial fibrillation hypertension history ldlcholesterol body mass index glycated hemoglobin homa median
subgroup_name, age years sex region ethnic origin baseline diabetes history myocardial infarction history pci ptca history cabg myocardial infarction cabg pci 2 years baseline total cholesterol peripheral artery disease nonsmokers receiving lipidlowering drugs p blockers timi risk score
subgroup_name, diabetes smoking status cad abi symptomatic pad pad lower extremities egfr
subgroup_name, completers n 5 327 hba1c 8 n 5 97 8 hba1c 9 n 5 161 hba1c 9 n 5 69 completers n 5 333 hba1c 8 n 5 94 8 hba1c 9 n 5 158 hba1c 9 n 5 81
subgroup_name, completers hba1c 8 8 hba1c 9 hba1c 9 hba1c 9
subgroup_name, individuals without diabetes n 3 662
subgroup_name, individuals diabetes n 632
subgroup_name, women men age 60 years age 60 years diabetes diabetes nonsmoker smoker bmi 30 kg m2 bmi 30 kg m2 ldl cholesterol 207 mmol l ldl cholesterol 207 mmol l hscrp 2 4 mg l hscrp 4 mg l hdl cholesterol 117 mmol l hdl cholesterol 117 mmol l triglycerides 169 mmol l triglycerides 169 mmol l overall
subgroup_name, women n4416 men n13 728
subgroup_name, primary endpoint cardiovascular death chd death death myocardial infarction hospitalization unstable angina coronary revascularization 230 days randomization stroke cardiovascular death myocardial infarction stroke
subgroup_name, dm absent dm present
subgroup_name, cdmard mtx none cdmardnaive past use baseline
subgroup_name, geographical region pah classification congenital shunts exposure
subgroup_name, overall population age years baseline weight kg region pooled disease duration years seropositivity corticosteroid use
subgroup_name, overall population prior bdmards prior tnfi prior tnfi treatment nontnfi tnfi among nontnfi naive
subgroup_name, sex qualifying event unstable angina age hypertension diabetes smoking total cholesterol ldl cholesterol hdl cholesterol triglycerides
subgroup_level, 66 yr 566 yr white nonwhite yes current former never diabetes betablocker use 315 mg dl 5315 mg dl triglycerides 151 mg dl 5151 mg dl ldl cholesterol 112 mg dl 5112 mg dl 104 mg dl 104121 mg dl 121 mg dl
subgroup_level, diabetic patients nondiabetic patients
subgroup_level, 65 yr 65 yr male female yes united states acute coronary syndrome 3025
subgroup_level, randomized women hormonal status premenopausal without hormone replacement therapy asa 4626 placebo 4703 premenopausal hormone replacement therapy asa 530 placebo 481 postmenopausal without hormone replacement therapy asa 3 261 placebo 3264 postmenopausal hormone replacement therapy asa 6 091 placebo 5957
subgroup_level, aldl cholesterol 340 aab42 alathosterol acholesterol a24shydroxy cholesterol
subgroup_level, diagnosed diabetes n 627 undiagnosed diabetes n 142 impaired fasting glucose level n 323 normal fasting glucose level n 1425 p value
subgroup_level, present absent male female 3044 yr 4564 yr 6589 yr 2 1 1 yr 1 yr 2 mo 2 mo
subgroup_level, 9 9
subgroup_level, 9 9
subgroup_level, 9 9
subgroup_level, 9 9
subgroup_level, 9 9
subgroup_level, previous myocardial infarction stsegment depression cardiac troponin level 003 pg l cardiac troponin level median iqr pg l none 1 2 3 left ventricular ejection fraction median iqr age median iqr women active smoker serum cholesterol median iqr mg dl arterial hypertension diabetes mellitus insulindependent previous balloon angioplasty previous cabg surgery
subgroup_level, 70 70 female male white black hispanic yes
subgroup_level, 70 yr 70 yr male female yes
subgroup_level, middle tertile range 1620 mg dl mean sd 18 01 mg dl highest tertile range 2136 mg dl mean sd 24 03 mg dl
subgroup_level, ii iii iv
subgroup_level, 4554 5564 65+ total
subgroup_level, 4554 5564 65+ total
subgroup_level, current smoker current nonsmoker
subgroup_level, female sex male sex age 65 yr age 65 yr white race nonwhite race lvef30 lvef30 qrs 120 msec qrs 120 msec 6min walk test 950 ft 9501275 ft 1275 ft betablocker betablocker diabetes diabetes
subgroup_level, 4554 yr 5564 yr 65 yr current past never 250 250 299 300 premenopausal uncertain postmenopausal current hrt postmenopausal hrt yes 120 75 mm hg 120129 7584 mm hg 130139 8589 mm hg 140 90 mm hg
subgroup_level, overall 65 yr 65 yr male female anterior nonanterior fibrinspecific nonfibrinspecific lowmolecularweight unfractionated none characteristic
subgroup_level, tg31 tg 31
subgroup_level, atv 10 mg atv 20 mg study protocol 803 804 65 yrs 65 yrs sex male female 272 kg m2 272 kg m2 hypertension yes 34 mmol l 34 mmol l
subgroup_level, postmi chd none s65 65 male female yes 90 90 52 5265 65 35 3545 45 sso9 o9ii 11 14 1420 20 overall
subgroup_level, postmi chd none 65 65 male female yes s90 90 52 5265 65 35 3545 45 s09 o9ii 11 ssi4 1420 2 0 overall
subgroup_level, participants 003 g l 003 lg l 3 h 3 h yes
subgroup_level, asian black hispanic white
subgroup_level, entire cohort gender race age baseline ldlc chd status
subgroup_level, male caucasian noncaucasian 65 years 65 years baseline ldlc 160 mg dl 160mg dl chd status chd chd entire cohort gender female
subgroup_level, simva eze simva gender female simva female eze simva male simva male eze simva caucasian simva caucasian eze simva noncaucasian simva noncaucasian eze simva 65 years simva 65 years eze simva 65 years simva 65 years eze simva baseline ldlc 160 mg dl simva 160 mg dl eze simva 160 mg dl simva 160 mg dl eze simva chd simva chd eze simva chd simva chd eze simva
subgroup_level, antiplatelets without antiplatelets lipidlowering agents without lipidlowering agents p blockers without p blockers one two none revascularisation without revascularsation revascularisation+antiplatelets+ lipidlowering agents+p blockers revascularisation antiplatelets lipidlowering agents p blockers
subgroup_level, male female 60 years 260 years 621 mmol l 2621 mmol l 401 mmol l 2401 mmol l 135 mmol l 2135 mmol l 142 mmol l 2142 mmol l yes 24 kg m2 224 kg m2
subgroup_level, metabolic syndrome n813 neither n 1 044
subgroup_level, age 70 n 1220 age 70 n802
subgroup_level, age 70 n 1220 age 70 n802
subgroup_level, 20 20 30 30 yes
subgroup_level, 096 099 081 083 104 121 091 094 085 089 100 095 092 097
subgroup_level, aspirin use p019t ppi use p036t aspirin use p092t ppi use p028t aspirin use p026t ppi use p097t
subgroup_level, 61 61 female male 24 24 absent present nonsmoker smoker hypertension absent 70 70 17 17 15 15 47 47
subgroup_level, age yrs 65 65 men caucasian body mass index kg nr coronary heart disease metabolic syndrome diabetes mellitus crp mg l median sd total cholesterol mg dl ldl cholesterol mg dl tg mg dl median sd apolipoprotein b mg dl hdl mg dl
subgroup_level, 65 65 men women 140 140 yes 75 75 combined macro+micro
subgroup_level, 77 yr 77 yr sex female male nyha class ii iii iv ejection fraction 030 030 26 26 1225 mm hg 1225 mm hg diastolic blood pressure 73 mm hg 73 mm hg heart rate 755 bpm 755 bpm current smoker yes yes previous revascularization diabetes sinus rhythm atrial fibrillation ldl cholesterol level 312 mmol liter 312 mmol liter apobapoal ratio 076 076 hdl cholesterol level 105 mmol liter 105 mmol liter triglyceride level 212 mmol liter 212 mmol liter estimated gfr 51 ml min 173 m2 51 ml min 173 m2 ntprobnp 2776 pmol liter 2776 pmol liter hscrp level 58 mg liter 58 mg liter antiplatelet agents patients
subgroup_level, baseline hb 120 g 1 1 n499 baseline hb 120g 1 n788 combined n1287
subgroup_level, cox bsl onlyc cox bsl+yr 1 hbd
subgroup_level, women men total n2476
subgroup_level, 56 2718 46 28 1248 50 33 2718 27 27 1248 47 39 2718 31 36 2718 29
subgroup_level, 60 years 47 1425 74 55 years 50 years 60 years
subgroup_level, dd ii id composite endpoint doubling serum creatinine esrd
subgroup_level, women men
subgroup_level, age years smoking status bmi kg m2 exercise postmenopausal hormone use vitamin e
subgroup_level, prior mi prior mi
subgroup_level, 5 yr since menopause 5 yr since menopause overall
subgroup_level, secondary prevention subgroup primary prevention subgroup
subgroup_level, men women white black hispanic 65 65 lean 25 kg m2 overweight 25 30 kg m2 obese 30 kg m2 current smokers current nonsmokers
subgroup_level, men women white black hispanic 65 65 lean 25 kg m2 overweight 25 30 kg m2 obese 30 kg m2 current smoker current nonsmoker diabetic nondiabetic
subgroup_level, 600 without dm n 8i7
subgroup_level, 65 yr 65 yr male female 140 mm hg 140 mm hg 72 72 79 mmol liter 79 mmol liter 28 28 yes overall
subgroup_level, 0 1 2
subgroup_level, recurrent stroke previous stroke tia atherosclerotic event neither 010 low risk 1014 moderate risk 14 high risk 0 drinks wk 114 drinks wk 15 drinks wk 65 yr 65 75 yr 75 yr male female african chinese south asian asian white european native latin yes placebo telmisartan slo days 10 days largeartery atherosclerosis smallartery occlusion undetermined cardioembolism 135 mm hg 135 150 mm hg 150 mm hg
subgroup_level, age 70 years median age 70 years median lvef 40 lvef 40 ischaemic cause nonischaemic cause nyha ii nyha iii iv diabetes diabetes total cholesterol 4 97 mmol lt total cholesterol 497 mmol lt
subgroup_level, age 69 years median age 69 years median lvef 40 lvef 40 ischaemic cause nonischaemic cause nyhaii nyhaiiioriv diabetes diabetes total cholesterol 487 mmol lt total cholesterol 487 mmol lt
subgroup_level, prior lgi event prior lgi event 65 6575 75 aspirin aspirin cigarette smoker nonsmoker corticosteroid corticosteroid ascvd ascvd femaleb male prior ugi event prior ugi event rheumatoid arthritis osteoarthritis
subgroup_level, 4554 years 5564 years 65 years 250 kg m2 25299 kg m2 30 kg m2 yes premenopausal uncerlain poslmenopausal ht poslmenopausal ht 518 mmol l 518620 mmol l 621 mmol l 259 mmol l 259335 mmol l 336412 mmol l 413 mmol l 130 mmol l 130 mmol l 40 4059 60 336 mmol l 50 50 10mg l 1029 mg l 30 mg l
subgroup_level, full cohort 55 55 65 65 75 75 male female former current ii iii iv asia e europe latin america usa w europe white black asian yes 20 20 25 25 30 30 laba ics laba + ics anticholinergic
subgroup_level, patients 65 yr 6574 yr 75 yr female male 59 59 yes europe north america
subgroup_level, 65 n433 65 n127 75 n18 65 n422 65 n125 75 n19
subgroup_level, 625 yrs male nonanterior 720 min 47 min
subgroup_level, diabetes mellitus diabetes mellitus
subgroup_level, 69 yr 69 yr yes amiodarone none patients
subgroup_level, ng n 14 080 lgm n 4565
subgroup_level, ng n 14 080 igm n 4565
subgroup_level, ng igm
subgroup_level, 2830 n8 689 2427 n2 231 23 n212
subgroup_level, gold stage ii gold stage iii gold stage iv
subgroup_level, gold stage ii gold stage iii gold stage iv
subgroup_level, 70 yr open endovascular 50 mg liter 50 mg liter 30 mmol liter 30 mmol liter 55 mmol liter 55 mmol liter low intermediate high yes 70 yr
subgroup_level, age 65 years age 65 years
subgroup_level, subjects female male 75 75 1 1 yes unknown anterior anterior north america rest world hub spoke 3 3 tertile 3 tertile 2 tertile 1 tertile 1 index pci performed
subgroup_level, subjects female male 75 75 baseline killip class 1 1 yes unknown anterior anterior north america rest world hub spoke 3 3 tertile 3 tertile 2 tertile 1
subgroup_level, 65 65 male female 09 1019 20 181210 211240 241270 yes nonsmoker current smoker exsmoker itt population
subgroup_level, intentiontotreat intentiontotreat without stsegmentelevation myocardial infarction intentiontotreat stsegmentelevation myocardial infarction
subgroup_level, hscrp 20 nlg l hscrp mg l randomized hscrp 20 mg l hscrp j20 mg l hscrp _20 mg l cause mortality hosp worsening hf hscrp 20 mg l hscrp j20mg l
subgroup_level, hscrp 20 mg l hscrp 20 mg l hscrp 20 g l
subgroup_level, hscrp 20 mg l hscrp 20 mg l
subgroup_level, neither t2dm mets metabolic syndrome w t2dm t2dm
subgroup_level, neither t2dm mets mets w t2dm t2dm
subgroup_level, women men
subgroup_level, men women
subgroup_level, men women
subgroup_level, 520 20249 25299 30349 35399 40
subgroup_level, male female
subgroup_level, pad baseline pad baseline
subgroup_level, jbs2 secondary prevention only3 jbs2 primary prevention only3 nice secondary prevention onlyb nice primary prevention onlyb baseline ldlc 20 25 mmol lc baseline ldlc 25 42 mmol lc ldlc 25 mmol l
subgroup_level, 625 yrs 625 yrs female male yes anterior nonanterior 180 min 180360 min 361720 min 720 min 47 min 47 min 745 min 745 min
subgroup_level, laba users laba nonusers
subgroup_level, women level 1 level 2 men
subgroup_level, 55 55e64 65e74 75 male female current former 30 30e50 50 yes
subgroup_level, age 65 years n4031 65 years n2474 male n4970 female n1535 pblocker intake randomisation n685 pblocker intake randomisation n582o nonischaemic n2o87 ischaemic n44l8 nyha class ii n3l69 nyha class iii iv n3334 history diabetes n4526 history diabetes n1979 history hypertension n2191 history hypertension n4314 77 bpm n3144 77 bpm n3357
subgroup_level, diabeticb nondiabetic
subgroup_level, overall population baseline triglycerides 150 mg dl baseline trig 150 millycerides g dl
subgroup_level, 335 years 6575 years 75 years 570 kg 7090 kg 90 kg wssng mae female 280rrmnl 5080 nlmw 50nwrrtn cardiac disease ns cardiac cisease 3 mortis 5 mentis 12 months ns yes scoitarojs dvtpe secondary dvtfe known tiromtcchc ccndifeon known frtrontxtfufoc cond aon extensive nonextensive msng adk e cancer ac tve cancer immobazaton immomtedion warfarin acenocoumaroi western friroce eastern europe austrafca new zealand sonti amenca north america asia israel sou ti africa
subgroup_level, 65 years 6575 years 75 years 570 kg 7096 kg 96 kg missing mate female sd ml min 5080 mvmin 50 ml min 3 months 6 months 12 montlts yes active cancer active cancer available white black asian american indian hispanic uncodable
subgroup_level, adjusted change baseline mean se difference vs pbof mean se moderate renal impairment severe renal impairment esrd baseline hba1c mean se week 12 hba1c mean se
subgroup_level, moderate renal impairment severe renal impairment esrd saxa 25 mg n 15 pbo n 18
subgroup_level, north america united states ukraine russia romania poland new zealand latvia italy israel hungary estonia germany czech republic canada brazil belgium austria australia rest world europe zone 2 europe zone 1
subgroup_level, migraine aura migraine without aura prior migraine
subgroup_level, history migraine migraine aura migraine without aura prior migraine p
subgroup_level, age years mean sd female male caucasian asian african america weight kg mean sd bmi kg m2 mean sd duration diabetes hbalc mean sd fpg mmol l mean sd u+3001 past current priorbone disease current bone disease priorother predefined medical conditions priorother predefined medical conditions current predefined medical conditions currentother notpredefined medical conditions condition osteoporosis hip fracture current n former n years mean sd yes n units per week mean sd
subgroup_level, overall male female premenopausal postmenopausal
subgroup_level, single stemi nonstemi ua pci cabg none 5 mg bid 25 mg bid asia pacific eastern europe north america south america western europe 65 6574 75 female male white black african american asian s28 kg m2 2933 kg m2 34 kg m2 severe moderate mild normal s2 2 yes antiplatelet therapy dual
subgroup_level, 79 79 70 69 82 80 67 68 84 81 65 67 88 80 61 68 86 77 63 71 63 60 86 88 55 58 27 22 42 48 25 20 47 52 35 28
subgroup_level, 65 65 male female white black asian yes 15 15
subgroup_level, 8 8 9 9 65 65 male female 30 30 3 3 6 6
subgroup_level, 75 75 men women 60kg 60kg mi pad stroke yes 60 60 north america europe europe ii latin america australia nz asia
subgroup_level, overall 26352 75 women 60kg stroke yes 60
subgroup_level, crohns disease ulcerative colitis
subgroup_level, patients ra psa n 280 patients without ra psa n 18 609
subgroup_level, baseline 39 meq l eos 39 meq l baseline 39 meq l eos 39 meq l baseline 39 meq l eos 39 39 meq l
subgroup_level, black nonblack
subgroup_level, 600 without dm n 8i7
subgroup_level, without diabetes diabetes
subgroup_level, male female 75 yr 75 yr 60 kg 60 kg yes 60 60 stemi nstemi unknown north america europe 1 europe 2 latin america australia nz asia overall
subgroup_level, gold ii gold iiiiv
subgroup_level, moderate copdb n z 207 severe copdc n z 140
subgroup_level, median median pvalue
subgroup_level, coronary bypass n valve surgery n cardiac surgery n atrial fibrillation supraventricular tachycardia ventricular tachycardia fibrillation ii iii iv available aspirin clopidogrel ticlopidine others warfarin heparin
subgroup_level, 70 years n556 female n422 italy n728 usa n446 yes n756 yes n1135 yes n362 418mmol l n730 42 mm n555 50 n1208 2 servings wk n127 4 n323 1 n34 2 n640 3 n286 4 n137 5 n385 yes n1060 yes n966 yes n160 yes n861 l36hrsmin n742 111 hrsmin n739
subgroup_level, current smoker systolic diastolic americas europe asia duration diabetes mellitus previous metformin use metformin dose mg hba1c glucose mmol l insulin pmol l homair ldlc mmol l hdlc mmol l nonhdlc mmol l triglyceride mmol l hscrp mg l il6 ng l fibrinogen g l age female body mass index kg m2
subgroup_level, mean kg 60 kg 60 kg data missing 30 ml min 30 50 ml min 50 80 ml min 80 ml min deepvein thrombosis pulmonary embolism unprovoked associated transient reversible risk factor active cancer persistent permanent immobilization previous deepvein thrombosis pulmonary embolism known prothrombotic genotype use antiplatelet agents
subgroup_level, overall event rate 75 yr 75 yr 0 2 hr 2 hr male female 100 mm hg 100 140 mm hg 140 160 mm hg 160 mm hg iiiv anterior inferior yes 60 kg 60 90 kg 90 kg ambulance community hospital 5 5 amendment amendment
subgroup_level, 75 75 s8 8 s9 9 frail nonfrail
subgroup_level, male n z 2477 female n z 774 current smoker n z 936 exsmoker n z 2315 tiotropium n z 1714 control n z 1537 iorii n z 1698 iii n z 1326 iv n z 179 55 n z 478 55 65 n z 1232 65 75 n z 1257 75 n 284 50 n 355 50 100 n 260 100 150 n 371 150 200 n 379 200 n 1786 asia n 196 eastern europe n 785 latin america n 254 usa n 699 western europe n 1317
subgroup_level, a1c baseline 90 a1c baseline 90
subgroup_level, 35 male female 1 3y 3 7y 7y left sided colitis extensive colitis pancolitis 9 9 503 ug g 500 ug g prior antitnf treatment failure prior immunnosupressive failure antitnf failure prior corticosteroid failure concomitant corticosteroid use concomitant cortcosteroid use concomitant immunosuppressive prior antitnf use concomitant immunosuppressive prior antitnf use
subgroup_level, 70 yrs 70 yrs male female yes 45 45 60 ml min 60 ml min 140 ml 140 ml 5 5
subgroup_level, first n2701 second n2344 18 mon n4097 18 mon n948 65 yo n2739 65 yo n2306 male n3498 female n1547 yes n3063 n1982 yes n1418 n3627 40 n191 40 n4172 yes n839 n4206 yes n314 n4731 n3852 yes n1604 n3441 older des n3318 new des n1727
subgroup_level, male n asian black white current former mild moderate severe severe prebronchodilator fev1 l postbronchodilator fev1 l prebronchodilator fev1 predicted postbronchodilator fev1 predicted concomitant treatment laba n pretreatment age mean
subgroup_level, age 75 age 75 male female stemi nsteacs sa diabetic yes diabetic drugeluting stent bare metal stent lm bifurcation treated lm bifurcation treated single vessel pci 22 vessel pci 600 mg clopidogrel load 300 mg clopidogrel load bivalirudin heparin cangrelor clopidogrel
subgroup_level, asthma population n 33 copd population n 42
subgroup_level, exsmokers smokers yes 12 12 moderate severe chinese
subgroup_level, age 75 aqc75 woman men bmi 30 bmi 30 diabetes diabetes smoking smoking acs acs number stent1 number stent 2 full population
subgroup_level, age 75 aqc75 woman men bmi 30 bmi 30 diabetes diabetes smoking smoking acs acs number stent1 number stent 2 full population
subgroup_level, 75 75 02 2 yes male female 100 100 140 140 160 160 l ii iv anterior inferior 60 60 90 90 ambulance community hospital 5 5 amendment amendment
subgroup_level, 65 years 65 years 75 years 75 years male female yes stemi anterior nonanterior 02 36 6 1 1
subgroup_level, class 1 symptoms class 11 yes 75 beats min 75 beats min 65 yr 65 yr male female
subgroup_level, 8 64 mmol mol 8 9 64 75 mmol mol 9 75 mmol mol
subgroup_level, 65 65
subgroup_level, 8 64 mmol mol 8 9 64 5 mmol mol 9 75 mmol mol
subgroup_level, female male 75 75 1 1 paroxysmal persistent permanent yes 1 median 21 mm median median 30 mm median 60 patients
subgroup_level, 65 female male former smoker current smoker yes 25 kg m2 25 kg m2 21 kg m2 21 kg m2 ii fev150 predicted iii fev130 50 predicted iv fev1 30 predicted 64
subgroup_level, overall 1 st 27 2nd 27 75 3rd 75
subgroup_level, egfr 50 ml min 173 m2 egfr 3050 ml min 173 m2 egfr 30 ml min 173 m2
subgroup_level, egfr50 egfr 3050 egfr 30 hosji fcrhypoglycemia major hypoglycemia ebria
subgroup_level, egfr 50 ml min 173 m2 n 10 621 egfr 3050 ml min 173 m2 n 1 533 egfr 30 ml min 173 m2 n 206
subgroup_level, yes
subgroup_level, hba1c patients baseline hba1c 8 64 mmol l mmol mol la n baseline sd adjusted mean change 95 ci placebosubtracted change se hba1c patients baseline hba1c 8 9 64 75 mmol mol mmol mol la n baseline sd adjusted mean change 95 ci placebo subtracted change se hba1c patients baseline hba1c 9 75 mmol mol mmol mol la n baseline sd adjusted mean change 95 ci placebosubtracted change se
subgroup_level, diabetes mellitus diabetes mellitus
subgroup_level, patients treated statins n113 patients treated statins n485 patients treated statins n117 patients treated statins n473
subgroup_level, rivaroxaban enoxaparin vka age 60 years age 60 years asa use baseline asa use baseline bmi 30 kg m2 bmi 30 kg m2 crcl 50 ml min crcl 50 ml min cardiac disease cardiac disease female male
subgroup_level, rivaroxaban enoxaparin vka age 60 years age 60 years asa use baseline asa use baseline bmi 30 kg m2 bmi 30 kg m2 crcl 50 ml min crcl 50 ml min cardiac disease cardiac disease female male
subgroup_level, patients age 75 age 75 female male nstemi stemi unknown 2 years 2 years diabetes diabetes 75 mg 75 mg prior pci prior pci north america south america europe asia caucasian noncaucasian median 81 kg median 81 kg second mi second mi multivessel disease multivessel disease renal dysfunction renal dysfunction
subgroup_level, myocardial infarction presentation n3576 myocardial infarction presentation n8072
subgroup_level, male female 75 75 60 kg 60 kg yes 60 60 north america europe europe ii latin america australia nz asia
subgroup_level, overall white black african american male female 65 65 75 75 hispanic latino hispanic latino 30 30 highintensity statin highintensity statin statin llt statin without llt prior history ml stroke prior ml stroke moderate ckd moderate ckd diabetes diabetes
subgroup_level, pci po pa pa pci
subgroup_level, white black african american asian
subgroup_level, pooled analysis bmi 270 299 bmi 300 349 bmi 350 399 bmi 40
subgroup_level, pooled analysis bmi 270 299 bmi 300 349 bmi 350 399 bmi 40
subgroup_level, bmi 300 349 bmi 350 399 bmi 40
subgroup_level, antitnfnaive patients antitnfir patients
subgroup_level, 100 100300 300 20 2060 60 05 0510 10 50 50100 100 32 3251 51 05 08 812 1216
subgroup_level, overall 50 years 5067 years 67 years male female 30 kg 2 30 kg m2 yes 65 65 10 10 250 microg l 250 microg l 2 2
subgroup_level, baseline hba1c 80 baseline hba1c 80
subgroup_level, mtx 10 mg week mtx 10 15 mg week mtx 15 mg week interaction p
subgroup_level, aspirin aspirin 4 clopidogrel
subgroup_level, bdmardnaive bdmardir
subgroup_level, bdmardnaive bdmardir
subgroup_level, female 2 2 22 2h 26h 6h yes 1 1 75 yr 275 yr 40 40 proximalmainleft medialdistaldiag overall male
subgroup_level, diagnosis heterozygous familial hypercholester genotyping clinical criteria3 age years mean + sd male n race white n body mass index kg m2 mean + sd coronary heart disease n b coronary heart disease risk equivalents n c current smoker n hypertension n type 2 diabetes n statin use n highdose statin use n e ezetimibe use
subgroup_level, 30 kg m2 30 kg m2 male female north america western europe eastern europe rest world 65 years 65 75 years 75 years white black african american hispanic latino hispanic latino yes high intensity lowzmedium intensity 40 mg 80 mg 20 mg
subgroup_level, mean sd 75 female sex white race diabetes mellitus hypertension hyperlipidemia crcl 60 ml min current smoker weight 60 kg coronary revascularization previous cabg total previous pci total previous stenting previous pci des previous stenting time qualifying mi 3 mo 36 mo 6 mo region north america europe europe ii latin america asia australia new zealand aspirin lipidlowering agents pblockers ace inhibitor arb
subgroup_level, thienopyridine thienopyridine
subgroup_level, patients 65 years 65 years male female white asian black africanamerican hispanic latino hispanic latino europe north america latin america africa asia 85 85 30 kg m2 30 kg m2 sbp 140 mmhg dbp 90 mmhg sbp 140 mmhg dbp 90 mmhg 90 ml min 173m2 60 90 ml min 173m2 60 ml min 173m2 30 mg g 30 300 mg g 300 mg g cerebrovascular disease coronary artery disease peripheral artery disease 2 3 high cardiovascular risk categories yes
subgroup_level, patients 65 years 65 years male female white asian black africanamerican hispanic latino hispanic latino europe north america plus australia new zealand latin america africa asia 85 85 30 kg m2 30 kg m2 sbp 140 mmhg dbp 90 mmhg sbp 140 mmhg dbp 90 mmhg 90 ml min 173m2 60 90 ml min 173m2 60 ml min 173m2 30 mg g 30 300 mg g 300 mg g cerebrovascular disease coronary artery disease peripheral artery disease 2 3 high cardiovascular risk categories yes
subgroup_level, overall femoral radial
subgroup_level, diabetes mellitus diabetes mellitus
subgroup_level, diabetes mellitus diabetes mellitus
subgroup_level, p value hba1c 7 n 4119 hba1c 78 n 5416 hba1c 89 n 3139 hbalc 9 n 3525
subgroup_level, hba1c7 hba1c 78 hba1c 89 hba1c9 overall
subgroup_level, hba1c7 hba1c 78 hba1c 89 hba1c9 overall
subgroup_level, 2640 n 1 459 415 n 1 762 1618 n 1 637 1921 n 1 675 2225 n 1 842
subgroup_level, 03 n 1 499 4 n 1 314 5 n 1 325 6 n 987 712 n 987
subgroup_level, male female 65 years age 65 years age duration t2dm 10 years duration t2dm 10 years egfr 60 ml min 173 mz egfr 60 ml min 173 mz fracture history fracture history
subgroup_level, 75 75 white nonwhite male female median median diabetes diabetes current tobacco use current tobacco use prior mi prior mi prior pci prior pci prior cabg prior cabg history cancer history cancer north america european union australia new zealand mi mi 100 mg 100 mg clopidogrel prasugrel drug eluting stent bare metal stent
subgroup_level, age #75 yrs age 75 yrs cha2ds2vasc #4 cha2ds2vasc 4 modified hasbled 3 modified hasbled 3 history tia stroke history tia stroke female male
subgroup_level, overall placebo allocation omega 3 allocation male female age65 age65 bmi30 bmi30 alc64 alc64 prior cv event prior cv event metformin use metformin use statin use statin use neither acei arb use acei arb use ifg igt new om prior om age65 new dm prior dm standard care allocation insulin glargine allocation heart rate 69 bpm heart rate 69 bpm betablocker use betablocker use omega3 fa intake 1st third omega3 fa intake 2nd third omega3 fa intake 3 third triglycerides 1st third triglycerides 2nd third triglycerides 3 third
subgroup_level, overall japan notjapan
subgroup_level, white 844 black africanamerican 103 asian 32 21
subgroup_level, white black african american asian
subgroup_level, men women
subgroup_level, 3 3 1 1 0
subgroup_level, ukpds 10year risk score 20 ukpds 10year risk score 20
subgroup_level, nonstelevation mi stelevation mi 65 65 male female yes invasive conservative pci cabg surgery medical management 30 30 3 3 6 6 0 1 2 3 overall
subgroup_level, 2 days 23 days 48 days 60 yr 6165 yr 65 yr 25 kg m2 25 kg m2 80 mg dl 80 100 mg dl 100 mg dl yes 55 55 patients
subgroup_level, 60 yr 60 yr male female yes 004 ng ml 004 ng ml 3 days 3 days pump pump cabg avr patients
subgroup_level, 2 days 23 days 48 days 60 yr 6165 yr 65 yr 25 kg m2 25 kg m2 80 mg dl 80 100 mg dl 100 mg dl yes 55 55 patients
subgroup_level, male female white asian former smoker current smoker moderate severe severe group b group 1 exacerbation 2 exacerbations use use overall
subgroup_level, 65 65 75 75 male female caucasian black mild moderate copd severe severe copd yes
subgroup_level, egfr 60 ml min 173 m2 egfr 3059 ml min 173 m2 egfr 30 ml min 173 m2
subgroup_level, gold 2 gold 3 gold gold b gold c gold naive naive yes ics ics yes overall
subgroup_level, 3 months 36 months 612 months 12 months prior hf hospitalization p value interaction
subgroup_level, overall 65 yr 65 yr male female yes 24 hr 24 hr time treatment hospital factor #1 15 enroll 15 enroll hospital factor #2 850 beds 850 beds lesion location cortical noncortical vascular territory #1 anterior circulation posterior circulation vascular territory #2 mca others
subgroup_level, n 457 without n 14 214
subgroup_level, participants 65 years 65 years male female black african american white yes goal goal 30 30 present absent present 100 mg dl absent 100 mg dl present 110 mg dl absent 110 mg dl 46 46 57 57 40 men 50 women 40 men 50 women 150 mg dl 150 mg dl 80 80
subgroup_level, entire cohort subset patients metformin subset patients metformin
subgroup_level, omt omt
subgroup_level, stroke n13 889 stroke n213 p value
subgroup_level, diabetes diabetes renal dysfunction renal dysfunction history chf history chf history af history af prior stroke tia prior stroke tia
subgroup_level, full population age 85 age 85 women men weight 60 kg weight 60 kg diabetes diabetes hypertension hypertension current smoking current smoking st+ st creat clearance 30 ml min creat clearance 30 ml min prior ml prior ml prior cancer prior cancer prior heart failure prior heart failure one vessel multi vessel left main des bms length stent median length stent median number stentl 2 3 number stent 3
subgroup_level, patients n1306 highdosage ics plus laba baseline blood eosinophils a300 cells per pl n728 highdosage ics plus laba baseline blood eosinophils 300 cells per pl n363
subgroup_level, patients n1204 highdosage ics plus laba baseline blood eosinophils 300 cells per pl n809 highdosage ics plus laba baseline blood eosinophils 300 cells per pl n395
subgroup_level, type 2 diabetes ifg mets dysglycaemia mets
subgroup_level, type 2 diabetes ifg mets dysglycaemia mets
subgroup_level, cohort 1 uacr 225 mg g cohort 2 uacr 225 mg g uacr available
subgroup_level, overall 556 55678 781143 11431588 15 8822495 224953462 346260 60133685 13368539444 39444
subgroup_level, sa acs
subgroup_level, overall 35 3550 5065 265 25 2530 3035 235 290 90 white black asian hispanic latino hispanic latino
subgroup_level, egfr 90ml min 173m2 n3 325 229 egfr 6089 ml min 173m2 n7 879 542 egfr 4559 ml min 173m2 n2 538 175 egfr 3044 ml min 173m2 n783 54
subgroup_level, egfr 90 ml min 173m2 egfr 6089 ml min 173m2 egfr 4559 ml min 173m2 egfr 3044 ml min 173m2
subgroup_level, mra baseline mra baseline
subgroup_level, overall population patients syndesmophytes baseline patients without syndesmophytes baseline elevated hscrp normal hscrp male female smokers baseline nonsmokers baseline
subgroup_level, cardiac rhythm disorder baseline yes
subgroup_level, female male 65 years 6575 years 7585 years 85 years white asian africanamerican gold 1 gold 2 gold 3 gold 4 yes
subgroup_level, full analysis set chinese subgroup
subgroup_level, full analysis set chinese subgroup
subgroup_level, overall n554 vs 279 ss 10 n352vs 168 ss9 n202vs111 black race n58 vs 33 nonblack race n496 vs 246 black race ss 9 n19 vs 15 black race ss 10 n39 vs 18 nonblack race ss 9 n183 vs 96 nonblack race ss 10 n313 vs 150 q1 5505 kg n139vs70 q2 5505 6515 kg n141 vs 66 q3 6515 7825 kg n135 vs 73 q4 7825 kg n139vs70 steroids n480 vs 240 steroids n74 vs 39
subgroup_level, 3 36 6 yes 32 32 05 05 05 10 10 20 20 60 60 10 50 50 100 100 055 055 179 179 030 030 241 241 08 8 12 12 16
subgroup_level, evaluable acr20 week 16 n received 1 prior antitnf therapy n received 2 prior antitnf therapies n received 1 prior biologic therapy n received 2 prior biologic therapies n received 3 prior biologic therapies n
subgroup_level, overall n 17 717 low 01 n 8 032 45 intermediate 2 n 5 292 30 high 3 n 4 393 25
subgroup_level, overall low risk ri01 intermediate risk ri2 high risk ri3
subgroup_level, participants 65 years 65 years male fema le black african american white 30 30 present 100 mg dl absent 100 mg dl 6569t 5764 57 yes 150 mg dl 150 mg dl
subgroup_level, 10 years l0 years l0 years
subgroup_level, age yr 65 yr 65 yr male sex nonblack race j bodymass index 40 40 north america latin america western europe eastern europe 6 hr 6 hr coronary artery disease diabetes previous episode heart failure 1 ii iii iv systolic diastolic heart rate beats min median nterminal probnp iqr pg ml median cardiac troponin iqr pg ml hemoglobin g dl serum creatinine mg dl intravenous nitrates intravenous dobutamine
subgroup_level, overall 65 65 male female white caucasian others 40 40 140 mmhg 140 mmhg 6 hrs 6 hrs reported ecrf reported ecrf 60 ml min 60 ml min yes eastern europe western europe latin america north america median median
subgroup_level, white asian coronary artery disease peripheral arterial disease previous stroke previous myocardial infarction diabetes target organ disease hypercholesterolaemia hypertension diabetes mellitus medication antithrombotic coagulant antiplatelet therapy lipidlowering medication statin rasaldosterone inhibitor betablockers beta1 selective calcium channel blockers dihydropyridine longacting shortacting nitrates diuretics
subgroup_level, current smoker n3804 former smoker n4428 55 years n824 55 years 65 years n2819 65 years 75 years n3523 75 years n1066 4060 cv disease n1761 6080 cv disease n4096 female n2049 male n6183 hispanic latino n588 hispanic latino n7644 white n6660 asian n1360 n83 usa n1293 asia n1337 europe 1 n2643 europe 2 n2314 restofworld n645 yes n1731 yes n1582
subgroup_level, total population tnfi naive tnfi exposed
subgroup_level, patients canvas canvasr 65 yr 65 yr male female white black asian north america central america south america europe rest world 30 30 systolic blood pressure 140 mm hg diastolic blood pressure 90 mm hg systolic blood pressure 140 mm hg diastolic blood pressure 90 mm hg 10 yr 10 yr 8 8 30 60 ml min 173 m2 60 90 ml min 173 m2 90 ml min 173 m2 yes
subgroup_level, participants baseline hbalc85 69 mmol mol 131 baseline hbalc 85 69 mmol mol 49 baseline uacr 300 mg g baseline uacr 300 mg g asia europe north america
subgroup_level, normoalbuminuria baseline 59 patients treated microalbuminuria baseline 29 patients treated macroalbuminuria baseline 11 patients treated
subgroup_level, uric acid tertile 1 52 mg dl uric acid tertile 2 52 651 mg dl uric acid fertile 3 651 mg dl uric acid tertile 3 651 mg dl
subgroup_level, 65 65 75 75 female male current exsmokers 0 1 60 60 12 12 2 form bud sfc
subgroup_level, 65 265 75 275 female male current exsmokers 128 0 21 60 260 163 s12 12 65 s1 22 231 laba lama others
subgroup_level, age 75 n2010 age 75 n8932
subgroup_level, bodymass indexf systolic diastolic cholesterol mmol liter tobacco use hypertension diabetes previous stroke previous myocardial infarction heart failure coronary artery disease peripheral arterial disease 30 ml min 30 60 ml min 60 ml min white black asian north america south america western europe israel australia south africa eastern europe asiapacific ace inhibitor arb calciumchannel blocker diuretic betablocker lipidlowering agent nsaid nontrial ppi age yr female sex
subgroup_level, 3 hr 36 hr men women 100to140mmhg 140 to160mmhg 2l60mmhg iiiv yes 60kg 60 90kg
subgroup_level, 65 65 70 70 male female coronary heart disease cerebrovascular disease peripheralartery disease diabetes heart failure 12 months 12 months europe north america china low high 125 125 140 140 75 75 85 85 25 25 30 30 medium current drinker former nondrinker current smoker former smoker nonsmoker ace inhibitor arb anti platelet therapy diuretic calcium channel blocker betablocker 54 54 66 66 85 85 101 101 35 35 43 43 124 124 143 143 106 106 151 151 110 110 125 125 60 60 70 15 15 55 55 60 normal microalbuminuria macroalbuminuria
subgroup_level, cat10 cat0
subgroup_level, pfo closure group n 238 antiplateletonly group n 235 anticoagulant group n 187 antiplateletonl group n 174
subgroup_level, patients prevalent kidney disease baseline patients without prevalent kidney disease baseline
subgroup_level, patients egfr 60 ml min 173m2 baseline patients egfr 60 ml min 173m2 baseline
subgroup_level, t2dm t1dm
subgroup_level, t2d t1d
subgroup_level, 30 kg m2 30 kg m2 male female white nonwhite north america europe 65 years 65 75 years 75 65 years 131 years 131 193 years 193 years yes statin without llt statin statin + llt statin alone statin + llt highintensity statin medium lowintensity statin 60 ml min 173 m2 60 90 ml min 173 m2 90 ml min 173 m2 30 mg g 30 300 mg g 300 mg g category 1 category 2 category 3 category 4 5 100 mg dl 100 130 mg dl 130 160 mg dl 160 mg dl 130 mg dl 160 190 mg dl 190 mg dl 30 mg dl 30 mg dl 18 mg dl 18 25 mg dl 25 32 mg dl 32 43 mg dl 43 mg dl low hdlc men 40mg dl women 50mg dl high hdlc men 40mg dl women 50mg dl 150 mg dl 150 200 mg dl 200 mg dl 150 mg dl 97 mg dl 97 133 mg dl 133 165 mg dl 165 226 mg dl 226 mg dl 30 50 mg dl 50 mg dl 508 ng ml 508 ng ml 242 ng ml 242 ng ml 7 7 9 9 controlled uncontrolled 1 u kg day 1 u kg day
subgroup_level, diabetes nondiabetes
subgroup_level, age median iqr age 75 female white bmi median iqr kg m2 diabetes mellitus current smoking hypertension heart failure peripheral artery disease prior ml index acs prior cabg index acs prior stroke atrial fibrillation cha2ds2vasc score median iqr score 13 score 49 lipidlowering agent statin aspirin stemi nstemi unstable angina total cholesterol median iqr mg dl ldlc median iqr mg dl hdlc median iqr mg dl triglycerides median iqr mg dl time acs randomization median iqr thienopyridine p blocker acei arb hscrp median iqr mg l egfr median iqr ml min 1 73m2 egfr 60 ml min 173m2
subgroup_level, overall prior stroke prior stroke males females age75 age75 caucasian noncaucasian diabetes diabetes current smoking smoking htn htn crcl 60 crci6090 crci90 prior llt prior llt nsteacs stemi ldlcsmedian ldlcmedian
subgroup_level, stroke vs tia large vessel atherosclerosis lacunar cardioembolic defined uncertain motor weakness aphasia 0 1 2 3 4 prior stroke atrial fibrillation coronary artery disease hypertension history peripheral artery disease current smoker systolic blood pressure mean sd mm hga hemoglobin a1c mean sd b age mean sd male sex
subgroup_level, 80+ 7079 6569 65 yes
subgroup_level, yes male female
subgroup_level, 65 years 65 years male female black african american white yes 259 mmol l 259 mmol l 30 kg m2 30 kg m2 6569f 5764 57
subgroup_level, 65 6575 5 male f emale north america south america w est europe east europe asia pacific white black asian es n 2 years 25 years 5 years previous myocardial infarction yes 4 mmol l 4 mmol l 01 2 38 overall
subgroup_level, yes current former never 09 09 60 60 overall pad
subgroup_level, women men
subgroup_level, women men
subgroup_level, women men
subgroup_level, age years asia eastern europe latin america north america western europe australia time since pah diagnosisc years idiopathic heritable associated ctd associated corrected associated hiv infection associated drug toxin 6min walk distance female sex
subgroup_level, 2 mg 4 mg 65 565 median median europe usa canada rest world 10 510 rf acpa positive rf acpa negative8 yes
subgroup_level, 2 mg 4 mg 3 s3 1 s2 etn yes etn ada yes ada inflix yes inflix 0 s1
subgroup_level, female male myocardial infarction hospitalization 55 yr 5564 yr 6569 yr 570 yr yes current smoker former smoker nonsmoker 213 mg dl 213250 mg dl 5251 mg dl 135 mg dl 135173 mg dl 5174 mg dl 39 mg dl 539 mg dl 133 mg dl 133230 mg dl 5 231 mg dl
subgroup_level, mmse 1226 mmse 1220 mmse 2126
subgroup_level, never daily former
subgroup_level, patients normoalbuminuria baseline patients microalbuminuria baseline patients macroalbuminuria baseline
subgroup_level, yes
arms;measures, placebo gemfibrozil risk reduction 95 cl p value
arms;measures, stent plus placebo stent plus abciximab balloon angioplasty plus abciximab p pt
arms;measures, sr ii b 5 cjl 3 placebo n476 pvalue
arms;measures, aspirin asa 19 934 placebo n 19 942 odds ratio 95 ci
arms;measures, clopidogrel n 864 ticlopidine n 870 p
arms;measures, placebo group n253 warfarin group n255 p value
arms;measures, calcium antagonist strategy cas events n noncalcium antagonist strategy ncas events n rr 95 cl
arms;measures, betacarotene n 18 405 placebo n 18 330 rr 95 ci
arms;measures, betacarotene n 18 405 placebo n 18 330 rr 95 ci
arms;measures, betacarotene placebo rr 95 ci p interaction
arms;measures, asp pla rr 95 ci p value
arms;measures, patients end point
arms;measures, losartan placebo prespecified hr 95 cl adjusted hr 95 cl
arms;measures, abciximab n635 placebo n585 p abciximab n377 placebo n425
arms;measures, abciximab n635 placebo n585 p abciximab n377 placebo n425
arms;measures, placebo n infliximab combined 3 mg kg 5 mg kg n difference 95 ci difference p value
arms;measures, postfibrinolysis angioplasty n 104 primary angioplasty n 108 pvalue
arms;measures, etoricoxib diclofenac hazard ratio 95 ci
arms;measures, p value placebo group n 210 f certolizumab group n 215
arms;measures, losartan placebo rrr 95 cl pvaluea interaction13
arms;measures, 065 041102 006
arms;measures, aspirin n18 652 placebo n18 618 p value
arms;measures, aspirin group n 18 652 181 467 person years placebo group n 18 618 180 652 person years hazard ratio 95 ci p value
arms;measures, patients 22 192 verapamilsr 11 094 atenolol 11 098 pvalue
arms;measures, verapamilsr strategy atenolol strategy hazard ratio 95 ci pvalue
arms;measures, placebo n 166 denosumab n 166 n 332
arms;measures, epa group n457 epa group n485 p value epa group n8862 epa group n8841
arms;measures, usual care n 276a p value8 proactive intervention n 436a usual care n 38la
arms;measures, intensive control n5571 noof patients percent standard control n5569 noof patients percent relative risk reduction 95 cl percent
arms;measures, value arm n risk
arms;measures, verapamil sr n 3622 atenolol n 3596 hr 95 cl
arms;measures, aspirinerdp clopidogrel patients total
arms;measures, rosuvastatin events patients placebo events patients hr 95 cl
arms;measures, n3 pufa events patients placebo events patients hr 95 cl
arms;measures, aliskiren n567 hydochlorothiazide n557 p
arms;measures, abciximab n401 placebo n399 p
arms;measures, placebo ranozaline hr
arms;measures, placebo sal 50 mg fp 500 mg sfc 50 mg 500 mg total
arms;measures, nonepa number epa hr events 95ci p
arms;measures, tiotropium control ratio 95 ci p value
arms;measures, rosuvastatin events patients placebo events patients hr 95 cl pvalue
arms;measures, primary pci n 806 abciximabfacilitated pci n 818 reteplase abciximabfacilitated pci n 828 p value
arms;measures, primary pci ret abx facil pci hazard ratio 95 cl pvalue
arms;measures, primary pci abxfacil pci hazard ratio 95 cl pvalue
arms;measures, alteplase placebo odds ratio 95 cl p value
arms;measures, azathioprine n 170 infliximab n 169 combination therapy n 169 patients n 508 p valued
arms;measures, control difference
arms;measures, events n
arms;measures, extendedduration enoxaparin n n placebo n n absolute risk difference ci
arms;measures, n placebo n 1544 salmeterol n 1542 fp n 1552 sfc n 546
arms;measures, ivabradine group placebo group hr
arms;measures, interaction p value placebo n rate rosuvastatin n rate hazard ratiof 95 clf subgroup p valuef
arms;measures, rolofylline placebo
arms;measures, bosentan placebo hr 95 cl
arms;measures, placebo n 1231 sal n 1232 fp n 1248 sfc n 1240 total ho population n 4951 total population n 6112
arms;measures, asa pla r r 95 ci rr 95 ci
arms;measures, patients ra psa n 280 patients without ra psa n 18 609 p
arms;measures, atorvastatin 80 mg n 156 atorvastatin 10 mg n 55 simvastatin 40 mg n 69 p+ atorvastatin 80 mg n 9 278 atorvastatin 10 mg n 4 951 simvastatin 40 mg n 4 380 pt
arms;measures, usual care n 276a p value8 proactive intervention n 436a usual care n 38la
arms;measures, vorapaxar placebo 3yr km hr 95ci p value interaction
arms;measures, placebo veflonzumao estimated difference 35 cl p value
arms;measures, statin n 252 control n 252 p value
arms;measures, ff 100 gg n 1 010 ff vi 100 25 gg n 1 009 total n 2 019
arms;measures, indacaterol 150 ug n 187 indacaterol 300 ug n 188 placebo n 186 total n 561
arms;measures, pharmacoinvasive n944 primary pci n948 relative risk 95 cl pvalue
arms;measures, fp sal 250 50 pg n 314 sal 50 pg n 325 total n 639
arms;measures, saxa+dapa+met n 179 saxa+met n 176 dapa+met n 179 total n 534
arms;measures, rivaroxaban pvalue placebo
arms;measures, placebo saxagliptin
arms;measures, placebo n 107 p vs placebo
arms;measures, liraglutide 30 mg mean n placebo mean n estimated difference
arms;measures, hr 95 cl warfarin placebo p
arms;measures, apixaban placebo apixaban vs placebo
arms;measures, cangrelor clopidogrel pvalue
arms;measures, pbo n 261 brv 100 mg day n 253 brv 200 mg day n 250
arms;measures, aliskiren n 55 placebo n 60 pvalue aliskiren n 170 placebo n 173
arms;measures, aliskiren n 55 placebo n 60 pvalue aliskiren n 170 placebo n 173
arms;measures, treatment arm pvalue
arms;measures, subgroup stent n 459 medical therapy n 472 difference p value
arms;measures, subgroup value stent medical therapy hazard ratio 95 cl
arms;measures, placebo n 582 selexipag n 574 patients n 1156
arms;measures, p value pad n 20 017 pad n 1 143
arms;measures, rosuvastatin placebo odds ratio 95 cl trend het test
arms;measures, rosuvastatin placebo percentage difference 95 cl heterogeneity test
arms;measures, rosuvastatin placebo percentage difference 95 cl trend het test
arms;measures, pbo+mtx n213 czp+mtx n655 patients n868
arms;measures, liraglutide placebo hazard ratio 95 ci
arms;measures, us n4097 nonus n6845 p value
arms;measures, cangrelor clopidogrel 95 ci
arms;measures, pioglitazone events n placebo events n hr 95 cl pvalue
arms;measures, stent hazard ratio 95 ci pvalue medical therapy
arms;measures, clopidogrel 95 cl inter pvalue
arms;measures, statin users n276 statin nonusers n348 p value
arms;measures, statin users n276 statin nonusers n348 p value hr 95 ci
arms;measures, placebo n 132 tocilizumab n 225 pvalue
arms;measures, peripheral revascularization n 4 911 peripheral revascularization n 934 p value
arms;measures, patients receiving enl incidencea patients receiving lcz hr enl vs lcz 95 cl p value adjusted hr enl vs lcz 95 cl
arms;measures, placebo n294 50 mg sirukumab every 4 weeks n292 100 mg sirukumab every 2 weeks n292 total n878
arms;measures, pioglitazone pts n placebo pts n hr 95 cl pvalue
arms;measures, copd n 1060 copdplacebo n 522 copdrosuvastatin n 538 p
arms;measures, unadjusted adjusted
arms;measures, abatacept placebo estimated difference 95 ci abatacept openlabel abatacept placebo openlabel abatacept
arms;measures, linagliptin placebo treatment difference 95 ci
arms;measures, p value total n344 phi n171 ppci n173
arms;measures, ppci in1671 phi n161 rr 96 cl
arms;measures, placebo tiotropium difference tiotropium placebo ml 95 ci p values
arms;measures, simva n346 n ez simva n336 n hr 95 cl arr 95 cl simva n8728 n ez simva n8727 n
arms;measures, pioglitazone placebo risk difference
arms;measures, liraglutide 30 mg placebo liraglutide 30 mg etd 95 ci
arms;measures, pbo simva 7yr km rale eze simva 7yr km rale hr 95ci
arms;measures, diabetes absent 13202 726 diabetes present 4933 274 p value
arms;measures, pvalue trend ef40 hfref n 4323 57 ef 4049 hfmref n 1322 17 ef 50 hfpef n 1953 26
measures, event total
measures, number reporting migraine 12month questionnaire
measures, events 100 personyr
measures, patients n baseline mean sd week 26 mean sd comparison baseline mean change 95 ci comparison placebo mean difference 95 ci
measures, patients n baseline mean sd week 26 mean sd comparison baseline mean change 95 ci comparison placebo mean difference 95 ci
measures, patients n baseline geometric mean cv week 26 geometric mean cv comparison baseline mean change 95 ci comparison placebo mean difference 95 ci
measures, patients n baseline mean sd week 26 mean sd comparison baseline mean change 95 ci comparison placebo mean difference 95 ci
measures,
measures, strategy hr 95 cl
measures, n ms ri 149 ri 622 n 609
measures, amiodarone vs placebo hazard ratio 975 cl icd therapy vs placebo hazard ratio 975 cl
measures, mean baseline ldlc mmol l
measures, p value
measures, primary end point events total
measures, n w n mean sd range gm
measures, n event rate w event rate
measures, treatment difference
measures, n pyr rate
measures, n n rate
measures, number patients event relative risk reduction 95 cl
measures, n2497 n 2514
measures, n k rate n
measures, hazard ratio 95ci p value heterogeneity p value
measures, incidence rate 1000personyears hazard ratiof 95ci p value f
measures, n811 n864 n836
measures, n645 n590 n605
measures, n adverse outcome death nonfatal mi nonfatal stroke
measures, difference baselinea difference placeboa
measures, imt 1 aggressive 2 standard 3 group dif 4 lvmi 61 aggressive 7 standard 8 group dif 9 pval 5 pval 10
measures, age group sex race body mass index category l weight median interquartile range kg blood pressure mean sd mm hg smoking status diabetes concomitant therapy hctz hydrochlorothiazide based wilcoxon 2sample ranksum tests age body mass index tests systolic diastolic blood 2 tests categorical variables data missing patients age median interquartile range
measures, incidence hazard ratio 95 confidence interval p
measures, rates per 100 patientyears hazard ratio 95 ci
measures, evenls evenls per 1 000 palienlyears
measures, pvalue n mean se atio pla
measures, number patients mean u+58eb sd
measures, baseline mean u+58eb sd week 18 mean u+58eb sd lsmean change baseline 95 ci lsmean betweengroup difference 95 ci
measures, baseline mssbp msdbp mm hg change bp mm hg mssbp msdbp
measures, events patients
measures, n n i1
measures, n_ 11 ni
measures, patients n hospitalizations n
measures, baseline median iq range 3month followup median iq range difference median p net difference
measures, hr 95 cl p 1 interaction women vs men
measures, n ml pred
measures, least square mean se difference se pvalue 95 cl
measures, percentage patients reaching target
measures, preamendment postamendment total population
measures, baseline mean mg dl final mean mg dl mean change se
measures, n n 139 1716 81 n n 138 1711 81
measures, 95 ci p value baseline hba1c mean se week 12 hba1c mean se adjusted change baseline mean se
measures, baseline fpg mean se week 12 fpg mean se mean se 95 ci mean se p value
measures, avm u+25b3 se metu+25b3 se treatment difference avm u+25b3 se met u+25b3 se avm u+25b3 se
measures, interaction p value n n hr 95 cl
measures, patients indacaterol placebo treatment difference ml
measures, n baseline amu+25b3u+58eb se ama u+58eb se
measures, hazard ratio 95 cl
measures, percent patients
measures, n 179 n 445 n 193 n 434 n 189 n 404 n 435
measures, difference ls mean8 95 cl
measures, absolute change percent change
measures, events events odds ratio pfor
measures, events patients
measures, hr 95 ci p
measures, n baseline change baseline
measures, n difference placebo difference placebo
measures, n1 n2 lsm 95 ci pvalue
measures, treatment group pvalue
measures, n
measures, age years women white african american asian bmi kg m2 duration diabetes years hba1c hba1c mmol mol 8 64 mmol mol 8 9 64and 75 mmol mol 9 75 mmol mol fpg mg dl ppg mg dl fasting cpeptide ng ml egfr ml min 173 m2
measures, baseline mean sd mmol mol n adjusted mean change baseline 95 ci mmol mol mean 95 ci difference vs saxa+dapa+met
measures, baseline mean sd mmol mol n adjusted mean change baseline 95 ci mmol mol mean 95 ci difference vs saxa+dapa+met
measures, baseline mean sd mmol mol x n proportion 95 ci adjusted baseline hba1c mean 95 ci difference vs saxa+dapa+met
measures, events patients
measures, arr 95 ci annt bnnh 95ci
measures, odds ratio adj 95 cl p value
measures, total worsened change improved p value
measures, adjusted meanse 95 ci pvalue
measures, km event rate hr 95 ci p value
measures, n n hazard ratio 95 cl interaction pvalue
measures, baselinemean _ sdmg dl ls mean change baseline _ se baselinemean _ sd mg dl baselinemean _ sdmg mg
measures, estimated means difference pooled analysis
measures, estimated response rate odds ratio pooled analysis
measures, 328 2432 101 1220 434 383
measures, value odds ratio versus placebo 95 ci p value versus placebo
measures, n mtss cfb meansd
measures, patients events
measures, n e r n
measures, rate n hr 95 ci
measures, events total
measures, n 3yr km event rate
measures, event total hr cl 95
measures, p value trend risk score category points
measures, ratet 95 cl hr 95 cl
measures, n 1939 n 1937
measures, early n201 established n172 early n207 established n190 early n107 established n79
measures, ls mean change baseline1 difference ls means 95 ci 4 ls mean change baseline2 ls mean change baseline3
measures, n
measures, number patients difference 95 cl
measures, crude analysis n bivariate frailty model statin users vs nonusers
measures, participants p value mra vs mra
measures, pav mean 95 ci
measures, patients n baseline change week 104
measures, n n
measures, baseline week 24 change baseline difference placebo
measures, sri response 95 ci pvalue
measures, total patients n159 patients entering pt period n108 total patients n157 patients entering pt period n71
measures, n mean sd
measures, acr20 response week 16 n
measures, baseline 1yr
measures, n1939 n1937
measures, hr 95 cl p
measures, patients ind gly sfc annualized rate ind gly sfc rate ratio 95 ci
measures, age mean sd years female n 01 24 5 baseline focal seizure frequency 28 days median q1 q3
measures, baseline n week 30 mean change week 30 mean difference seb pvalue n mean sd
measures, hazard ratio 95 cl 093 075 114
measures, acr20 acr50 acr70
measures, noof participants per 1000 patientyr
measures, n analysed change baseline difference vs placebo difference vs placebo
measures, number patients laba+ics versus indzgly lsm difference 95 cl
measures, number patients laba lama versus ind gly lsm difference 95 cl
measures, panentstotal 1
measures, lipid difference mg dl participants events
measures, n mean se
measures, baseline week 12 change baseline week 12 difference vs placebo week 164 change baseline week 164 week 28 change baseline week 28
measures, patients total
measures, events n risk
measures, events n risk
measures, incidence rate per 100 personyears hr 95 ci
measures, incidence rate unadjusted hr unadjusted hr unadjusted irr
measures, n event reductionin risk 95 ci
measures, rate
measures, py27667 py29576 py26128
measures, py21872 py1948 py16308
measures, ls mean ci b p value c
measures, n mean sd inter
measures, 64 n63 n 176 n 181 n173
measures, n 81 n 83
measures, 1200 mg n 201 2400 mg n 196
measures, baseline ontreatment
measures, db baseline week 0 pt baseline week 52
measures, n17717 n6830 n6753 n6492 n3286 n3206 n4037 n2030 n2007 n3054
measures, change 95 cl baseline six weeks
measures, n py
measures, n py
outcomes, total death death large mi large mi tvr
outcomes, hba1c fpg mg dl
outcomes, primary outcome death cause nonfatal ml nonfatal stroke cardiovascular death cardiovascular hospitalization
outcomes, total cataract total cataract extraction
outcomes, total major cv event stroke ischemic stroke myocardial infarction
outcomes, ml c itherchdt vasculars noneh
outcomes, tc tg+ hdlc nonhdlc apo b apo ai
outcomes, clinical ae n laboratory ae n
outcomes, ldlc mmol l mean tg mmol l median hdlc mmol l mean nonhdlc mmol l mean total c mmol l mean apo b apo al ratio mean hscrp mg l median key tc triglyceride hscrp ldlc lowdensity lipoprotein fc fasting glucose ncep atp category include ar _ 3 indicated char leastsquare means except tc note treatment subgroup
outcomes, death myocardial infarction death myocardial infarction targetvessel revascularization mace major bleeding hemorrhagic stroke minor bleeding blood transfusion profound thrombocytopenia 20x109 l moderate thrombocytopenia 50x109 l mild thrombocytopenia 100x 109 l
outcomes, esrd esrd death
outcomes, chd+ cerebrovascular disease men 71 1248 129 stroke total mortality
outcomes, chd+cerebral infarction stroke total mortality
outcomes, esrd death doubling serum creatinine esrd death
outcomes, number patients fractures fractures site specified lower limb fractures hip fracture others ankle fracture femur fracture fibula fracture foot fracture lower limb fracture patella fracture tibia fracture skull facial bone fractures spinal fractures thoracic cage fractures upper limb fractures clavicle fracture hand fracture humerus fracture radius fracture upper limb fracture wrist fracture
outcomes, number patients fractures fractures site specified lower limb fractures hip fracture others ankle fracture femur fracture fibula fracture foot fracture lower limb fracture patella fracture tibia fracture pelvic fractures skull facial bone fractures spinal fractures thoracic cage fractures upper limb fractures clavicle fracture forearm fracture hand fracture humerus fracture radius fracture upper limb fracture wrist fracture
outcomes, primary outcome allcause mortality nonfatal ml nonfatal stroke
outcomes, primary outcome death nontatal ml nonfatal stroke fatal nonfatal ml fatal nonfatal stroke cv death
outcomes, lipid profile fatty acid profile glucose metabolism blood pressure
outcomes, major cardiovascular events allcause death cardiovascular death
outcomes, one copd exacerbations n n median time first exacerbation months 95 ci mean number exacerbations per patientyear 95 ci
outcomes, primary endpoint4 allcause mortality coronary events5
outcomes, allcause cardiovascular worsening heart failure noncardiovascular
outcomes, ldl cholesterol mmol l hdl cholesterol mmol l triglycerides mmol lf hscrp mg l
outcomes, primary endpoint cardiovascular death myocardial infarction recurrent ischemia
outcomes, fev1 prebronchodilator fev1 postbronchodilator fvc prebronchodilator fvc postbronchodilator
outcomes, vte day 28+ major bleeding events
outcomes, hdlc tg ldlc
outcomes, major cvd stroke ischemic stroke hemorrhagic stroke tia myocardial infarction coronary revascularization cvd death
outcomes, cv death ml ischemic stroke
outcomes, total cholesterol mg dl ldl cholesterol mg dl hdl cholesterol mg dl total cholesterohhdl cholesterol ratio ldl cholesterohhdl cholesterol ratio triglycerides mg dl apo b mg dl apo ai mg dl apo bapo ai ratio
outcomes, disease duration b 2 years n 93 disease duration 2 b5 years n148 disease duration 5 years n 536
outcomes, sedbp sesbp
outcomes, 10year framingham chd risk total cholesterol lowdensity lipoprotein cholesterol diastolic blood pressure mm hg systolic blood pressure mm hg
outcomes, total c ldlc triglyceride nonhdlc apob tc hdlc
outcomes, teaes drugrelated teaes discontinuations teaes teaes 5 treatment group headache bronchitis edema peripheral muscle spasms hvookalemia
outcomes, crp il6 fibrinogen
outcomes, total asthma symptom score albuterol use aqlq score change baseline predicted fev1
outcomes, mean sd change prebronchodilator fev1 l
outcomes, renal events cvd events composite events
outcomes, hba1c fpg mg dl weight kg
outcomes, minimental state examination insulin glargine vs standard care b digit symbol substitution insulin glargine vs standard care
outcomes, minimental state examination omega3 fatty acids vs placebo b digit symbol substitution omega3 fatty acids vs placebo
outcomes, ischemic stroke ischemic stroke hemnrrhnaic cnnversinn ischemic stroke without hemorrhagic conversior stroke
outcomes, major cardiovascular event colorectal cancer noncolorectal cancer major gastrointestinal bleeding total total adjusted weight 05 gastrointestinal bleeding total adjusted weight 025 gastrointestinal bleeding total adjusted weight 01 gastrointestinal bleeding
outcomes, cv death mi ischemic stroke cv death mi ischemic stroke hospitalization hf coronary revascularization ua cv death mi ischemic stroke hospitalization hf
outcomes, cv death ml ischemic stroke cv death ml ischemic stroke hosp hf cor revasc ua cv death ml ischemic stroke hosp hf primary renal endpoint primary renal endpoint death initiation insulin new antihyperglycemic rx
outcomes, fevi auc03l trough fevi l
outcomes, cvd mi stroke cv death mi stroke death cvd mi cvd mi stroke recurrent ischemiaurgent revascularization cvd mi stroke recurrent ischemia urgent revascularization hospitalization unstable angina recurrent ischemia urgent revascularization hospitalization unstable angina coronary revascularization
outcomes, recurrent vte statin use vs nonuse
outcomes, major bleeding statin use vs nonuse
outcomes, primary secondary mi cv mortality noncv mortality allcause mortality nonfatal ischemic stroke coronary revascularization heart failure hypoglycemia unstable angina initiation dialysis renal transplantation creatinine 60 mg dl 530 mmol l end point
outcomes, primary ep cvd mi ri cv death ml recurrent ischemia rec ischemia requiring revasc rec ischemia leading hasp rec ischemia due ecg changes rec ischemia due worsening angina
outcomes, hdlcy ldlcz ldlc hdlcx nonhdlc triglycerides
outcomes, acr20 response acr50 response acr70 response pasi75 response pasi90 response
outcomes, acr response mean change radiographic end points
outcomes, cv death mi ischemic stroke death cv death mi ischemic stroke stent thrombosis timi major bleeding timi major minor bleeding
outcomes, cdai 10t cdai 28 sdai 11 sdai 33 das284 esr 32t das284 esr 26 haqdi improvement 022 haqdi improvement 05
outcomes, cv death mi stroke cv death mi stroke ucr cv death ml stroke ischemic stroke ucr
outcomes, fracture followup p value
outcomes, primary endpoint death mi idr st death ml ischemia driven revascularization stent thrombosis
outcomes, death nonfatal stroke nonfatal myocardial infarction hospitalization acs arterial revascularization hospitalization heart failure first mace hyperkalemia 55 meq l elevated creatinine 177 pmol l elevated bun 143 meq l
outcomes, cv death hf hospitalization n cv death n hf hospitalization n allcause death n
outcomes, first coprimary outcome second coprimary outcome cardiovascular death
outcomes, primary outcomes secondary outcomes
outcomes, primary outcomes secondary outcomes
outcomes, efficacy primary end point death mi idr st key secondary end point st mi qwave mi idr death cause death cardiovascular causes death qwave mi idr death st safety noncabgrelated bleeding gustodefined bleeding primary safety end point severe lifethreatening moderate severe moderate mild timidefined bleeding major minor acuitydefined bleeding blood transfusion efficacy safety net adverse clinical events death mi idr st gustodefined moderate severe bleeding
outcomes, hf hospitalization cardiovascular death hf hospitalization cardiovascular death allcause mortality significant worsening kccq clinical score 5 8 months3
outcomes, elevated serum potassium 60 mmol l drug discontinuation due death dose reduction average daily dose target
outcomes, hba1c fpg mg dl 2h pmg mg dl
outcomes, mi macce gusto moderate severe bleeding
outcomes, parameter hbalc tx difference vs pbo median change baseline se 1 fpg tx difference vs pbo median change baseline se 1 insulin tx difference vs pbo median change baseline se 1 cpeptide tx difference vs pbo median change baseline se 1 homa_b tx difference vs pbo median change baseline se 1 homajr tx difference vs pbo median change baseline se 1 lipid parameters lowdensity lipoprotein cholesterol tx difference vs pbo ls mean change baseline se lipoprotein tx difference vs pbo ls mean change baseline se triglycerides tx difference vs pbo ls mean change baseline se highdensity lipoprotein cholesterol tx difference vs pbo ls mean change baseline se apolipoprotein b tx difference vs pbo ls mean change baseline se
outcomes, mi idr st st death ml qmi idr
outcomes, diseaseprogression composite outcome allcause mortality absolute fvc decrease 10 6mwd decrease 50 allcause ipfrelated absolute decrease 10 relative decrease 10 absolute decrease 5 relative decrease 5 death absolute fvc decrease 10 death 6mwd decrease 50 respiratoryrelated
outcomes, 4point mace 3point mace cv death hospitalization unstable angina myocardial infarction stroke allcause death hospitalization heart failure
outcomes, hyperkalemiab severe hyperkalemiac
outcomes, total patients n aes n tachyarrhythmias n supraventricular tachyarrhythmias incl atrial ventricular tachyarrhythmias ischaemic heart disease n myocardial infarction ischaemic heart disease noninfarction cardiac failure n cerebrovascular disorders n haemorrhagic ischaemic hypertension n
outcomes, hba1c fpg mmol l
outcomes, allcause mortality cv mortality non cv mortality allcause hospitalization
outcomes, t2dm duration years hba1c fpg mmol l 2h ppg mmol l daily iglar dose week 30 u
outcomes, death mi idr st death mi idr st st arc definite ipst gusto moderate severe gusto severe gusto moderate timi major minor timi major timi minor acuity major death mi idr st gusto severe bleeding death mi idr st gusto moderate severe bleeding death mi idr st timi bleeding
outcomes, prebronchodilation fev1 postbronchodilation fev1 prebronchodilation fvc postbronchodilation fvc
outcomes, hba1c weight kg serum uric acid mg dl systolic blood pressure mmhg hemoglobin g dl ldlcholesterol mg dl hdlcholesterol mg dl
outcomes, baseline week 24 change baseline mean se
outcomes, diabetes diabetes
outcomes, stroke etiology ischemic stroke hemorrhagic stroke primary trial end point ml coronary revascularization urgent coronary revascularization unstable angina cv death coronary heart disease death allcause mortality cv death ml stroke
outcomes, ibdq total score week 52 mean se
outcomes, body weight body weight kg waist circumference cm hba1c fpg mmol l sbp mm hg dbp mm hg iwqollite total score arbitrary units # iwqollite physical score arbitrary units
outcomes, body weight body weight kg waist circumference cm hba1c fpg mmol l sbp mm hg dbp mm hg iwqollite total score arbitrary units # iwqollite physical score arbitrary units
outcomes, permanently stopped study drug adverse events alt ast 3x uln gallbladderrelated aes rhabdomyolysis rhabdomyolysis myopathy rhabdomyolysis myopathy myalgia ck elevation 5x uln cancer
outcomes, alt ast 3x uln gallbladderrelated aes rhabdomyolysis myopathy rhabdomyolysis myopathy myalgia ck elevation 5x uln cancer
outcomes, alanine aminotransferase aspartate aminotransferase 3x upper limit normal n432 cholecystectomy n267 gall bladder adverse event n603 rhabdomyolysis n31 hemorrhagic stroke n102 cancer n1480
outcomes, cv death + hf hospitalization hf hospitalization recurrent hf hospitalization cv death allcause hospitalization allcause death
outcomes, clinical ae drug related ae serious ae discontinuations due ae myopathyt deaths alt ast 3 times uln consecutive# cpk 10 times uln
outcomes, yes n 481 n 16 011
outcomes, major cardiovascular cardiovascular cause mortality major coronary major cerebrovascular nephropathy cancer
baseline_level_1, age yr male sex weight kg diabetes hypertension smoker coronaryartery bypass grafting percutaneous coronary revascularization myocardial infarction cerebrovascular accident l eft anterior descending coronary artery r ight coronar artery left circumflex artery bypass graft restenotic vessel
baseline_level_1, history hypertension c history diabetes smoking alcohol intake exercise least weekly postmenopausal use hormone replacement therapy randomized active yitamin e age years body mass index kg m2
baseline_level_1, age years women n diabetes n smoking habit n hypercholesterolemia n systemic arterial hypertension n previous myocardial infarction n previous balloon angioplasty n previous bypass surgery n unstable angina n platelet count x 103 mm3
baseline_level_1, women men age yr disease duration yr mmse points adascog score serum ldl cholesterol csf 340 pm csf 342 pm csf lathosterol jlg cll csf cholesterol csf 24shydroxy mers disease assessment density lipoprotein csf
baseline_level_1, medication use blood pressure mean sd mm hg lipids mean sd mg dlt
baseline_level_1, age yr female sex race ethnic group bodymass index history diabetes 2 previous venous thromboembolisms family history venous thromboembolism factor v leiden prothrombin mutation duration fulldose warfarin therapy enrollment mo time cessation fulldose warfarin therapy enrollment mo
baseline_level_1, race
baseline_level_1, medical characteristics characteristics index ml ejection fraction category treatment index ml current prescribed medications psychosocial risk factors
baseline_level_1, age mean sd race ethnicity white bmi mean sd kg m2 myocardial infarction abnormal angiogram prior ml abnormal angiogram angina pectoris cabg 1 month ago pci 1 month ago cabg pci stroke left ventricular hypertrophy unstable angina 1 mo ago arrhythmia heart failure class llll peripheral vascular disease diabetesf hypercholesterolemiat renal impairmentt aspirin antiplatelet agent nsaids antidiabetic medication lipidlowering agent potassium supplement hormone replacement
baseline_level_1, age yr women bodymass index arterial hypertension type 2 diabetes current smoker hypercholesterolemia prior myocardial infarction prior aortocoronary bypass surgery angina class iii iv multivessel disease left ventricular ejection fraction duration clopidogrel pretreatment hr median 25th75th percentiles drug therapy admission aspirin ace inhibitors betablockers calciumchannel antagonists nitrates statins
baseline_level_1, patients ft asian black white hispanic clinical parameters age yr male gender body mass index kg m2 systolic bp mmhg diastolic bp mmhg mean bp mmhg oral antidiabetic drugs insulin smoking laboratory parameters hbalc total cholesterol mg dl hdl cholesterol mg dl triglycerides mg dl potassium meq l uric acid mg dl creatinine clearance ml min per 173 m2 mean sd range median albumin creatinine ratio g mg
baseline_level_1, mean age yrs medical history health habits
baseline_level_1, sex pace 36 baseline lipid lipoprotem values
baseline_level_1, age yr female sex nonwhite race ejection fraction diabetes pulmonary disease hypercholesterolemia hypertension atrial fibrillation flutter syncope electrophysiological study weight ibj systolic blood pressure mm hg diastolic blood pressure mm hg heart rate beats min serum sodium meq liter serum creatinine mg dl medication use
baseline_level_1, smoking status bodymass index menopausal status use hrt hypertension blood pressure hyperlipidemia diabetes parental history myocardial infarction 60 yr age 10yr risk coronary heart disease risk factors
baseline_level_1, age yr male sex white race f weight kg hypertension hyperlipidemia current smoker diabetes mellitus prior myocardial infarction prior percutaneous coronary intervention anterior myocardial infarction tenecteplase reteplase alteplase streptokinase none initial aspirin unfractionated heparin lowmolecularweight heparin neither median interquartile range angiography betablockers statins ace inhibitors angiotensinreceptor blockers openlabel clopidogrel completion study drug ticlopidine completion study drug
baseline_level_1, age years weight kg bmi kg m2 men diabetes metabolic syndrome b ldlc mmol l tc mmol l hdlc mmol l tg mmol l c nonhdlc mmol l apo b g l apo al g l hscrp mg l c fibrinogen pmol l c
baseline_level_1, age years race patient history disease atorvastatin dose baseline lipids mean sd mmol 1
baseline_level_1, age bmi smoking status alcohol use drinks wk physical activity kcal wk menopausal status use ht family history cancerf randomized receive vitamin e randomized receive beta carotene
baseline_level_1, age years race n patient history disease n concomitant therapies n baseline lipids mean sd mmol l
baseline_level_1, race ara functional class global assessment disease status score womac score health assessment questionnaire score sf36 score
baseline_level_1, age mean sd women arterial hypertension diabetes insulintreated diabetes current smoking hypercholesterolemia prior myocardial infarction prior aortocoronary bypass surgery body mass index mean sd elevated troponin 003 pg l elevated creatine kinase mb 24 u l hours clopidogrel loading mean sd multivessel disease left ventricular ejection fraction mean sd left circumflex artery complex lesions lesion length mean sd mm vessel size mean sd mm diameter stenosis mean sd baremetal stent statins pblockers ace inhibitors nitrates calcium antagonists
baseline_level_1, gender smoking age years bmi kg m2 weight kg dbp mmhg sbp mmhg hba1c hemoglobin gm dl serum creatinine mg dl cholesterol mg dl albuminuria g g proteinuria3 g day
baseline_level_1, gender n age years mean range race n diagnoses risk factors n bmi kg m2 lipid lipoprotein values mg dl hs crp mg l
baseline_level_1, randomisation scheme demographics qualifying event time longest event randomisation rankin grade additional investigations history blood pressure mm hg type vessel involved antithrombotic drug use time event dose aspirin
baseline_level_1, age years female previous myocardial infarction pci cabg previous stroke ortransient ischaemic attack peripheralartery disease current smokers diabetes hypertension serum cholesterol mg l systolic blood pressure mm hg diastolic blood pressure mm hg medications antiplatelet agents p blockers lipidlowering agents diuretics calciumchannel blockers
baseline_level_1, demographics age years women bodymass index kg m2 systolic blood pressure mm hg diastolic blood pressure mm hg hypertension diabetes current past smoker men lipid concentrations total cholesterol mmol l triglyceride mmol l hdl cholesterol mmol l ldl cholesterol mmol l lipoprotein mmol l medications antihypertensive drugs calciumchannel blockers ace inhibitors arb p blockers diuretics aspirin
baseline_level_1, race n metabolic syndrome characteristics n
baseline_level_1, therapy discharge age women diabetes arterial hypertension body mass index kg m2 current smoking hypercholesterolemia 240 mg dl prior myocardial infarction prior pci prior coronary artery bypass surgery interval clopidogrel loading h serum creatinine mg dl elevated troponin 003 xg l elevated creatine kinasemb 24 u l
baseline_level_1, race ethnic background f region time since diagnosis diabetes anthropometric characteristics blood pressure insulin sensitivity 8cell function total cholesterol mg dl ldl cholesterol mg dl hdl cholesterol mg dl triglycerides mg dl
baseline_level_1, baseline characteristic medical treatment time symptoms treatment randomization
baseline_level_1, demographics disease characteristics medications n extent disease n healthrelated quality life
baseline_level_1, risk factors hmgcoa rl medication use
baseline_level_1, demographic characteristics race comorbid diseasesa diabetesb recurrent infections 1 per year cardiovascular risk factors
baseline_level_1, intestinal area involved n antibodies infliximab n concomitant medication n
baseline_level_1, previous vascular disease blood pressure control major risk factors
baseline_level_1, age nyha class blood pressure mm hg medical history cholesterol mmol liter serum creatinine estimated gfr ntprobnp pmol literj hscrp mg liter current medication
baseline_level_1, race ethnicity n
baseline_level_1, age
baseline_level_1, sex race ethnic group known duration diabetes yr blood pressure mmhg medical history laboratory variables serum cholesterol mg dld
baseline_level_1, time since diagnosis diabetes
baseline_level_1, age category sex race prior treatment severity hypertensionb diabetic status
baseline_level_1, smoking status exercise alcohol consumption postmenopausal hormone use
baseline_level_1, sbp mean sd mmhg dbp mean sd mmhg heart rate mean sd bpm age mean sd year female caucasian prior myocardial infarction arrhythmias angina pectoris heart failure class iiii coronary revascularization stroke stroke tia diabetes renal impairment smoking ever
baseline_level_1, cholesterol mg dl diabetes therapy aspirin use 80 mg carotid cardiac
baseline_level_1, stroke total cholesterol mmol l ldl cholesterol mmol l hdl cholesterol mmol l triglyceride mmol l aa mol epa mol epa aa ratio sbp mm hg dbp mm hg antiplatelet agents antihypertensive agents sbp indicates systolic blood pressure dbp diastolic blood pressure aa arachidonic acid epa eicosapentaenoic acid values age bmi total cholesterol ldl cholesterol hdl cholesterol sbp dbp aa epa epa aa ratio represent mean values represent median interquartile range p values differences epa epa groups age male smoker bmi kg m2 diabetes hypertension coronary artery disease
baseline_level_1, cardiovascular risk factors preoperative cardiac medications surgery anaesthesia analgesia
baseline_level_1, 65 65 male female white black hispanic lean 25 kg m2 overweight 25 30 kg m2 obese 30 kg m2 systolic diastolic current past never aspirin statins hormone therapy oral contraceptives
baseline_level_1, male n age years mean sd race n asian black white current smoker n bmi kg m2 mean sd sbp mm hg mean sdc dbp mm hg mean sdc heart rate beats min mean sd tc mg dl mean sd ldlc mg dl mean sd hdlc mg dl mean sd tg mg dl mean sd 10year framingham chd risk
baseline_level_1, patients male female white black asian native american pacific islander mean age years sd 65 years 65 years msdbp mmhg sd mssbp mmhg sd mean weight kg sd mean bmi kg m2 sd diabetes mellitus serum creatinine mean sd pmol l
baseline_level_1, age race severity
baseline_level_1, demographic race ethnicity medical history medications blood pressure
baseline_level_1, mean age sd age 70 female race ethnicity white black hispanic asian multiracial mean bmi kg m2 sd abnormal angiogram concordant stress test abnormalities angina pectoris cabg pci stroke tia left ventricular hypertrophy unstable angina arrhythmia heart failure class llll peripheral vascular disease smoking history ever smokingcurrent diabetes dyslipidemia renal impairment cancer medications lipidlowering agent nitrates aspirin antiplatelet agents nsaids antidiabetic medications hormone replacement others baseline sbp mm hg baseline dbp mm hg baseline heart rate beat min values expressed percentages unless otherwise indicated bmi body mass index cabg coronary artery bypass ischemic attack nsaids nonsteroidal antiinflammatory drugs sbp systolic bp dbp diastolic bp history currently taking antidiabetic lipidlowering medications
baseline_level_1, region ethnic group tobacco use alcohol use exercise category time qualifying stroke randomization toast classification qualifying stroke score modified rankin scale baseline nihss score #
baseline_level_1, ethnic group clinical history smoking status use medication baseline toast classification score modified rankin scale baseline nih stroke scale
baseline_level_1, patients characteristics heart disease risk factors nyha class medical history heart failure cause physical examinations ecg findings medical treatment
baseline_level_1, patients characteristics heart disease risk factors nyha class medical history cause heart failure physical examination ecg findings medical treatment
baseline_level_1, mean sd women osteoarthritis rheumatoid arthritis smoker diabetes lowdose aspirin use proton pump inhibitor use traditional nsaid use methotrexate use dmard use
baseline_level_1, age category bmi category ethnicity
baseline_level_1, smoking status bronchodilation bronchodilation gold stage f respiratory medication inhaled anticholinergic inhaled j82agonist corticosteroid
baseline_level_1, demographic clinical quality life laboratory measurements medication
baseline_level_1, race mean body mass index kg m2 ncep atp iii risk factors visit 2 ldl cholesterol strata
baseline_level_1, nationality duration type 2 diabetes mellitus years naive antihyperglycemic agent therapy hba1c
baseline_level_1, sex n age years age group n race n pacific islander alaska native body mass index kg m2 baseline hba1c n diabetes duration years glyburide dose duringthe study mg
baseline_level_1, age male race n white asian black body mass index kg m2 obese patients n metabolic syndrome n diabetes mellitus n duration hypertension mssbp mm hg msdbp mm hg concomitant medication
baseline_level_1, age mean yrs sd age 65 yrs men caucasian body mass index kg m2 body mass index 30 kg m2 cad diabetes mellitus crp mean mg dl sd ldl cholesterol mean mg dl sd triglycerides mean mg dl sd highdensity lipoprotein cholesterol mean mg dl sd
baseline_level_1, sex n race ethnicity n mean blood pressure mmhg sdj severity n populations
baseline_level_1, male age years mean sd baseline cdai score mean sd mean sd median range crp concentration 10 mg dl 10 mg l n previous tnf antagonist exposure n glucocorticoid prednisone budesonide immunosuppressive agent azathioprine 6mercaptopurine methotrexate 5aminosalicylates current smoker
baseline_level_1, patient characteristics infarct characteristics arterial blood pressure mm hg
baseline_level_1, blood pressure mm hg inclusion criteria coexisting conditions electrocardiographic findings randomization concomitant cardiovascular therapies
baseline_level_1, risk factors atherosclerosis cardiac history ccsc 1 month enrollment cardiac medications index hospital stay discharge
baseline_level_1, sex smoking status
baseline_level_1, clinical history lipid profile fatty acid profile glucose metabolism blood pressure
baseline_level_1, characteristics race ethnicity chads2 score atrial fibrillation pattern atrial fibrillation onset
baseline_level_1, age years female n age completion highest education years sd duration diabetes years history major cardiovascular disease n myocardial infarction n stroke n history major microvascular disease n macroalbuminuria n major diabetic eye disease n history hypertension n past smoker n current smoker n current alcohol use n hba1c sd systolic bp mmhg sd diastolic bp mmhg sd serum total cholesterol mmol l sd serum creatinine mol l estimated gfr ml min1 173 m2 sd estimated gfr 60 ml min1 173 m2 n uacr mg mmol interquartile range b bmi kg m2
baseline_level_1, fev1 l fev1 predicted smoking status
baseline_level_1, medical history heart failure cause physical examinations ecg findings lipid profile laboratory examination medical treatment
baseline_level_1, age yr male sex risk factors myocardial infarction angina pectoris congestive heart failure diabetes mellitus stroke tia renal insufficiency hypertension copd medication use betablocker antiplatelet anticoagulant ace inhibitor calcium antagonist angiotensin llreceptor antagonist nitrate diuretic surgery carotid artery abdominal aortic open endovascular lowerlimb arterial
baseline_level_1, sex n age years race n baseline msdbp mmhg meansd baseline mssbp mmhg meansd duration hypertension months
baseline_level_1, gender ethnicity disease duration mean yr sd prior ms treatment ifnbeta edss score edss stratification total gadoliniumenhancing lesion count brain volume cm3 t2 lesion volume mm3
baseline_level_1, cigarette smoker location infarction
baseline_level_1, smoking status time treatment min
baseline_level_1, age yr sex race ethnic group total f weight kg medical history total periprocedural medications total target vessels angiographic complications sitereported total duration infusion hr
baseline_level_1, gender race bmi kg m2 risk factors atherosclerosis n 20 n chd n baseline ldlc strata n
baseline_level_1, ldlc hdlc total cholesterol triglycerides nonhdlc apolipoprotein b apolipoprotein ai total cholesterol hdlc ldlc hdlc apo b apo al nonhdlc hdlc hscrp
baseline_level_1, women mean age years race white black body mass index 30 kg m2 1 concomitant medication atherosclerotic cardiovascular disease coronary heart disease forms atherosclerosis diabetes mellitus type 1 2 metabolic syndrome visit 2 lowdensity lipoprotein cholesterol strata 70 100 mg dl 100 130 mg dl 130 mg dl
baseline_level_1, antidiabetes drug usage n
baseline_level_1, gastrointestinal area involved total type according daily dose
baseline_level_1, demographics smoking status gold stage n fev1 l fev1 predicted fvc l fvc predicted b concomitant respiratory medications n
baseline_level_1, number subjects mean age sd years female asthma duration sd years fev1 percent predicted sd pef sd l min pm pef sd l min symptom score sd albuterol use sd puffs day
baseline_level_1, n age yr mean sd male sex n bmi mean sd ics users n smoking history packyears mean sd fevi l mean sd 1 fevi predicted mean sd 1 fev1 fvc mean sd 1 reversibility b2agonist mean sd 1 reversibility anticholinergic mean sd
baseline_level_1, race n cardiovascular disease diabetes fasting lipid levels mmol l
baseline_level_1, location crohns disease medications baseline n
baseline_level_1, prevalence metabolic syndrome criterion low hdl cholesterol elevated tg elevated blood pressure elevated fasting glucose increased waist circumference changes metabolic syndrome parameters hdl cholesterol blood pressure systolic diastolic fasting blood glucose waist circumference
baseline_level_1, screening visit randomisation visit baseline
baseline_level_1, menwomen age years current smokerexsmoker smoking history packyears time since copd diagnosis yrs prebronchodilator fev1 l prebronchodilator fev1 predicted normal prebronchodilator fvc l prebronchodilator fev1 fvc postbronchodilator fev1 l postbronchodilator fev1 predicted normal reversibility fev1 postbronchodilator fvc l postbronchodilator fev1 fvc fev1 l fev1 predicted normal fvc l medication longacting b2agonists shortacting b2agonists inhaled corticosteroids oral corticosteroids xanthines mucolytics tiotropiumc shortacting anticholinergics supplementary oxygen
baseline_level_1, race ethnicity n region enrollment n + primary enrollment diagnoses n risk factors immobility level n previous medications n
baseline_level_1, geographical region n previous copd treatment n
baseline_level_1, demographic characteristics nyha class medical history duration heart failure years primary cause heart failure
baseline_level_1, demographics medical history n laboratory measurements medication n
baseline_level_1, demographic characteristics measurements blood pressure mm hg medical history treatment admission treatment admission medications day 7 medications discharge day 7 earlier
baseline_level_1, age race n ethnicity n medical history n
baseline_level_1, hdl3c triglyceride apo b total ldlc ldl c ldl2c ldl3c lduc nonhdlc hdl2c
baseline_level_1, creatinine clearance time onset symptoms randomization days cause dvt pe
baseline_level_1, sex n race n age years body weight kg n comorbidities n dm medication n c mean lipid values mg dl
baseline_level_1, disease location concomitant medication n
baseline_level_1, n age years age 65 male female caucasian black asian body mass index kg m2 fev1 la fev1 predicteda ics use yes exsmoker smoker history current cardiac disorders treatment duration days patients treated 24 weeks
baseline_level_1, age category years n gender n race n renal impairment n duration t2dm years hba1c category n
baseline_level_1, clinical presentation medical therapy treated vessel antithrombotic therapy
baseline_level_1, location n age yr smoking history n pulmonary function tests predicted blood oxygenation mean sd digital clubbing n presence honeycombing 1 n healthrelated quality life
baseline_level_1, age years smoking history location baseline fvc l
baseline_level_1, race risk group baseline lowdensity lipoprotein cholesterol mg dl
baseline_level_1, geographical region
baseline_level_1, diagnosis mean sd location disease n concomitant medication n hrqol
baseline_level_1, age yrs 1840 240 male female caucasian noncaucasian bmi kg m2 25 225 crp mg l 10 210 smoker nonsmoker disease location type terminal ileum colon lleocolon inflammatory stricturing penetrating prior surgery yes disease duration baseline mean 2baseline mean 1 yr 12 yrs 25 yrs 25 yrs cdai score 250 2250 300 300 335 2335 im use cs use im cs use im cs use previous current im use previous current cs use previous current use im cs previous current use im cs
baseline_level_1, involved intestinal area n creactive protein mg dl_ crohns diseaserelated medication baseline n
baseline_level_1, body mass index smoking
baseline_level_1, age yr risk factors specified inclusion criteria f medical history time event randomization days type event management event selected medications
baseline_level_1, age weight kg
baseline_level_1, race severity copd gold 20087
baseline_level_1, gender patients race patients diabetes duration known patients previous oral glucoselowering agents patients cv risk factors patients egfr using cg mdrd formulae patients cv medication patients framingham 10year cv risk score
baseline_level_1, age years age category female n body weight bmi kg m2 hba1c fpg mmol l 2h ppg mmol l duration t2dm
baseline_level_1, age qualifying type atherosclerosis selected clinical characteristics total qualifying myocardial infarction qualifying peripheral arterial disease qualifying stroke use medications
baseline_level_1, inadequate response intolerance prior therapy extent disease
baseline_level_1, race severity copd n
baseline_level_1, age years age 65 years women obesity bmi 25 kg m2 bmi mean sd kg m2 current smoker diabetes n fpg mmol l mg dl hypertension n sbp mm hg dbp mm hg tc mmol l mg dl ldlc mmol l mg dl hdlc mmol l mg dl tg mmol l mg dl
baseline_level_1, blood pressure mean sd mm hg history cardiovascular events risk factors concomitant therapy
baseline_level_1, demographic clinical characteristics prior diabetes fasting plasma glucose mg dl glycated hemoglobin glycemic drugs drugs
baseline_level_1, overall placebo allocation omega 3 allocation male female age 65 yrs age 65 yrs bmi 30 bmi 30 a1c64 median a1064 median prior cv event prior cv event metformin metformin statin use statin use acei arb acei arb ifg igt new dm prior dm
baseline_level_1, baseline crp mg dl mean smoking status n
baseline_level_1, demographics age group ethnicity clinical history smoker clinical details regular alcohol consumption per week exercise toast classification qualifying stroke antihypertensive medication openlabel
baseline_level_1, wml load baseline mri wml load followup mri total periventricular wml score mean sd subcortical wml load diameter mm mean sd
baseline_level_1, diabetes status baseline serum k+ meq l eos serum k+ meq l
baseline_level_1, duration rheumatoid arthritis yr tender swollen joints mean das284 esr 1 prior treatment
baseline_level_1, time qualifying myocardial infarction concomitant drugs
baseline_level_1, age yr female sex body weight kg medical history risk factors prior cardiovascular event concomitant medication coronary intervention
baseline_level_1, index event overall sex age level renal impairment weight
baseline_level_1, race pah origin cause
baseline_level_1, age sex race bmi kg m2 uac mssbp mm hg msdbp mm hg 24hour masbp mm hg 24hour madbp mm hg
baseline_level_1, bun mg dl serum creatinine mg dl serum potassium meq l egfr ml min 173 m2
baseline_level_1, characteristic mean dlqi score 95 ci mean sf36 score 95 ci
baseline_level_1, sex n race n concomitant asthma medications n
baseline_level_1, age yr weight kg diagnosis presentation region cardiacbiomarker status total medical history total periprocedural medications total duration pci min
baseline_level_1, infarct location total
baseline_level_1, antianginal medications
baseline_level_1, islander chads score experience mellitus
baseline_level_1, geographic distribution prior cardiovascular event prior new diabetes impaired glucose tolerance impaired fasting glucose hypertension hyperlipidemia current smoking microalbuminuria macroalbuminuria dietary epadha intake mg day body mass index kg m2 heart rate beats per minute systolic blood pressure mmhg diastolic blood pressure ankle brachial index fasting plasma glucose mmol l glycated hemoglobin total cholesterol mmol l hdlcholesterol mmol l ldlcholesterol mmol triglycerides mmol l serum creatinine gmol estimated glomerular filtration rate ml min 173m2 urinary albumincreatinine ratio asa antiplatelet agent statin ace inhibitor arb thiazide diuretic anticoagulant betablocker calcium channel blocker metformin sulfonylurea oral hypoglycemic drug average maximum cimt mm average maximum common carotid cimt mm average maximum common bifurcation cimt mm average maximum far wall cimt mm mean age years women
baseline_level_1, randomized age years females prior cv event hypertension current smoker 2 drinks week 12 years education depression abi 09 fpg mmol l 2h pg mmol l a1c a1c mmol mol sbp mmhg dbp mmhg grip strength kg weight kg bm1 kg m2 waisttohip male waisttohip female urine acr mg g egfr ml min alt units l total cholesterol ldl mmol l hdl mmol l tg mmol l statin thiazide pblocker acei arb omega3 fa
baseline_level_1, race gfr mdrd ml min 173 m3 frailty status
baseline_level_1, smoking status prebronchodilator postbronchodilator gold stage concomitant medications
baseline_level_1, smokers n
baseline_level_1, race a1c distribution
baseline_level_1, sex race time since diagnosis type 2 diabetes
baseline_level_1, fecal calprotectin pg g site disease concomitant medications ulcerative colitis prednisoneequivalent dose mg prior failure antitnf therapy
baseline_level_1, geographic region race preenrollment antihyperglycemic therapy chronic kidney disease stage egfr ml min per 173 m2
baseline_level_1, disease location comorbidites n concomitant medication n
baseline_level_1, clinical presentation risk factors 200 mg dl laboratory variables baseline time intervals h randomization distribution time angiographic data treatment 140 ml additional angiography first procedure pci data 140 ml medications coronary angiography blockers medications discharge
baseline_level_1, clinical indication index procedure n discharge medication n type drugeluting stent n
baseline_level_1, pretreatment concomitant treatment age smoking status copd severity geographic region
baseline_level_1, ethnicity n mean sd body mass index kg m2 mean sd duration copd years severity disease gold 2008 n copd exacerbation history n ics use baseline n smoking history n mean sd duration smoking pack years mean sd fev1 l prebronchodilator mean sd fev1 l postbronchodilator mean sd postbronchodilator fev1 percentage predicted mean sd postbronchodilator fev1 reversibility mean sd postbronchodilator fev1 fvc mean sd age years gender n male
baseline_level_1, race hispanic ethnic groupno f bodymass index coronary artery disease congestive heart failure retinopathy blood pressure mm hg cholesterol mg dl triglycerides mg dl glycated hemoglobin serum creatinine mg dl serum potassium mmol liter estimated gfr urinary albumintocreatinine ratio urinary proteintocreatinine ratio use ace inhibitor arb bloodpressure medications randomization total age yr male sex
baseline_level_1, race bodymass index systolic blood pressure mm hg blood pressure target level estimated gfr ml min 173 m2 stage 3 chronic kidney disease method identification ofstenosis medical history risk factors angiographic findings age yr male sex
baseline_level_1, race ethnicity region enrollment cardiovascular risk factors cardiovascular disease history body mass index mean sd prior lipidmodifying therapy index diagnosis index event randomization median iqr h pci cabg surgery index event medications randomization sd mg dl creactive protein median iqr mg l concomitant atorvastatin dose mg age mean sd female sex
baseline_level_1, race n country n
baseline_level_1, current inhaler+ age years duration disease years selfreported disease severity 110 scale
baseline_level_1, age group n race ethnicity n severity copd n
baseline_level_1, ethnicity n severity airflow limitation gold 2013 n baseline copd exacerbation history n smoking history n
baseline_level_1, participants continuous variables mean sd
baseline_level_1, sex education ethnic origin minimental state examination digit symbol substitution
baseline_level_1, men age years body weight kg body mass index kg m2 drug treatment positive family history type 2 diabetes history stroke history myocardial infarction history peripheral arterial disease left ventricular hypertrophy alcohol intake + current smoker systolic bp mm hg diastolic bp mm hg pulse rate bpm fasting plasma glucose mg dl hba1c uric acid mg dl k mmol l na mmol l egfr mumin 173 m2 total cholesterol mg dl hdl cholesterol mg dl triglyceride mg dl
baseline_level_1, age years older 75 years women body weight index kg m2 diabetes dyslipidaemia hypertension current smoker high ontreatment platelet reactivity prior stroke prior heart failure prior myocardial infarction prior percutaneous coronary intervention prior coronary artery bypass graft ace inhibitors p blockers statin protonpump inhibitors calciumchannel inhibitor drugeluting stent implanted firstgeneration stentt secondgeneration stent left main left anterior descending circumflex right coronary artery coronary artery bypass graft
baseline_level_1, time randomization symptom onset infarct location place randomization
baseline_level_1, age female sex body weight kg diabetes mellitus timi risk score killip class first medical contact procedures index event study medication aspirin
baseline_level_1, blood pressure mmhg cardiovascular risk factors medical history angina status ccs class
baseline_level_1, age years female sex n white race n duration copd years chronic bronchitis emphysema smoking packyears body mass index kg m2 baseline pre bronchodilator fev1 l baseline predicted fev1 fev1 reversibility nonreversible reversible
baseline_level_1, demographic medical variables cardiac echocardiography parameters left ventricular ejection fraction af history concomitant medications
baseline_level_1, ldl cholesterol baseline mmol l ldl cholesterol screening lipid parameters hscrp nmol l unbound pcsk9 nmol l age years female sex coronary artery disease
baseline_level_1, geographic regionnumber
baseline_level_1, das28 crp haqdi number symptom duration pain 100 mm vas erosion osteitis synovitis
baseline_level_1, blood pressure mean sd range mm hg race ethnicity chads2 scoreb score risk factors stroke classification af onsetofaf previous warfarin use region enrollment
baseline_level_1, subject characteristics indication pci region treatment characteristics
baseline_level_1, age race sex bmi region aspirin dose randomization thienopyridine type des type
baseline_level_1, demographics clinical characteristics baseline medical therapy
baseline_level_1, total study population n 27 939 0 predicted arr n 18 524 0 1 predicted arr n 8 943 1 predicted arr n 472
baseline_level_1, age yr mean sd female sex n smoking status n former current total packyears mean sd baseline fev1 predicted postbronchodilator reversibility fev1 mean sd
baseline_level_1, risk factors laboratory variables baseline angiographic data time intervals h
baseline_level_1, smoking status comorbidities prebronchodilator screening fev1 ml postbronchodilator screening fev1 ml gold stage # baseline pulmonary medication participants n male age years
baseline_level_1, race n concomitant medications n
baseline_level_1, age gender race hdlc mg dl fcldlc mg dl use concomitant lipidmodifying therapy type concomitant statin fcldlc friedewaldcalculated
baseline_level_1, median age 25 75 women n body mass index 30 n hypertension n hyperlipidemia n current tobacco abuse n peripheral arterial disease n history heart failure n previous pci cabg n baseline gfr 60 ml min per 173 m2 n aspirin thienopyridine lipidlowering agent acei arb lifestyle modifications noninsulin therapy insulin therapy
baseline_level_1, mean age years men n mean bmi kg m2 creatinine clearance n 50 ml min 5080 ml min 80 ml min missing planned treatment duration n 6 months 12 months index event n dvt pe dvt index event confirmed immobilization randomization n active cancer randomization n ischemic heart disease n peripheral arterial disease n ischemic cerebrovascular disease n asa use baseline n asastoppedat randomization n hypertension n diabetes n
baseline_level_1, race use concomitant lipidlowering treatment type concomitant statin daily dose baseline lipid lipoprotein values
baseline_level_1, bmi kg m2 pharmacotherapy
baseline_level_1, years since myocardial infarction type myocardial infarction medication enrollment
baseline_level_1, patients indication pci thienopyridine randomization type des index procedure minimum stent diameter treated vessel
baseline_level_1, demographic characteristics qualifying type atherosclerosis n selected clinical characteristics n antiplatelet therapy
baseline_level_1, race n qualifying cv event n time recent qualifying duration hypertension n type treatment n oads n concomitant medications n
baseline_level_1, race ethnicity duration diabetes years qualifying hba1c urinary albumincreatinine ratio mg g cigarette smoking antihyperglycemic antihypertensive antiplatelet lipid lowering
baseline_level_1, race n copd severity n gold 2014 groups medication n copd exacerbation history n cat score category mmrc grade
baseline_level_1, age years 65 age years 6575 age years 75 smoking history current smoker smoking history exsmoker copd severity mild moderate copd severity severe severe baseline ics use yes baseline ics use copd exacerbation yes copd exacerbation overall
baseline_level_1, race n age mean sd years male n female n hba1c mean sd body weight mean sd kg sbp mean sd mmhg egfr mean sd ml min 173 m2
baseline_level_1, sex race ethnic group f bodymass index categories c blood pressure mm hg cholesterol mg dl
baseline_level_1, ethnic origin number previous antitnf treatments psoriatic arthritis patients specific disease characteristics baseline disease qualityoflife scores
baseline_level_1, age years female n weight kg bmi kg m2 ra duration months 3 months n 36 months n 612 months n previous dmards use n steroid use baseline n anticcp antibody positive n high titre 3 times uln n titre u ml rf positive n titre u ml bone erosion judged physician n tjc 28 joints sjc 28 joints ptgada mm phgada mm esr mm h crp mg dl mmp3 ng ml das28 esr sdai haqdi score mtss negative 05 n erosion score joint space narrowing score average weekly mtx dose mg week
baseline_level_1, creatinine clearance category ml min b medical conditions method used diagnose incident pulmonary embolism characteristics pulmonary embolism inclusion thrombophilia e treatmentofpulmonary embolismpriorto randomization main concomitant treatments accp bleeding risk inclusion f
baseline_level_1, mean sd hba1c mean sd fpg detemir insulin glargine
baseline_level_1, geographic region haqdi bdmard
baseline_level_1, killip class admission total
baseline_level_1, demographic characteristics race baseline measurements albumintocreatinine ratio baseline cv medications n baseline antihyperglycemic medications n
baseline_level_1, race ethnicity region time since diagnosis type 2 diabetes medication taken alone combination estimated glomerular filtration rate urine albumintocreatinine ratio
baseline_level_1, demographic age years weight kg medical history n
baseline_level_1, race f previous antitnf drugs tics area disease qualityoflife scores ease activity disease activity
baseline_level_1, antitnfnaive patients3 antitnfexperienced patients
baseline_level_1, region n number prior aeds n number concomitant aeds n concomitant aedsa lev status n
baseline_level_1, demographics clinical characteristics region qualifying event
baseline_level_1, age mean sd yrs men n bodymass index mean sd hypertension active smoking history myocardial infarction history pci statin antiplatelet therapy betablocker ace inhibitor arb time endofstudy ivus median iqr days
baseline_level_1, duration diabetes urine albumin creatinine ratio mg g
baseline_level_1, region nyha functional class
baseline_level_1, age mean sd years male white body weight mean sd kg psoriasis duration mean sd years bsa affected mean sd pasi score mean sd psoriatic arthritis
baseline_level_1, sex n race n
baseline_level_1, patients indication index pci thienopyridine randomization type stent index procedure
baseline_level_1, age yrs age 65 yrs male hypertension diabetes mellitus previous myocardial infarction previous stroke previous major bleeding chads2 cha2ds2vasc cha2ds2vasc 2 modified hasbled
baseline_level_1, b
baseline_level_1, age distribution geographic region pah classification functional class c use medications pah
baseline_level_1, demographic characteristics screening baseline
baseline_level_1, female male age years body weight kg body mass index kg m2 wc cm insulin pmol l vital signs systolic bp mmhg diastolic bp mmhg pulse beats min cholesterol mmol l total ldl hdl vldl triglycerides mmol l ffa mmol l hscrp nmol l prediabetes n dyslipidaemia n hypertension n dyslipidaemia hypertension n n hbaic fpg mmol l n 634 duration t2dm years hba1c insulin pmol l
baseline_level_1, number individuals age years body mass index kg m2 current weekly alcohol use history macrovascular disease history microvascular disease history stroke age completion highest level systolic blood pressure mm hg diastolic blood pressure mm hg heart rate bpm total cholesterol mmol l hdl cholesterol mmol l ldl cholesterol mmol l triglycerides mmol l hba1c exercise times per week minimum creatinine clearance ml min ace arb medication pblocker blood pressure medications lipidlowering medication aspirin thienopyridines duration diabetes years
baseline_level_1, medical history type mi
baseline_level_1, age median iqr age 65 n age 75 n white race n weight kg median iqr dx presentation n stable angina nsteacs stemi united states countries abnormal normal diabetes mellitus current smoker hypertension hyperlipidemia previous stroke tia previous mi previous pci previous cabg previous heart failure peripheral arterial disease baseline hemoglobin median iqr g dl baseline hematocrit median iqr periprocedural medications n clopidogrel 300 mg clopidogrel 600 mg bivalirudin ufh lmwh fondaparinux aspirin duration pci min median n iqr drugeluting stent n bare metal stent n poba n femoral radial brachial
baseline_level_1, demographic feature stroke total physical cognitive examination blood pressure mm hg laboratory data fasting cholesterol mg dl concomitant medication interval index event
baseline_level_1, total tnf inhibitors nontnf inhibitors scores global pain assessments
baseline_level_1, age women n white asian black bmi kg m2 t2dm duration baseline hba1c baseline fpg baseline 2h ppg current smoker sbp mmhg hdlc mg dl
baseline_level_1, demographics race region medical history baseline laboratory values median iqr qualifying myocardial infarction catheterization performed qualifying event pciperformed qualifying event time study drug administration coronary revascularization median iqr h useofmedical therapyathospitaldischarge
baseline_level_1, demographics medical history treatment indication index procedure
baseline_level_1, age yrs age 65 yrs male nonwhite race body mass index kg m2 systolic blood pressure mm hg egfr 60 ml min 173 m2 mdrd qualifying mi type nstemi stemi unknown qualifying mi 2 yrs prior history second prior mi nonendstage renal dysfunction multivessel coronary artery disease history hypertension history hypercholesterolemia current smoker history chf history atrial fibrillation history peripheral artery disease history stroke transient ischemic attack prior angina prior coronary artery bypass grafting history percutaneous coronary intervention statin betablocker acei angiotensin receptor blocker history diabetes requiring drugs type 2 diabetes insulin oral hypoglycemic
baseline_level_1, region qualifying mi type
baseline_level_1, bmi kg m2 region n
baseline_level_1, severity copd f
baseline_level_1, race n smoking history n severity copd airflow limitation n severity copd combined assessment n copd exacerbation history n mmrc dyspnea scale n cardiovascular risk factors
baseline_level_1, geographic region renal function
baseline_level_1, age weight medical history periprocedural medications duration pci min
baseline_level_1, smoking status n mean sd prebronchodilator mean sd postbronchodilator baseline pulmonary medication n
baseline_level_1, racial group n seizure types reported baseline b n prior aeds c n common concomitant aeds n lev status n
baseline_level_1, medical history n
baseline_level_1, age yrs 2 3 lvef sbp mm hg diabetes ischemic cardiomyopathy history af history stroke icd crt ace arb diuretics mra ntprobnp pg ml bnp pg ml
baseline_level_1, race ethnicity region glycatedhemoglobin category priorvascular disease baseline heart failure severity amongthose priorheartfailure bloodpressure mean sd hg cigarettesmoking antihyperglycemictherapies cardiovascular medications
baseline_level_1, laboratory data mean sd ada ifg idf ifg antihypertensive medication number features present
baseline_level_1, race bmi category duration t2dm homair b previous oad
baseline_level_1, demographics disease characteristics
baseline_level_1, hba1c sulfonylurea hba1c distribution
baseline_level_1, gender age years race duration ra years ara functional class
baseline_level_1, comorbidities cardiovascular history medical therapies
baseline_level_1, age years sex medical history risk factors previous cardiovascular events concomitant medication randomisation killip class coronary angiography intervention stented vessels
baseline_level_1, age group years sex race ethnic group smoking history
baseline_level_1, age group years sex race ethnic group
baseline_level_1, ncep risk category study entry n
baseline_level_1, age race systolic blood pressure mm hg total cholesterol hdl bmi albumin creatinine ratio core laboratory percent stenosis egfr
baseline_level_1, age yrs male white race weight kg smokers previous mi peripheral artery disease congestive heart failure diabetes mellitus prior stroke tia previous pci previous cabg us site
baseline_level_1, age n race n ethnicity n diabetes duration n hba1c n b number antidiabetes drugs screening n renal function egfr ml min 173 m2 according mdrd n
baseline_level_1, age year female n duration rheumatoid arthritis year anticyclic citrullinated peptide positive n rheumatoid factor positive n 1 erosion n mtss units erosion score joint space narrowing score 1 2 3 swollen joint count 66 swollen joint count 28 tender joint count 68 tender joint count 28 physicians global assessment patients global assessment patients assessment pain haqdi highsensitivity creactive protein mg ltt erythrocyte sedimentation rate mm hour das28crp das28esr simplified disease activity index
baseline_level_1, sex n medical history n cardiovascular risk factors n
baseline_level_1, copd severity n gold 2014 groups n copd exacerbation history n catscorecategory n mmrc grade n
baseline_level_1, cigarette smoking glucoselowering therapies cardiovascular medications
baseline_level_1, age female sex white ethnicity current smoker disease duration years das28 number previous dmards baseline diabetes creactive protein mg dl il6 pg ml serum creatinine mmol l tender joint count n 66 swollen joint count n 68 haemoglobin g l troponin pg ml ntprobnp pg ml
baseline_level_1, demographics clinical characteristics peripheral artery disease details baseline medical therapy
baseline_level_1, race ethnicity clinical features hf nyha class medical history treatment randomization
baseline_level_1, race ethnicity lntensityd baseline medications
baseline_level_1, age years median n195 206 age years median n228 217 male n308 306 female n115 117 race nonwhite n26 24 race white n397 399 history mi n278 281 history mi n 145 142 nonsmoker n328 313 current smoker n95 110 baseline pav median n209 220 baseline pav median n214 203 baseline tav median n210 214 baseline tav median n213 209 nonhigh density lipoprotein mg dl baseline median n204 212 nonhigh density lipoprotein mg dl baseline median n214 199 proprotein convertase subtil kexin typ9 ng ml baseline median n215 203 proprotein convertase subtil kexin typ9 ng ml baseline median n201 209 family history chd n290 274 family history chd n133 149 type 2 diabetes n336 335 type 2 diabetes n87 88 prior statin n44 51 prior statin n379 372 non high dose statin n168 170 high dose statin n255 253
baseline_level_1, race chd risk ldlc bq goal baseline prior diagnosis use concomitant lipidlowering therapy type concomitant statin daily dose baseline lipid lipoprotein values
baseline_level_1, medication use baseline n
baseline_level_1, smoking status n gold n baseline pulmonary medication n
baseline_level_1, race ethnicity nationality
baseline_level_1, enrollment region race ethnicity selenasledai range u1u5 organ system involvement disease hare 010cm vas medications immunosuppressants
baseline_level_1, age years female n weight kg bmi kg m2 ra duration months anticcp antibody positive n rf positive n bone erosion judged physician n tjc 28 joints sjc 28 joints esr mm hour crp mg dl mmp3 ng ml das28 esr sdai haqdi score mtss erosion score joint space narrowing score average weekly mtx dose mg week
baseline_level_1, age range years sex ethnic origin methotrexate dose baseline
baseline_level_1, demographics coexisting conditions medications type event randomization laboratory findings
baseline_level_1, ldlc total cholesterol hdlc tg nonhdlc hscrp apob
baseline_level_1, sex race bmi category waist circumference cm blood pressure mm hg cholesterol mmol l hdl cholesterol
baseline_level_1, demographic features clinical history n physical examination laboratory data concomitant medications n
baseline_level_1, clinical characteristics medical history physical examination ecg medications
baseline_level_1, blood eosinophils count
baseline_level_1, exposed n 578 naive n 743 exposed n 424 naive n 339 exposed n 428 naive n 696 exposed n 349 naive n 639
baseline_level_1, age yr weight bodymass indexf creatinine clearance index event classification index venous thromboembolism hormonal therapy individual intended study duration
baseline_level_1, sex age body weight body mass index presentation index event extent index event history recurrent venous thromboembolism risk factor profile index event duration prerandomization anticoagulant therapy creatinine clearance known thrombophilia active cancer fragile
baseline_level_1, sex race smoking status copd medication study entry
baseline_level_1, patient characteristics number prior csdmards n number concomitant csdmards n disease activity patientreported outcome measures haqdi 03 activity 0100 vas short form 36 sf36 european quality life5 dimensions5 level eq5d
baseline_level_1, inductiontrial group assignment duration disease yrt extent disease total creactive protein mg literj previous treatment failure
baseline_level_1, demographic characteristics disease characteristics medication use
baseline_level_1, copd severity
baseline_level_1, race n time since diagnosis diabetesa n egfr ckdepi cystatinc ml min 173 m2 n uacra mg g n
baseline_level_1, sex race hba1c time since diagnosis type 2 diabetes total cholesterol ldl cholesterolt hdl cholesterol triglycerides egfr
baseline_level_1, dyspnoea mmrc grade n number exacerbation previous 12 months n baseline treatments n
baseline_level_1, infarct location killip class timi risk score
baseline_level_1, age sex previous disease f region systolic blood pressure diastolic blood pressure bodymass index level ldl cholesterol nonhdl cholesterol hdl cholesterol glomerular filtration rate
baseline_level_1, renal function egfr ml min 173 m2
baseline_level_1, smoking history moderate severe copd exacerbations postbronchodilator lung function screening healthrelated quality life
baseline_level_1, 150 historical count 300 150 regardless historical count 150 300 300 500 500 150 historical count 300
baseline_level_1, medical history qualifying event modified rankin scale septal anomaly
baseline_level_1, asthma control test score baseline number exacerbations 12 months randomisation comorbidities
baseline_level_1, race ethnicity region cv risk factor time since diagnosis type 2 diabetes medication taken alone combination antihypertensive therapy lipidlowering therapy anticoagulants urine albumintocreatinine ratio
baseline_level_1, age group n race n ethnicity n mean sd fpg mean sd calculated ldl cholesterol mean sd measured ldl cholesterol mean sd nonhdl cholesterol total cholesterol median q1q3 tgs mean sd hdl cholesterol median q1q3 tgrich lipoprotein cholesterol concomitant lipidlowering therapy n statin intensity18 concomitant antihyperglycaemic drugs n median q1q3 total daily insulin dose5
baseline_level_1, ethnicity race region european subcategories history cardiovascular disease cigarette smoking status antihyperglycemic medication usage cardiovascular medication usage medication usage
baseline_level_1, race ethnicity n region n background aha therapy screening n
baseline_level_1, hba1c distribution baseline n
baseline_level_1, race3 region cause heart failure time since diagnosis heart failure lv ejection fraction nyha functional class screening physiological measures laboratory measures medical history medications randomization devices heart failure screening visit
baseline_level_1, years range ibdq domain scores mean sd sf36v2 domain scores mean sd
baseline_level_1, corticosteroid use baseline gender prior antitnf therapy
baseline_level_1, anatomic complexity characteristics
baseline_level_1, demographic features index event index event subtype clinical history physical examination laboratory data concomitant medications
baseline_level_1, sex n race n egfr category n
baseline_level_1, sex smokinq status previous treatment reqion
baseline_level_1, sex blood pressure smoking status risk factors pad history pad abi medications
baseline_level_1, age years female duration t2d years screening bmi kg m2 screening hba1c baseline hba1c basal insulin dose runin u day iglar dose randomization u day
baseline_level_1, sex qualifying myocardial infarction
baseline_level_1, qualifying event randomization
baseline_level_1, medical history medications admission medications randomization index event laboratory values admission median iqr laboratory values randomization median iqr
baseline_level_1, age years mean sd male n weight kg mean sd time since psa diagnosis years mean sd tender joint count 68 joints mean sd swollen joint count 66 joints mean sd haqdi total score mean sd van der heijde mtss mean sd
baseline_level_1, overallb fc ii symptoms baseline fc iii symptoms baseline
baseline_level_1, age years female n prior tobacco use n disease duration years acpa positive n rf positive n clinical patientreported characteristics baseline randomization das28 sdai cdai tjc 028 sjc 028 crp mg l esr 0100 mm hour pga 010 ptga 010 general health vas 0100 mm pain vas 0100 mm total haq 03 radiographic characteristics baseline randomization mtss 0448 erosion score 0280 jsn score 0168
baseline_level_1, age yrs male caucasian diabetes mellitus hypertension hyperlipidemia smoking egfr 60 ml min 173 m2 chf pad qualifying mi stemi prior cabg prior pci
baseline_level_1, sex race n prebronchodilator fev1
baseline_level_1, sex race smoking status clinical copd phenotype
baseline_level_1, race nyha class
baseline_level_1, anthropometry mean sd number patients risk factors medication within 7 days enrolment medication enrolment f mean sd age years
baseline_level_1, age sex qualifying event time qualifying event randomization coronary risk factors vascular disease previous coronary revascularization medication use
baseline_level_1, sex race concurrent illness concurrent medications plasma lipoproteins mmol l
baseline_level_1, age race f nyha class blood pressure mm hg electrocardiographic findings cause heart failure medical history score minnesota living heart failure scaled hemoglobin estimated glomerular filtration rate ntprobnp pg ml
arms, tirofiban n2398 abciximab n2411
arms, placebo n 20 simvastatin n 24
arms, placebo simvastatin
arms, placebo rsg 4 mg day rsg 8 mg day
arms, placebo rsg 4 mg day rsg 8 mg day
arms, placebo rsg 4 mg day rsg 8 mg day
arms, placebo rsg 4 mg day rsg 8 mg day
arms, placebo rsg 4 mg day rsg 8 mg day
arms, usual care n 1243 intervention n 1238
arms, 1 prolonged antithrombotic pretreatment n 207 1 early intervention n 203
arms, calcium antagonist strategy n 11 267 noncalcium antagonist strategy n 11 309
arms, abciximab n1079 placebo n1080
arms, abciximab total placebo total
arms, verapamil sr n3169 atenolol n3231
arms, betacarotene n 18 405 placebo n 18 330
arms, placebo eze pooled simva pooled eze simva
arms, amiodarone n 845 placebo n847 icd therapy n
arms, aspirin n 19 934 placebo n 19 942 total n 39 876
arms, clopidogrel n1752 placebo n1739
arms, placebo n 64 eze 10 mg n 187 feno 160 mg n 189 feno 160 mg eze 10 mg n 185
arms, placebo eze feno feno + eze
arms, placebo n 230 ezetimibe 10 mg n 220
arms, eze simva 10 20 mg n 221 atv20 mg n 214
arms, placebo n 313 glucosamine n 317 chondroitin sulfate n 318 glucosamine + chondroitin sulfate n 317 celecoxib n 318
arms, placebo n 1010
arms, abciximab placebo
arms, simva eze simva
arms, aspirin+dipyridamole n1363 aspirin alone n1376
arms, diet group n3966 diet plus pravastatin group n3866
arms, pbo + statin n261 eze + statin n552 pbo + statin n353 eze + statin n691
arms, pbo + statin 1 ze + statin pbo + statin eze + statin
arms, rosiglitazone n 1456 metformin n 1454 glyburide n 1441
arms, etoricoxib group n17 412 diclofenac group n17 289
arms, infliximab
arms, controls n9319 epa treatment n9326
arms, ranolazine n 3279 placebo n 3281
arms, placebo n269 etanercept n 266
arms, placebo group n 166 adalimumab group n 159
arms, placebo n 257 ezetimibe 10 mg n 246 simvastatin monotherapy n 1 031 ezetimibe + simvastatin n 1 007 atorvastatin monotherapy n 917 ezetimibe + simvastatin n 915
arms, active n5569 placebo n5571
arms, pctindopnl indapamide n5569 placebo n5571
arms, placebo rosuvastatin
arms, placebo events rosuvastatin patients rate
arms, losartan n26 1 placebo n238 losartan n387 placebo n401 losartan n648 placebo n639
arms, diet n2718 dietipravastatin n2638 total n5356
arms, diet diet+pravastatin
arms, ii n 370 id n 674 dd n 399
arms, rosiglitazone metformin glyburide
arms, rosiglitazone metformin glyburide
arms, rosiglitazone metformin glyburide
arms, placebo denosumab
arms, v alsartan hctz n valsartan n
arms, atenolol strategy n 2 973 verapamil sr strategy n 2 922
arms, atenolol verapamil sr
arms, v total n 7218 rerapamilsr strategy n 3622 atenolol strategy n 3596 p
arms, aspirinerdp n 10 181 clopidogrel n 10 151
arms, telmisartan n 10 146 placebo n 10 186
arms, rosuvastatin n2285 placebo n2289
arms, n3 pufa n3494 placebo n348l
arms, etoricoxib n 17 412 diclofenac n 17 289
arms, etoricoxib diclofenac
arms, aspirin placebo
arms, tiotropium n 2986 placebo n 3006
arms, placebo n2061 irbesartan n 2067
arms, atorvastatin 40 mg + ezetimibe 10 mg n 288 atorvastatin 80 mg n 291
arms, placebo n 178 sitagliptin n 352
arms, 169 339 79 158 59 119 31 131 297 66 144 41 100 24 53
arms, placebo n 5 99 alogliptin 125 mg n 5 203 alogliptin 25 mg n 5 198
arms, aliskiren hydrochlorothiazide
arms, placebo + statin n 1 584 ezetimibe 10 mg + statin n 2 315
arms, amlodipine vaisartan n 286 amlodipine n 286
arms, placebo n 47 adalimumab n 70 patients fistulas n 117
arms, placebo
arms, valsartan n 722 placebo n 720
arms, placebo n 1 776
arms, nonepa n 7057 epa n 7023 nonepa n 2262 epa n 2303
arms, nonepa n 7057 epa n 7023 nonepa n 2262 epa n 2303
arms, intervention group n463 control group n244
arms, perindopril placebo
arms, tiotropium n1384 control n1355 tiotropium n1304 control n1331 tiotropium n250 control n271
arms, rosuvastatin n 1855 placebo n 1835
arms, fluvastatin n 250 placebo n247
arms, amlodipine valsartan 10 160 mg v473 amlodipine 10mg v471
arms, placebo n147 rituximab n 292 total n 439
arms, alteplase n418 placebo n403
arms, cangrelor n 4433 clopidogrel n 4444 cangrelor n 3946 clopidogrel n 3935 cangrelor n 487 clopidogrel n 509
arms, placebo rosuvastatin
arms, a40 + ez10 a80
arms, a40 + ez10 a80 n 61 n 66 a40 + ez10 a80 n 67 n 68 a40 + ezio a80 n 149 n 145
arms, a10 + e10 n 526 a20 40 n 527
arms, placebo ranolazine
arms, tiotropium nz2251 control nz2222 tiotropium nz735 control nz784
arms, indacaterol 150 mg indacaterol 300 mg tiotropium placebo
arms, aml val 5 80 mg ami 5 mg
arms, control epa
arms, ezetimibe simvastatin 10 40 mg n 261 atorvastatin 40 mg n 263 rosuvastatin 510 mg n 262
arms, exetimibe simvastatin atorvastatin rosuvastatin
arms, infliximabnaive n 322 infliximabexperienced n 103
arms, fenofibric acid lowdose statin moderatedose statin highdose statin fenofibric acid + lowdose statin fenofibric acid + moderatedose statin
arms, tiotropium 5 mg respimat n 1952 placebo n z 1965
arms, tiotropium 5 mg respimat n z 1058 placebo n z 1033 tiotropium 5 mg respimat n z 894 placebo n z 932
arms, extended duration enoxaparin n 2159 placebo n 2176 extended duration enoxaparin n 816 placebo n 812 extended duration enoxaparin n 2975 placebo n 2988
arms, placebo n 1544 salmeterol n 1542 fp n 1552 sfc n 1546
arms, ivabradine group n3241 placebo group n3264
arms, rosuvastatin n251 fenofibric acid 72254 rosuvastain + fenofibric acid 72253
arms, treatment group
arms, a40 + ez n 225 a80 n 222 a40 + ez n 136 a80 n 140 a40 + ez n 89 a80 n 82
arms, rivaroxaban n 1731 standard therapyy n 1718 rivaroxaban n 602 placebo n 594
arms, riva roxa ban n n 3671731 21 enoxaparin vka n n 51 1718 30
arms, rivaroxaban enoxaparin vka
arms, fa 135 mg 123 r 5 mg n68 r 5 mg + fa 73 r 10 mg 52 r 10 mg + fa 52 r 20 mg n53 r 20 mg + fa 52
arms, fa 135 mg r 5 mg r 5 mg + fa r 10 mg r 10 mg + fa r 20 mg r 20 mg + fa
arms, placebo n 130 ada 80 40 n 130 ada 160 80 n 130
arms, placebo n 130 ada 80 40 n 130 ada 160 80 n 130
arms, indacaterol 150 gg qd indacaterol 300 gg qd indacaterol 600 gg qd formoterol 12 gg bid salmeterol 50 gg bid tiotropium 18 gg qd placebo
arms, saxa 25 mg n 85 pbo n 85
arms, saxa 25 mg pbo
arms, saxa 25 mg n 44 pbo n 40 saxa 25 mg n 18 pbo n 23
arms, highdose statin pretreatment n1692 controls n1649
arms, bosentan n 407 placebo n 209
arms, r5 + ezio n 99 r10 n 98 r10 + ezio n 122 r20 n 121
arms, certolizumab pegol n 223 placebo n 215
arms, placebo n 107 40 mg eow n 99 40 mg ew n 107 placebo n 154 40 mg eow n 161 40 mg ew n 150
arms, aspirin 1029 placebo 1030 aspirin 1559 placebo 1556 aspirin 1040 placebo 1116
arms, met n 334 avm n 344
arms, apixaban n 3705 placebo n 3687
arms, indacaterol group n 163 placebo group n 160 patients n 323 indacaterol group n 159 placebo group n 159 patients n 318
arms, linagliptin n 3319 total comparators n 1920
arms, vildagliptin 50 mg bid n 146 vildagliptin 50 mg qd n 148 placebo n 144
arms, vildagliptin 50 mg bid vildagliptin 50 mg qd placebo
arms, vorapaxar n 13 225 placebo n 13 224
arms, abatacept 30 10 mg kg n 65 abatacept 10 mg kg n 128 abatacept 3 mg kg n 130 placebo n 128 abatacept 30 10 mg kg n 141 abatacept 10 mg kg n 139 abatacept 3 mg kg n 70 placebo n 140
arms, indacaterol + tiotropium n 570 tiotropium + placebo n 561 indacaterol + tiotropium n 572 tiotropium + placeb n 570
arms, insulin glargine standard care
arms, telmisartan n390 placebo n381 mri substudy n1014
arms, telmisartan group n390 placebo group n381
arms, val hctz n80 aml hctz n63 val hctz n63 aml hctz n87 val hctz n46 aml hctz n46
arms, om 40 mg aml 10 mg om 40 mg hctz 25 mg aml 10 mg hctz 25 mg om 40 mg aml 10 mg hctz 25 mg
arms, placebo n 122 tofacitinib 5 mg n 243 tofacitinib 10 mg n 245
arms, vorapaxar group n8898 placebo group n8881
arms, indacaterol n 163 placebo n 160 indacaterol n 159 placebo n 159
arms, indacaterol 75 pg placebo
arms, indacaterol 150 mg n z 73 indacaterol 300 mg n z 68 placebo n z 66 indacaterol 150 mg n z 41 indacaterol 300 mg n z 48 placebo n z 51
arms, om 40 aml 10 om 40 aml 10
arms, conventional treatment n 1227 monitoring n 1213
arms, canakinumab dose per mo placebo n179 total group n551
arms, canakinumab dose per month 150mg placebo
arms, apixaban 25 mg n 840 apixaban 5 mg n 813 placebo n 829
arms, apixaban 25 mg apixaban 5 mg placebo
arms, oral treprostinil n233 placebo n116 oral treprostinil n151 placebo n77
arms, aliskiren valsartan n574 valsartan n565
arms, v n574 v n565 v n200 v n190 v n63 v n51 v n17 v n14
arms, psa n 1330 psa n 523
arms, cangrelor n 5472 clopidogrel n 5470
arms, ranolazine n 462 placebo n 465
arms, insulin glargine n533 standard care n558 n3 fatty acids n539 placebo n552
arms, overall glargine standard therapy
arms, vildagliptin n139 placebo n139
arms, vildagliptin n137 placebo n137
arms, tiotropium n z 2986 control n z 3006
arms, acei vs nonacei
arms, sita 100 pio 15 pio 30 pio 45 sita 100+ pio 15 sita 100+ pio 30 sita 100+ pio 45
arms, sita 100 pio 15 pio 30 pio 45 sita pio 100 15 sita pio 100 30 sita pio 100 45
arms, placebo empagliflozin 10 mg empagliflozin 25 mg total randomized penlabel empagliflozin 25 mg baseline hba1c 10
arms, placebo empagliflozin 10 mg empagliflozin 25 mg
arms, vedolizumab total n 895
arms, placebo dapagliflozin 5mg dapagliflozin 10 mg
arms, dapagliflozin 5 mg dapagliflozin 10 mg
arms, placebo n 483 adalimumab n 480
arms, aspirin alone n2514 clopidogrel+aspirin n2531
arms, aspirin alone n2514 24 aspirin+ clopidogrel n2531 26 094 066 135 075
arms, glycopyrronium 50 mg n 1059 placebo n 528 tiotropium 18mg n267
arms, losartan plus placebo n 724 losartan plus lisinopril n724
arms, stenting plus medical therapy n459 medical therapy n 472
arms, placebo n 2573 varespladib n 2572
arms, n indacaterol 150 ug indacaterol 300 ug placebo indacaterol 150 ug versus placebo indacaterol 300 ug versus placebo indacaterol 300 ug versus indacaterol 150 ug
arms, ind + gly n226 ind + pbo n221
arms, coenzyme q10
arms, overall nu685 insulin glargine n58ll standard care n5874 omega3 fatty acid n5855 placebo n583o
arms, diuretics group n544 nodiuretics group n586
arms, non diuretics
arms, continuation n635 interruption n624
arms, pharmacoinvasive n944 primary pci n948
arms, prehospital ticagrelor n 909 inhospital ticagrelor n 953
arms, preh inh 95 cl
arms, ivabradine n 9550 placebo n 9552
arms, fish oil n 153 placebo n 163
arms, placebo every 2 weeks n54 evolocumab 140 mg every 2weeks n110 placebo monthly n55 evolocumab 420 mg monthly n110
arms, saxa+dapa+met n179 saxa+met n176 dapa+met n179
arms, saxa+dapa+met n179 saxa+met n176 dapa+met n179
arms, saxa+dapa+met n179 saxa+met n176 dapa+met n179
arms, abatacept plus mtx n119 abatacept monotherapy n116 mtx n116 total n351
arms, abatacept plus mtx n119 abatacept monotherapy n116 mtx n116
arms, device group n 463 warfarin group n 244
arms, continued thienopyridine n5020 subjects placebo n4941 subjects
arms, + thienopyridine thienopyridine
arms, vi 25 mg n 818 ff vi 50 mg 25 mg n 820 ff vi 100 mg 25 mg n 806 ff vi 200 mg 25 mg n 811
arms, p
arms, saxagliptin placebo
arms, olodaterol 5 mg tiotropium 25 mg tiotropium 5mg tiotropium+olodaterol 25 5 mg tiotropium+olodaterol 5 5 mg
arms, tiotropium+olodaterol 5 5 pg tiotropium+olodaterol 25 5 pg
arms, placebo n 108 dapagliflozin 10 mg day n 108
arms, placebo n 108 dapagliflozin 10 mg n 108
arms, anacetrapib 100 mg n 811 placebo n 812
arms, anacetrapib 100mg n204 placebo n102
arms, placebo n 4 271 saxagliptin n 4 290 placebo n 7 051 saxagliptin n 7 111 placebo n 1 161 saxagliptin n 1 169
arms, ticagrelor 90 mg n 7050 ticagrelor 60 mg n 7045 placebo n 7067
arms, thienopyridine n1805 placebo n1771 thienopyridine n4057 placebo n4015
arms, vorapaxar n10 080 placebo n10 090
arms, placebo group n 459 dapagliflozin 10 mg group n 455
arms, aiirocumab n 209
arms, n14 671 sitagliptin n7332 placebo n7339
arms, qva149 110 50 ig od n372 sfc 50 500 ig bid n369
arms, placebo n 1256 cana 100 mg n 1441 cana 300mg n1461 total n4158
arms, pbo cana 100 mg cana 300 mg
arms, liraglutide n 2487 placebo n 1244
arms, liraglutide 30 mg mean n placebo mean n estimated odds ratio
arms, 459 65 91 43 846 290
arms, secukinumab 300 mg n100 secukinumab 150 mg n100 secukinumab 75 mg n99 placebo n98
arms, secukinumab 300 mg secukinumab 150 mg secukinumab 75 mg placebo
arms, czp+mtx n159 pbo+mtx n157
arms, czp+mtx pbo+mtx
arms, warfarin n 184 placebo n 187
arms, liraglutide 18 mg day n225 placebo n 225
arms, liraglutide 18 mg n 94 placebo n95
arms, pbo n5 164 czp 200 mg n 5 326 czp 400 mg n 5305 pbo n5119 czp 200 mg n5201 czp 400 mg n 5 221 pbo n542 czp 200 mg n 5111 czp 400 mg n5109
arms, placebo n651 tofacitinib 5 mg twice daily n1071 tofacitinib 10 mg twice daily n1090 placebo n193 tofacitinib 5 mg twice daily n259 tofacitinib 10 mg twice daily n253
arms, placebo n638 tofacitinib 5 mg twice daily n1043 tofacitinib 10 mg twice daily n1066 placebo n191 tofacitinib 5 mg twice daily n258 tofacitinib 10 mg twice daily n251
arms, cyclosporine n 474 control n 495
arms, alirocumab n 323 placebo n 163 alirocumab n 167 placebo n 82
arms, placebo alirocumab
arms, saxagliptin placebo
arms, placebo n 2333 empagliflozin 10 mg n 2345 empagliflozin 25 mg n 2342 pooled empagliflozin n 4687
arms, placebo
arms, placebo empagliflozin
arms, secukinumab 150 mg n 202 secukinumab 75 mg n 202 placebo n 202
arms, secukinumab placebo
arms, aliskiren dmvs dm+ placebo dmvs dm+ dm aliskiren vs placebo dm+ aliskiren vs placebo placebo dm vs dm+
arms, enalapril lcz696 n 747 n 752 enalapril n 665 lcz696 n 649 enalapril n 642 lcz696 n 683 enalapril n 490 lcz696 n 497 enalapril n 491 lcz696 n 496
arms, placebo n 503 adalimumab n 966
arms, placebo n 1441 cana 100 mg n 1445 cana 300 mg n 1441 total n 4327
arms, cana pbo
arms, continued thienopyridine n 5 5862 placebo n 5 5786
arms, laa closure n 732 longterm warfarin n 382
arms, placebo ff vi 100 25 pg od ff 100 pgod
arms, liraglutide 30 mg n 2845 placebo n 1651 liraglutide 30 mg n 348 placebo n 202 liraglutide 30 mg n 115 placebo n 53 liraglutide 30 mg n 76 placebo n 35
arms, bivalirudin n 127 control n 265
arms, cangrelor n1558 clopidogrel n1493 cangrelor n3914 clopidogrel n3977
arms, pioglitazone placebo
arms, placebo n 176 baricitinib 2 mg daily n 174 baricitinib 4 mg daily n 177
arms, baricitinib 2 mg baricitinib 4 mg
arms, saxagliptin 25 mg n z 264 saxagliptin 5mg n z 247 placebo n z 261 saxagliptin 25 mg n z 492 saxagliptin 5mg n z 509 placebo n z 435
arms, losmapimod n 1731 placebo n 1758
arms, losmapimod placebo
arms, indacaterol glycopyrronium group n 1680 salmeterolfluticasone group n 1682 patients n 3362
arms, gly 156 mg bid n 251 ind 75 mg qd n 256
arms, gly 156 gg bid n n ind 75 gg qd n n
arms, liraglutide n4 668 placebo n4 672
arms, brv dosage mg
arms, enalapril sacubitril valsartan
arms, placebo plus aspirin clopidogrel plus aspirin
arms, pioglitazone n 1 939 placebo n 1 937
arms, linagliptin n z 1624 placebo n z 600
arms, tofacitinib 5 mg two times day tofacitinib 10 mg two times day mtx
arms, sitagliptin n249 placebo n249
arms, sitagliptin n243 placebo n236 sitagliptin n111 placebo n112 sitagliptin n132 placebo n124
arms, placebo n 118 n etoricoxib 60 mg n 818 n etoricoxib 90 mg n 468 n total n 1404 n
arms, control group n442 monitoring group n435
arms, placebo n440 benralizumab 30 mg q4w n425 benralizumab 30 mg q8w n441 placebo n248 benralizumab 30 mg q4w n241 benralizumab 30 mg q8w n239 placebo n122 benralizumab 30 mg q4w n116 benralizumab 30 mg q8w n125
arms, placebo n407 benralizumab 30 mg q4w n399 benralizumab 30 mg q8w n398 placebo n267 benralizumab 30 mg q4w n275 benralizumab 30 mg q8w n267 placebo n140 benralizumab 30 mg q4w n124 benralizumab 30 mg q8w n131
arms, pbo n 43 evomab n 77 pbo n 99 evomab n 194 pbo n 107 evomab n 182 pbo n 119 evomab n 274
arms, pbo n 43 vs pbo n 99 vs pbo n 107 vs pbo n 119 vs
arms, stent n199 medical therapy n214 stent n209 medical therapy n204 stent n51 medical therapy n54
arms, linagliptin metformin linagliptin
arms, placebo n228 baricitinib 2 mg qd n229 baricitinib 4 mg qd n227
arms, ind gly110 50 pg od n 298 sfc50 500 pg bid n 297
arms, sitagliptin placebo adjusted hr 95 ci interaction p value
arms, mra baseline mra baseline
arms,
arms, placebo evolocumab 420 mg
arms, anacetrapib 25 mg n 152 anacetrapib 100 mg n 153 placebo n 154
arms, secukinumab intravenous 150 mg n86 secukinumab intravenous 75 mg n82
arms, placebo secukinumab 150 mg placebo secukinumab 75 mg placebo secukinumab pooled
arms, olodaterol 5 mg n 1038 tiotropium 5 mg n 1033 tiotropium olodaterol 5 5 mg n 1029
arms, olodaterol 5 g tiotropium 5 g tiotropium olodaterol 5 5 mg
arms, olodaterol 5 mg tiotropium 25 mg tiotropium 5 mg tiotropium olodaterol 25 5 mg tiotropium olodaterol 5 5 mg total
arms, placebo n 189 sitagliptin 100 mg n 191 placebo n 123 sitagliptin 100 mg n 128
arms, placebo n 180 sitagliptin 100mg n 185 placebo n 117 sitagliptin 100 mg n 122
arms, placebo n 5280 belimumab 200 mg sc n 5556
arms, czp+mtxmtx pbo+mtxmtx
arms, czp+mtx mtx pbo+mtx mtx
arms, placeboa sirukumab 50 mg q4w sirukumab 100 mg q2w
arms, pooled simva ez simva
arms, liraglutide 30 mg n1505 placebo n749
arms, pioglitazone placebo
arms, levetiracetam carbamazepine topiramate lamotrigine
arms, rivaroxaban aspirin 100 mg n 1131
arms, rivaroxaban 20 mg aspirin 100 mg
arms, fixed triple n1077 tiotropium n1076 open triple n537
arms, iglarlixi fixedratio combination iglar insulin glargine l00 u
arms, ularitide n 1088 placebo n 1069
arms, placebo n228 baricitinib 2 mg n229 baricitinib 4 mg n227
arms, placebo n4111 fluticasone furoate n4135 vilanterol n4118 combination therapy n4121 total n16 485
arms, placebo n 122 tofacitinib 10 mg n 476 placebo n 112 tofacitinib 10 mg n 429 placebo n 198 tofacitinib 5 mg n 198 tofacitinib 10 mg n 197
arms, abatacept n213 placebo n211
arms, ab ff 400 12 pg n 720 ab 400 pg n720 ff 12 pg n715 placebo n 525
arms, linagliptin n 182 placebo n 178
arms, placebo n1382 empagliflozin n2789 placebo n675 empagliflozin n1338 placebo n260 empagliflozin n509
arms, placebo empagliflozin
arms, laba + ics n 269 ind gly n 811 laba lamab n 268 ind glyb n 811
arms, laba+ics indzgly
arms, laba lama ind gly
arms, rivaroxaban plus aspirin n 9152 rivaroxaban alone n 9117 aspirin alone n 9126
arms, anacetrapib n 15 225 placebo n 15 224 patients n 30 449
arms, liraglutide n4668 placebo n4672
arms, mepolizumab 100 mg n 233 placebo n 229 mepolizumab 100 mg n 417 placebo n 419 mepolizumab 100 mg n 223 mepolizumab 300 mg n 225 placebo n 226
arms, usual care n2119 fluticasone furoate vilanterol n2114
arms, placebo n752 empagliflozin n1498 placebo n1569 empagliflozin n3149
arms, placebo n607 empagliflozin 10 mg n605 empagliflozin 25 mg n607 placebo n1726 empagliflozin 10 mg n1740 empagliflozin 25 mg n1733
arms, alirocumab n 294 placebo n 147 alirocumab n 51 placebo n 25
arms, alirocumab n 287 placebo n 142 alirocumab n 49 placebo n 25 difference vs placebo 95 cl p
arms, ali pbo
arms, exenatide n7356 placebo n7396
arms, placebo ertugliflozin 5 mg ertugliflozin 15 mg
arms, enalapril + aliskiren n 665 aliskiren n 627 enalapril n 652 enalapril + aliskiren n 1675 aliskiren n 1713 enalapril n 1684
arms, pioglitazone n 1939 placebo n 1937
arms, placebo n 122 tofacitinib 10 mg bid n 476 placebo n 112 tofacitinib 10 mg bid n 429 placebo n 198 tofacitinib 5 mg bid n 198 tofacitinib 10 mg bid n 197
arms, placebo tofacitinib 10 mg bid
arms, placebo tofacitinib 5 mg bid tofacitinib 10 mg bid
arms, pioglitazone n1939 placebo n1937
arms, canagliflozin dose
arms, lowdose rivaroxaban plus aspirin n8313 rivaroxaban alone n8250 aspirin alone n 8261
arms, lowdose rivaroxaban plus aspirin n2492 rivaroxaban alone n2474 aspirin alone n2504
arms, iglarlixi iglar
arms, iglarlixi iglar
arms, placebo n3182 canakinumab hscrp 20 mg l 3 months n2868 canakinumab hscrp 20 mg l 3 months n3484
arms, placebo canakinumab
arms, pbo n69 ixeq4w n68 ixeq2w n63 pbo n59 ixeq4w n57 ixeq2w n53 pbo n37 ixeq4w n39 ixeq2w n40
arms, selexipag n 179 placebo n 197 selexipag n 55 placebo n 60 selexipag n 122 placebo n 133
arms, etn 50 mg + mtx n 834 etn 50 mg + mtx n 202 etn 25 mg + mtx n 202 mtx n 200
arms, montelukast n 101 placebo n 105 lebrikizumab n 104
arms, placebo baricitinib 2 mg baricitinib 4 mg
arms, placebo baricitinib 2 mg baricitinib 4 mg
arms, bdp ff g n764 ind gly n768
arms, placebo candesartan
arms, placebo n635 abciximab n630
arms, placebo n 4502 pravastatin n 4512
arms, placebo pravastatin
arms, cilostazol placebo
arms, 10 mg 20 mg 40 mg 80 mg 10 10 mg 10 20 mg 10 40 mg 10 80 mg
arms, 5 mg kg n 242 10 mg kg n 242 combined n 484
arms, fenofibric rosuvastatin + rosuvastatin lvalue jvalucl
arms, aml hctz
arms, 5mg n93 15 mg n95 50 mg n92 150 mg n92
arms, 15mg 50mg
arms, apixaban placebo
arms, 50 n 5 161 100 n 5 332 200 n 5 249
arms, enalapril n 1812 sacubitril valsartan n 1916 enalapril n 2400 sacubitril valsartan n 2271
arms, 100 mg n 74 300 mg n 72 total n 146
arms, acid fenofibric acid
arms, 10 mg 25 mg
arms, common study baseline versus olodaterol 5 pg versus tiotropium 5 pg versus tiotropium 25 pg versus tiotropium+olodaterol 25 5 pg
measures;arms, patients irofiban abciximab
measures;arms, gfr ml min per 173 nr patients esrd losartan esrd placebo risk reduction 95 ci p losartan versus placebo chf losartan chf placebo
measures;arms, etoricoxib diclofenac
measures;arms, metoprolol group n4174 placebo group n4177
measures;arms, mean yearly decline tiotropium control
measures;arms, placebo n n czp 400 mg n n odds ratio 95 cl p value
measures;arms, linagliptin patients events total patients total comparators patients events total patients cox hr 95 ci cmh rr 95 ci
measures;arms, hr 95 cl insulin glargine n 100py standard care n 100py p
measures;arms, lsm 95 cl n1 n2
measures;arms, n12 410 vorapaxar n6203 placebo n6207 n4487 vorapaxar n2255 placebo n2232
measures;arms, indacaterol glycopyrronium group salmeterol fluticasone group rate ratio 95 cl
measures;arms, mepolizumab group placebo group rate ratio 95 cl
measures;arms, placebo n 153 ertugliflozin 5 mg n 156 ertugliflozin 15 mg n 153 total n 462
measures;arms, liraglutide 30 mg placebo placebo etd 95 ci
baseline_level_2, history high cholesterol 3 infarction age 60 never past current rarely monthly weekly daily
baseline_level_2, cabg aspirin digoxin ace inhibitor anyantianginal agent calcium channel blocker pblocker bmi mean sd waist circumference mean sd systolic diastolic hdlc triglycerides ldlc total cholesterol fpg mean sd mg dlt fpi mean sd pu mlt age mean sd race nonwhite smoking current alcohol 1 drink hypertension prior myocardial infarction prior stroke congestive heart failure ptca cabg ptca
baseline_level_2, median interquartile range nonhispanic white nonhispanic black hispanic
baseline_level_2, gender male female white black bmi kg m2 mean sd patients n age years mean sd
baseline_level_2, diabetes hypertension smoking history hypercholesterolemia cerebrovascular disease renal insufficiency previous ml previous cabg surgery previous ptca chf history comorbidity score mean sd peripheral vascular disease systolic blood pressure mean sd mm hg body mass index mean sd q wave nonq wave indeterminate unknown anterior inferior severe dysfunction moderate dysfunction mild dysfunction normal killip class llliv thrombolytic therapy cabg surgery cardiac catheterization ptca 24 h ace inhibitors anticoagulants aspirin pblockers lipidlowering drugs depressed low perceived social support depressed low perceived social support age mean sd sex female race nonwhite marital status married education high school higher
baseline_level_2, 70 women black hispanic asian multiracial concordant stress test abnormalities smoking past within last 30 never cancer nitrates
baseline_level_2, 4554 5564 65+ reported hypertension reported high cholesterol reported diabetes mellitus mean body mass index kg m2 parental history mii never past current daily weekly rarely never physical activity multivitamin use current
baseline_level_2, female male white b lack hispanic ldlc mean sd mg dl tg median sdy rng cjl tc mean sd rrig dl hdlc mean sd mg dl nonhdlc mean sd rng dl ldlcihdlc mean sd tchdlc mean sd apo b mean sd mg dl apo a1 mean sd mg dl crp median se rng l plpc mean sd mg dl
baseline_level_2, median interquartile range nonsustained ventricular tachycardia j ace inhibitor enrollment ace inhibitor last followup arb enrollment arb last followup ace inhibitor arb enrollment ace inhibitor arb last followup betablocker enrollment betablocker last followup loop enrollment loop last followup potassiumsparing enrollment potassiumsparing last followup thiazide enrollment thiazide last followup digoxin enrollment digoxin last followup aspirin enrollment aspirin last followup warfarin enrollment warfarin last followup statin enrollment statin last followup
baseline_level_2, 65 yr current past never mean sd 250 250 299 300 premenopausal uncertain postmenopausal current hrt postmenopausal hrt yes 120 75 mm hg 120129 7584 mm hg 130139 8589 mm hg 140 90 mm hg 50 50 99 100 0 1 2 3 mean sd yr 4554 yr 5564 yr
baseline_level_2, mean sd range number patients 65 years number females white black weight mean sd kg body mass index mean sd kg m2 duration hypercholesterolemia mean sd years hypertension dm 10 mg 20 mg ldlc tc tg hdlc nonhdlc ldlc hdlc ratio tc hdlc ratio apo b g l
baseline_level_2, mean sd 4554 5564 65 25 25 30 30 current past never 1 1 1000 1000 premenopausal uncertain postmenopausal current ht postmenopausal ht yes
baseline_level_2, mean sd range number patients 65 years number females n white black weight mean sd kg body mass index mean + sd kg duration hypercholesterolaemia mean sd year hypertension dm drugs used diabetes antithrombotic agents antihypertensive agents cardiac therapy peripheral vasodilators vasoprotectives ldlc tc tgt hdlc nonhdlc ldlc hdlc ratio tc hdlc ratio apo bt
baseline_level_2, female sex white black hispanic bodymass index duration osteoarthritis symptoms yr time since diagnosis osteoarthritis yr 500mg acetaminophen tablets day ii iii unknown kellgren lawrence radiographic reading grade 2 physician patient joint swelling effusion clinical examination pain subscale stiffness subscale function subscale normalized alternative disability pain physical component mental component age yr
baseline_level_2, 660 110 236 233 632 625 252 249 92 91 230 227 623 616 245 242 102 101 272 39 513 507 226 223 61 93 753 744 533 123 241 238 812 802 146 78 29 052 688 165 484 478 938 927 957 946 885 875 33 33
baseline_level_2, female male yes
baseline_level_2, female male c nonc known chd hyper tension diabetes mellitus baseline ldlc 160 mg dl ldlc tc tg hdlc non hdlc apo b apo ai
baseline_level_2, three arm two arm male age years mean sd transient monocular blindness transient ischaemic attack minor ischaemic stroke 1 week 1 week 1 month 16 months 0no symptoms 1minor symptoms limitations 2some restrictions help needed 3help needed still independent ct mr scan brain infarct relevant infarct ultrasound carotid arteries stenosis 50 stroke angina pectoris myocardial infarction intermittent claudication vascular intervention diabetes mellitus hypertension hyperlipidaemia current cigarette smoking systolic mean sd diastolic mean sd large vessel small vessel unspecified aspirin oral anticoagulants none 30 mg 40 mg 50 mg 75 mg 80 mg 100 mg 150 mg 160 mg 250 mg 300 mg 325 mg
baseline_level_2, 293 742 50 127 31 78 21 53 289 732 236 597 144 365 349 884 395 1000 n 388 323 + 72 blood pressure pbo patients diabe teristics ncep atp 609 + 114 210 532 185 468
baseline_level_2, aspirin ace inhibitors 0blockers statins
baseline_level_2, male sex white black asian hispanic north america europe 1 yr 12 yr 2 yr weight kg bodymass index waist circumference cm hip circumference cm waisttohip ratio systolic mm hg diastolic mm hg antihypertensive therapy fasting plasma glucose mg dl glycated hemoglobin fasting insulin pmol liter median interquartile range gad positive lipidlowering therapy age yr
baseline_level_2, age year median interquartile range male sex n hypertension n diabetes n current smoking n cholesterol 55 mmol l n family history n previous myocardial infarction n previous angina n previous angioplasty n heart rates beats minutes systolic blood pressure mm hg aspirin n betablockers n aceinhibitors n calcium antagonists n interval onset symptoms interval randomization angiography angiographic features infarct related artery location left anterior descending n left circumflex n rca n number vessels disease nonstenotic vessels n singlevessel disease n doublevessel disease n triplevessel disease n degree stenosis diameter evidence thombus n
baseline_level_2, age mean sd sex female n race white n disease duration yr mean sd mayo score mean sd aminosalicylates corticosteroids immunomodulatory agents left side extensive ibdq mean sd sf36 pcs mean sd sf36 mcs mean sd
baseline_level_2, cabgorptca smoking diabetes hypertension serum lipid values total cholesterol mmol l ldlcholesterol mmol l hdlcholesterol mmol l triglyceride mmol l blood pressure systolic mm hg diastolic mm hg pravastatin simvastatin statin antiplatelet agent calcium antagonist p blocker antihypertensive agents nitrate hypoglycaemic agents age years male bmi kg m2 cardiovascular history myocardial infarction angina
baseline_level_2, female age mean minmax yrs white hispanic black asian native american duration ra mean minmax yrs insulin dependentc oral hypoglycaemics comorbidities diabetes chronic pulmonary disease pneumonia past year bronchitis sinusitis urinary tract infection coronary artery disease myocardial infarction hypertension congestive heart failure definite arrhythmia least two cardiovascular risk factors
baseline_level_2, history major macrovascular disease n history myocardial infarction n history stroke n history major microvascular disease n history macroalbuminuriat n history microvascular eye diseaseu+672c n systolic blood pressure mm hg mean sd diastolic blood pressure mm hg mean sd history currently treated hypertension n current smokers n serum total cholesterol mmol l mean sd serum hdl cholesterol mmol l mean sd urinary albumincreatinine ratio pg mg median iqr microalbuminuria n serum creatinine pmol l mean sd serum haemoglobin a1c concentration mean sd bodymass index kg m2 mean sd
baseline_level_2, mean yr 75 yr female sex ii iii iv ejection fraction bodymass index systolic diastolic heart rate beats min current smoker myocardial infarction past current angina pectoris cabg pci hypertension diabetes mellitus current atrial fibrillation flutter ecg stroke pacemaker implantable cardioverterdefibrillator total lowdensity lipoprotein highdensity lipoprotein apobapoal ratio triglycerides mmol liter mean 130 tmol liter 60 ml min 173 m2 median interquartile range loop diuretic loop thiazide diuretic aldosterone antagonist ace inhibitor ace inhibitor arb betablocker digitalis glycoside antiarrhythmic therapy antiplatelet therapy anticoagulant therapy antiplatelet anticoagulant therapy
baseline_level_2, female n asian black white hispanic systolic bp mm hg diastolic bp mm hg uacr mgg 1 gm serum creatinine limo 1 1 egfr ml min 1 173 2 triglycerides mmolt1 gm serum albumin g 1 1 hemoglobin g 1 1 calcium mmol 1 1 phosphorus mmol 1 1 age years male n
baseline_level_2, mean sd 55 n 55 n bmi mean sd kg m2 sbp mean sd mm hg dbp mean sd mm hg hypertension n diabetes n smoker n drinking n lipid values mmol l tc mean sd ldlc mean sd hdlc mean sd tg median interquartile range lp mean sd bmi indicates body mass index sbp systolic blood pressure dbp lipoprotein ldlc calculated friedewald formula hypertension diabetes based physician diagnosis smoker includes current past smokers
baseline_level_2, age yr female male asian black hispanic white body mass index3 5 yr 5 yr available systolic diastolic use antihypertensive drugs angina pectoris myocardial infarction coronary revascularization procedure stroke lipid disorder amputation neuropathy retinopathy current smoking urinary albumin creatinine ratio median mg g range serum creatinine mg dlb glomerular filtration rate 3 ml min 173 m2 total ldl hdl serum triglycerides mg dle hemoglobin g dlf glycosylated hemoglobin serum albumin g dl
baseline_level_2, postmenopausal 1 year 12 years 2 years bmi kg m2 waist circumference cm waisttohip ratio systolic blood pressure mmhg diastolic blood pressure mmhg fasting plasma glucose mg dl a1c fasting insulin pmol l estrogencontaining hormones calcium supplements bisphosphonates glucocorticoids thiazide diuretics loop diuretics n age years
baseline_level_2, age ya 65 65 70 75 male female white black mssbp mm hga msdbp mm hga sitting pulse bpma arb acei pblocker ccb diuretic severe less severe diabetic nondiabetic
baseline_level_2, history diabetes never past current 15 cigs day current 15+ cigs day rarely 1 week 13 week 4 week 13 month 16 week 1 day postmenopausal current mean sd age years mean sd bmi kg m2 bmi 30 kg m2 history hypertension
baseline_level_2, waist cm total ldl hdl nonhdl triglycerides mg dl systolic blood pressure mm hg diastolic blood pressure mm hg ale lifestyle oral hypoglycemics insulin insulin plus oral egfr smoking never current former yes crp mg dl imt mm arterial area mm2 plaque score 18 plaque n lv mass lv mass index g m27 lv ejection fraction age years gender women n body mass index bmi kg m2
baseline_level_2, cerebral thrombosis cerebral embolism tia cerebral hemorrhage subarachnoid hemorrhage unknown
baseline_level_2, emergent urgent surgery history hypertension current smoker aspirin lowmolecular weight heparin intravenous unfractionated heparin ace inhibitor arb statin diuretic calcium channel blocker vascular intraperitoneal orthopaedic general spinal lumbar epidural general andthoracic epidural general lumbar epidural regional anaesthesia age years sex female preoperative heart rate beats per minute preoperative blood pressure mm hg patients fulfilling eligibility criteria coronary artery disease peripheral arterial disease stroke thought due atherothrombotic disease hospitalisation chf within 3 years randomisation undergoing major vascular surgery three seven risk factors intrathoracic intraperitoneal surgery history congestive heart failure diabetes currently oral hypoglycaemic agent orinsulin preoperative serum creatinine 175 pmol l age 70 years history transient ischaemic attack
baseline_level_2, agemean sd years age 70 female white hispanic black bmimean sd kg m2 history ml heart failure class llll chronic stable angina unstableangina dyslipidemia3 lvh arrhythmia stroke ortiab pvd renal insufficiency11 diabetes3 obese cancer eversmoker aspirin antiplatelet nsaids antidiabetic lipid lowering nitrates potassium hrt systolicmean sd mm hg diastolicmean sd mm hg controlled11no
baseline_level_2, female sex asia europe israel australia latin america south africa united states canada african chinese south asian asian white european native latin bmi waist circumference cm never currently previously regular consumption 114 drinks wk 15+ drinks wk obesity sedentary physical activity intense physical activity median days 10 days 1130 days 3190 days 90 days largeartery atherosclerosis cardioembolism smallartery occlusion lacune acute stroke determined cause stroke undetermined cause 0 1 2 35 01 23 45 614 14 previous stroke tia previous stroke tia atherosclerotic disease mi ischemic coronary artery disease paod chf hypertension diabetes mellitus hyperlipidemia atrial fibrillation valvular disease deepvein thrombosis age yr
baseline_level_2, female sex chinese south asian asian african white european native latin previous stroke tia atherosclerotic disease atrial fibrillation hypertension diabetes mellitus hyperlipidemia left ventricular hypertrophy current past statin ace inhibitor diuretic calciumchannel blocker betablocker index stroke 10 days randomization largeartery atherosclerosis cardioembolism smallartery occlusion 0 1 2 35 01 23 45 614 14 age yr blood pressure mm hg heart rate beats min bodymass index
baseline_level_2, age years age 70 years women bmi kg m2 sbp mm hg dbp mm hg heart rate beats per min current smoking history hypertension ii iii iv lvef lvef 40 admission hf previous year previous ami previous stroke diabetes cabg pci icd pacemaker history atrial fibrillation peripheral vascular disease copd neoplasia ischaemic dilatative hypertensive cause nondetectable unknown pulmonary rales third heart sound mitral insufficiency aortic stenosis qrs 120 ms atrial fibrillation pathological q waves left ventricular hypertrophy ace inhibitors arbs ace inhibitors arbs p blockers spironolactone diuretic drugs digitalis oral anticoagulant drugs aspirin antiplatelet agents nitrates calciumchannel blockers amiodarone
baseline_level_2, age years age 70 years women bmi kg rrr sbp mm hg dbp mmhg heart rate beats per min current smoking history hypertension ii iii iv lvef lvef 40 admission hf previous year previous ami previous stroke diabetes mellitus cabg pci icd pacemaker history atrial fibrillation peripheral vascular disease copd neoplasia ischaemic dilatative hypertensive nondetectable unknown pulmonary rales third heart sound mitral insufficiency aortic stenosis qrs 120 ms atrial fibrillation pathological q waves left ventricular hypertrophy ace inhibitors arbs ace inhibitors arbs p blockers spironolactone diuretic drugs digitalis oral anticoagulant drugs aspirin antiplatelet agents nitrates calciumchannel blockers amiodarone statin open
baseline_level_2, 65 65 75 75 prior lower gi clinical event prior upper gi clinical event established atherosclerotic cardiovascular disease cox2 selective nsaid use systemic corticosteroid use
baseline_level_2, total population n 4554 years 5564 years 65 years 250 kg m2 250299 kg m2 300 kg m2 white hispanic origin african american hispanic american indian alaskan native asian pacific islander unknown none family history diabetes current smoker exercise weekly alcohol consumption weekly history hypertension history hyperlipidemia postmenopausal baseline use hormone therapy available baseline blood specimen n total cholesterol mmol l ldl cholesterol mmol l hdl cholesterol mmol l total cholesteroltohdl cholesterol ratio nonhdl cholesterol mmol l a1c hscrp mg l
baseline_level_2, bodymass index current smoker smoking history packyr duration copd yr fev1 liters fev1 predicted value fvc liters ratio fev1 fvc ii iii iv sgrq total score units shortacting longacting inhaled oral theophylline compound mucolytic agent leukotrienereceptor antagonist supplemental oxygen male sex age yr
baseline_level_2, mean yr 75 yr female sex white black asian ii iii iv heart rate beats min systolic diastolic bodymass index left ventricular hypertrophy left bundlebranch block atrial fibrillation flutter ejection fraction ischemia hypertension hospitalization heart failure within previous 6 mo angina symptoms unstable angina myocardial infarction pci orcabg atrial fibrillation diabetes mellitus stroke transient ischemic attack median interquartile range mean g dl anemia creatinine mg dl mean ml min 173 m2 bodysurface area 60 ml min 173 m2 potassium mmol liter diureticff loop thiazide spironolactone ace inhibitor digoxin betablocker antiarrhythmic drug calciumchannel blocker nitrate oral anticoagulant antiplatelet lipidlowering agent
baseline_level_2, mean age yrs white black 30 30 chd forms atherosclerosis diabetes mellitus multiple 2 chd risk factors confer 10year risk chd 20 family history premature chdj metabolic syndrome 3 5 characteristics waist circumference s102 men 88 cm women triglycerides 150 mg dl hdl cholesterol 40 men 50 mg dl women hypertension fasting blood glucose 100 mg dl 70 100 mg dl 100 130 mg dl 130 160 mg dl men women
baseline_level_2, sex female chinese indian korean weight range kg body mass index range kg m2 randomized patients range randomized patients fpg range mmol l age range years
baseline_level_2, male female mean sd median range 65 years 65 years 75 years white asian black african american native hawaiian american indian median range patients 8 patients 8
baseline_level_2, age 65 years n male f emale black hispanic black mean bmi kg m2 sd diabetes n isolated systolic hypertension n mssbp msdbp mssbp 180mmhg mssbp 180mmhg mean pulse pressure mmhg sd intenttotreat population n safety population n mean age years
baseline_level_2, age women n arterial hypertension n hypercholesterolemia n diabetes mellitus n insulinrequiring current smoker n body mass index kg m2 history mi n history cabg surgery n infarct localization n anterior inferior lateral killip class n ii iii iv systolic diastolic heart rate bpm peak creatine kinasemb u l
baseline_level_2, 5 yr education systolic diastolic 2 episodes atrial fibrillation previous 6 mo cardioversion previous 2 wk duration last qualifying episode atrial fibrillation 7 days heart failure lvef 40 history hypertension 6 mo diabetes mellitus history stroke peripheral artery disease documented coronary artery disease atrial fibrillation alone peripheral embolism previous transient ischemic attack renal dysfunction chronic obstructive pulmonary disease neoplasia current smoker alcohol abuse heart rate bpm qrs interval 120 msec left ventricular hypertrophy pathologic q waves amiodarone sotalol class 1 antiarrhythmic agents ace inhibitors calciumchannel blockers betablockers digitalis diuretics aldosterone blockers statins oral anticoagulants aspirin age yr female sex bodymass index
baseline_level_2, 660 1 789 369 1 469 1 781 825 1 209 1 630 742 384 1 788 215 801 1 769 453 460 1 789 257 624 1 789 349 672 768 875 491 1 766 278 743 1 766 421 532 1 766 301 425 1 784 238 893 1 789 499 1 707 1 789 954 988 1 789 552 1 575 1 789 880 544 1 789 304 728 1 789 407 1 426 1 789 797 1 403 1 789 784 65 57 73 334 1 789 187 640 1 789 358 1 689 1 789 944 80 72 91
baseline_level_2, age yrs male female former current total packyrs baseline fev1# reversibility patients n
baseline_level_2, bmi25 coronary artery disease hypertension total cholesterol mg dl ldlcholesterol mg dl hdlcholesterol mg dl triglyceride median mg dl 1 2575 percentile epa mol fpg mg dl hba c systolic mmhg diastolic mmhg average age year male smoker drinker
baseline_level_2, age years male asian black africanamerican white hispanic latin american hawaiian pacific islander 1 2 3 4 5 6 congestive heart failure history hypertension age 75 years diabetes previous transient ischaemic attack ischaemic stroke previous warfarin use less 1 year 1 year estimate paroxysmal persistent permanent unknown left ventricular ejection fraction
baseline_level_2, age years prebronchodilator postbronchodilator bodymass index kg m2 current smoker smoking history packyears duration copd years sgrq total score units male
baseline_level_2, lvef mean sd admission hf previous year n previous ami n previous stroke n diabetes n cabg n pci n icd n pacemaker n history paroxysmal atrial fibrillation n peripheral vascular disease n chronic obstructive pulmonary disease n neoplasia n ischemic aetiology n pulmonary rales n third heart sound n mitral insufficiency n aortic stenosis n qrs 120 ms n available 3653 patients left ventricular hypertrophy n total cholesterol mg dl mean + sd available 3658 patients ldl cholesterol mg dl mean + sd available 3306 patients hdl cholesterol mg dl mean + sd available 3552 patients triglycerides mg dl mean + sd available 3643 patients haemoglobin g dl mean + sd available 3666 patients potassium meql mean + sd available 3662 patients aceinhibitors arbs n betablockers n spironolactone n diuretic drugs n digitalis n oral anticoagulant drugs n aspirin antiplatelet agents n nitrates n amiodarone n patients characteristics age years mean + sd age 70 years n women n risk factors bmi kg m2 mean + sd sbp mmhg mean sd heart rate bpm mean sd history hypertension n alcohol consumption n nyha class n ii llliv
baseline_level_2, female male meansd 65 years n 65 years n caucasian black total population 65 years 65 years
baseline_level_2, age mean yr sd male female white since onset since diagnosis prior ms therapies ended 90 days trial entry median min max mean sd 40 0 0 median minimummaximum msfc timed 25foot walk test median seconds
baseline_level_2, 75 past current current smoker diabetes treated insulin previous mi previous chf hypertension hypercholesterolemia treated anterior inferior posterior localized killip class ii iii iv unknown women age yrs mean sd
baseline_level_2, history stroke never smoked exsmoker current smoker time treatment initiation min 180210 211240 241270 age years men weight kg baseline nihss median iqr systolic blood pressure mm hg diastolic blood pressure mm hg diabetes previous use antiplatelet drugs hypertension atrial flutter fibrillation
baseline_level_2, median interquartile range male female white asian black hispanic interquartile range height cm stable angina unstable angina myocardial infarction without stsegment elevation stsegmentelevation myocardial infarction diabetes mellitus current smoker hypertension hyperlipidemia stroke transient ischemic attack family history coronary artery disease myocardial infarction ptca pci coronaryartery bypass grafting congestive heart failure peripheral artery disease bivalirudin unfractionated heparin lowmolecularweight heparin glycoprotein iib iiia inhibitors 1 2 3 drugeluting stent nondrugeluting stent threatened abrupt vessel closure unsuccessful procedure abrupt vessel closure new suspected thrombus acute stent thrombosis need urgent coronaryartery bypass grafting intravenous study drug administered bolus administered infusion administered total oral study drug administered total
baseline_level_2, mean age years sd male n female n white black 30 30 metabolic syndrome chd n forms multiple 2+ chd risk family history premature tg 150 mg dl n hbalc mean sd fasting glucose mg dl 70 100 mg dl 100 130 mg dl 130 160 mg dl characteristics
baseline_level_2, treatment difference 95 ci treatment difference 95 cl
baseline_level_2, current smoker sulfonylurea biguanide metformin insulin thiazolidinedione aglucosidase inhibitor meglitinide antidiabetic drug monotherapy dual therapy three drugs n age years median 25th 75th percentile female sex weight kg m2 median 25th 75th percentile bmi kg m2 median 25th 75th percentile hypertension hyperlipidemia
baseline_level_2, crohns disease activity index score ileum colon ileum colon ileum colon proximal gastrointestinal tract 0 20 mg 20 mg budesonide 5aminosalicylic compounds male sex white race median age yr median body weight kg median disease duration yr median creactive protein mg dl
baseline_level_2, age years bmi current history packyears duration copd years ii iii iv sgrq total score units prebronchodilator postbronchodilator patients 12 200 ml increase fev1 postbronchodilator pulmonary medication anticholinergics longacting anticholinergics shortacting bagonists longacting bagonists shortacting leukotriene receptor antagonists mucolytics supplemental oxygen steroids inhaled steroids theophyllines
baseline_level_2, male n caucasian asian black current smoker n current cvd diabetes n highrisk cvd n mean 10year cvd risk type 1 n type 2 n ldlc hdlc total cholesterol triglycerides median range age years 70 years n
baseline_level_2, mean duration disease years terminal ileum colon ileocolon upper gastrointestinal resection performed mean cdai score geometric mean crp concentration mg l penetrating disease corticosteroids immunosuppressants corticosteroids immunosuppressants corticosteroids immunosuppressants mean sd age years male
baseline_level_2, n met criterion blt n met criterion final n met criterion bl n met criterion finalt n bl mean mg dl mmol 1 mean sem bl mean mmhg mean sd mmhg mean sd mg dl mmol 1 bl mean cm mean sdt
baseline_level_2, menwomen age years current smokerexsmoker smoking history packyears time since copd diagnosis yrs prebronchodilator fev1 l prebronchodilator fev1 predicted normal prebronchodilator fvc l prebronchodilator fev1 fvc postbronchodilator fev1 l postbronchodilator fev1 predicted normal reversibility fev1 postbronchodilator fvc l postbronchodilator fev1 fvc fev1 l fev1 predicted normal fvc l proportion taking pulmonary medications b medication longacting b2agonists shortacting b2agonists inhaled corticosteroids oral corticosteroids xanthines mucolytics shortacting anticholinergics supplementary oxygen
baseline_level_2, men n white black hispanic asian oriental multiracial europe north america latin america africa asia middle east australia mean body mass index sd kg m2 body mass index 30 kg m2 n acute infection without septic shock acute respiratory insufficiency heart failure postacute ischemic stroke acute rheumatic disorders active cancer fracture multiple diagnoses active inflammatory bowel disease level 1 immobility level 2 immobility age 75 cancer history vte age 75 active previous cancer history vte obesity body mass index 30 kg m2 venous insufficiency hormone therapy chronic heart failure chronic respiratory failure chronic inflammatory disease family history vte thrombophilia antiplatelet antiinflammatory drugs antiplatelet drugs antiinflammatory drugs mean age sd
baseline_level_2, 50 n usa asia pacific eastern europe western europe current smoker n packyears smoked ics alone laba alone ics + laba neither ics laba previous mi n 0 1 2 baseline cv treatment n baseline shortacting anticholinergics n age enrolment years male gender n body mass index kg m2 postbronchodilator fev1 predicted 30 n 30e 50 n
baseline_level_2, age years sex male ethnic origin white asian current smoking bmi kg m2 cardiac parameters heart rate bpm sbp mm hg dbp mmhg lvef egfr ml min per 173 m3 class ii class iii class iv ischaemic nonischaemic myocardial infarction hypertension diabetes previous stroke history atrial fibrillation flutter treatment randomisation p blocker ace inhibitor arb diuretic drugs excluding antialdosterone antialdosterone agents cardiac glycosides devices crt icd
baseline_level_2, age yrs age 75 yrs n female sex n nyha functional class n ii iii iv ejection fraction bmi kg m2 systolic blood pressure mm hg diastolic blood pressure mm hg heart rate beats min myocardial infarction angina pectoris cabg ptca pci hypertension diabetes mellitus af atrial flutter stroke intermittent claudication total cholesterol mmol lt ldl cholesterol mmol lt hdl cholesterol mmol lt apoa1 g l apob g l triglycerides mmol l serum creatinine xmol l serum creatinine 130 xmol l n egfrmdrd ml min 173 m2 bsa ntprobnp pmol h hscrp mg l coenzyme q10 p g ml# loop diuretic aldosterone antagonist ace inhibitor arb betablocker digitalis glycoside antiarrhythmic therapy
baseline_level_2, variable age yr sex male female race white bodymass index systolic diastolic heart rate rest supine position beats min respiratory rate breaths min bnp pg ml h median interquartile range ntprobnp pg ml h creatinine clearance ml min left ventricular ejection fraction within previous 6 mo heart failure 1 mo admission ischemic heart disease myocardial infarction hypertension atrial fibrillation implantable cardioverterdefibrillator biventricular pacemaker diabetes copd asthma ace inhibitor arb betablocker aldosterone blocker nitrates oral topical digoxin days studydrug administration 1 day 2 3 days total intravenous loop diuretic mg median intravenous inotropes vasopressors intravenous vasodilators
baseline_level_2, mean sd 65 n gender n female white black asian hispanic latino waist circumference cm mean sd male body mass index kg m2 mean sd hypertension coronaiy artery disease myocardial infarction type 2 diabetes mellitus obesity metabolic syndrome11 baseline lipids mg dl hdlc mean sd tg median min max ldlc mean sd
baseline_level_2, missing data 30 ml min 3049 ml min 5079 ml min 80 ml min missing data initial diagnosis dvt pe median interquartile range unprovoked recent surgery trauma immobilization estrogen therapy active cancer puerperium known thrombophilic condition previous vte age yr male sex weight 50 kg 50100 kg 100 kg
baseline_level_2, male white black mean sd range 70 waist circumference cm cad hypertension metabolic syndrome1 obesity metformin glipizide pioglitazone rosiglitazone ldlc hdlcd tg apobe
baseline_level_2, weight kg mean sd extensive colitisy leftsided colitisz otherx disease duration years median range mayo score mean sd endoscopy subscore rectal bleeding subscore pga subscore stool frequency subscore crp mg l median range corticosteroid without imm imm without corticosteroid corticosteroid + imm corticosteroid imm aminosalicylates male age years median range
baseline_level_2, age years mean sd 65 65 75 men women white weight kg mean sd body mass index kg m2 moderate severe esrd mean sd 5 n 10 n hba1c 80 80to90 9 0 fpg mmol l crcb ml min mean se diabetes therapy n insulin oral blood glucoselowering drug 23 271 aglucosidase inhibitor sulphonylurea glinide thiazolidinedione oral blood glucoselowering
baseline_level_2, chronic stable angina acs 3blockers ace inhibitors sartans multivessel disease multivessel pci left main left anterior descending left circumflex right coronary saphenous vein graft lesions b2 c unfractionated heparin bivalirudin enoxaparin glycoprotein llb llla inhibitors
baseline_level_2, united states japan south korea mean sd median range sex men median duration symptoms range yr median time since diagnosis range yr ever smoked current former never smoked mean fvc sd mean dlco sd pao2 rest mm hg aapo2 rest mm hg yes corticosteroid use 11 n baseline dyspnea index mean total score sf36 health transition score eq5d visual analog score use supplemental oxygen n
baseline_level_2, patients median 64 median 64 never smoked ever smoked current former us japan south korea median 28 median 28 baseline dlco mmol kpa median 45 median 45
baseline_level_2, age years american indian alaska asian black african american multiracial white body mass index kg nr high risk atherosclerotic vascular disease high risk without atherosclerotic vascular disease+ moderately high risk without atherosclerotic vascular disease 70 70100 100130 130160 160 men women
baseline_level_2, bmi kg m2 usa asiapacific eastern europe western europe current smoker packyears smoked postbronchodilator fev1 l postbronchodilator fev1 predicted reversibility predicted fev1 prebronchodilator fev1 fvc ratio baseline sgrq total score age enrollment years male gender
baseline_level_2, mean body mass index kg m2 geometric mean baseline terminal ileum colon ileocolon inflammatory stricturing 0 1 2 3 3 corticosteroid without immunosuppressants immunosuppressant without corticosteroid corticosteroid immunosuppressant corticosteroid immunosuppressant neither corticosteroid immunosuppressant ibdq score mean sd
baseline_level_2, body weight kg mean sd colon ileum gastroduodenum draining cutaneous fistula baseline n baseline cdai score mean sd mean sd median range previous tnfantagonist use n immunosuppressants aminosalicylates current smoker n male patients n age years mean sd
baseline_level_2, 25 kg m2 25 299 kg m2 30 kg m2 never past current
baseline_level_2, median interquartile range female sex age 65 yr history diabetes mellitus myocardial infarction within previous 5 yr history cerebrovascular disease history peripheral vascular disease heart failure lvef 40 associated index acs event history impaired renal function revascularization index acs event heart failure prior coronary revascularization stsegment elevation myocardial infarction nonstsegment elevation myocardial infarction unstable angina elevated cardiac markers coronary angiography pci cabg medical therapy use parenteral antithrombotic agents angiotensinconvertingenzyme inhibitor angiotensinreceptor blocker betablocker statin protonpump inhibitor
baseline_level_2, sex male female white black asian duration copd moderate severe severe ics use yes exsmoker smoker smoking history packyears fev1 predicted postalbuterol fev1 fvc postalbuterol fev1 prealbuterol l fev1 postalbuterol l fev1 reversibility pre postalbuterol use rescue albuterol puffs day days without albuterol use baseline sgrq score age
baseline_level_2, male female age years bmi kg m2 white black asian hba1c mmol mol hba1c fpg mmol l 1 years 15 years 5 years none 1 2 3 metabolic syndrome coronary artery disease cerebrovascular disease peripheral artery disease hypertension ex current smoker normal mildly impaired moderately impaired severely impaired acetylsalicylic acid antihypertensive lipidlowering therapy score score 15 patients
baseline_level_2, median yr interquartile range yr 75 yr female sex white race total f myocardial infarction ischemic stroke peripheral arterial disease diabetes mellitus hypertension hyperlipidemia current smoker coronary artery disease previous coronary revascularization peripheral arterial disease previous cerebrovascular event estimated glomerular filtration rate 60 ml min 173 m2i aspirin thienopyridine dipyridamole lipidlowering agent angiotensinconvertingenzyme inhibitor angiotensin receptor blocker
baseline_level_2, mean disease duration sd oral aminosalicylates corticosteroidsa immunosuppressants antitnf agent mean hscrp mg l sd immunosuppressant use prednisone use mean cdai score sd mean mayo score sd leftsided disease extensive disease mean age sd sex female mean weight kg sd
baseline_level_2, sex men women caucasian black asian native american duration copd years mean sd moderatey severe severe ics use yes exsmoker smoker packyears mean sd fev1 predicted post salbutamol fev1 fvc post salbutamol fev1 litres pre salbutamol mean sd fev1 litres postsalbutamol mean sd fev1 reversibilityz pre post salbutamol fev1 litres pre ipratropium mean sd fev1 litres post ipratropium mean sd fev1 reversibilityz pre post ipratropium age years mean sd
baseline_level_2, sex female systolic diastolic cerebrovascular disease peripheral vascular disease angina pectorisf arrhythmia atrial fibrillation congestive heart failure bmi mean sd current smoker former smoker never smoked hypertension diabetes mellitus prerandomization statin therapy aspirin betablocker calcium antagonist ace inhibitors angiotensin ii blockers patients ra patients patients psa age mean sd years
baseline_level_2, characteristic age yr female sex prior cardiovascular event j prior myocardial infarction prior stroke hypertension current smoker albuminuria anklebrachial index 09 use oforal glucoselowering agent use ofdiabetes drugs new diabetes impaired glucose tolerance impaired fasting glucose duration ofdiabetes yr median interquartile range metformin sulfonylurea nonglycemic cardiovascular risk factors systolic blood pressure mmhg diastolic blood pressure mm hg weight kg bodymass index waisttohip ratio men women total cholesterol mg dl ldl cholesterol mg dl hdl cholesterol mg dl triglycerides mg dl creatinine mg dl urinary albumintocreatinine ratio statin thiazide diuretic ace inhibitor arb betablocker bloodpressure drug antiplatelet drug
baseline_level_2, white n mean 10 n baseline cdai baseline ibdq total score mean fistula baseline n current prior never age yrs mean women n
baseline_level_2, age mean sd 75 75 sex male asian white black tia hypertension hypertension treated atrial fibrillation diabetes mellitus hyperlipidemia current former never baseline nihss score median range body mass index kg m2 mean sd systolic blood pressure mm hg mean sd diastolic blood pressure mm hg mean sd 0 drinks 114 drinks 15 drinks sedentary intense largeartery atherosclerosis cardioembolism smallartery occlusion determined etiology undetermined etiology ace inhibitor alpha receptor antagonist beta receptor antagonist calcium channel blocker diuretic
baseline_level_2, total periventricular wml score mean sd subcortical wml load diameter mm mean sd subcortical wml load diameter mm mean sd none mild moderate severe
baseline_level_2, age yr mean range tender swollen mean score haqdi mean score score 51 mean score das283 crp erythrocyte sedimentation rate mm hr creactive protein mg liter positive rheumatoid factor anticyclic citrullinated peptide antibodies ff tnf inhibitor biologic agent methotrexate nonbiologic diseasemodifying drug methotrexate prior diseasemodifying drugs resulting inadequate response mean patient female sex white race f
baseline_level_2, weight 60 kg 3 months 36 months 6 months diabetes mellitus hypertension hyperlipidaemia current smoker previous coronary revascularisation peripheral arterial disease previous cerebrovascular event aspirin thienopyridine lipidlowering drug angiotensinconverting enzyme inhibitor angiotensin receptor blocker p blockers median age iqr years age 75 years women white ethnic origin
baseline_level_2, median interquartile range diabetes dyslipidemia hypertension current smoking prior stroke heart failure myocardial infarction percutaneous coronary intervention coronaryartery bypass grafting angiotensinconvertingenzyme inhibitor betablocker statin protonpump inhibitor calciumchannel blocker stent implanted drugeluting stent implanted left main coronary artery left anterior descending coronary artery left circumflex coronary artery right coronary artery saphenousvein graft
baseline_level_2, pe without dvt dvt male female 65 yr 65 75 yr 75 yr severe moderate mild normal renal function 60 kg 60 kg
baseline_level_2, female asian white black native american provided ipah hpah cvd repaired chd hiv functional class ii iii 6mwd years since pah diagnosis age
baseline_level_2, male female white black 30 mg g 30300 mg g 300 mg g missing
baseline_level_2, male n caucasian n mean age years 95 ci mean bmi 95 ci mean involved bsa 95 ci mean pasi score 95 ci total score daily activities leisure personal relationships symptoms feelings treatment satisfaction work school mean eq5d response 95 ci physical functioning physical role bodily pain general health vitality social functioning mental health emotional role physical component summary mental component summary mean hamd score 95 ci
baseline_level_2, mean body weight sd kg female white mean total serum ige sd iu ml mean prebronchodilator fev1 sd predicted hospitalized asthma n mean sd number exacerbations mean sd total asthma symptom scores mean sd number albuterol per day puff mean sd aqlq mean sd feno ppb mean eosinophil count per ml mean sd periostin ng ml m1 subgroup m2 subgroup m3 subgroup mean sd age yr
baseline_level_2, median interquartile range female sex white race total f stable angina nsteacs stemi united states countries normal abnormal diabetes mellitus current smoker hypertension hyperlipidemia prior stroke tia prior myocardial infarction ptca pci cabg congestive heart failure peripheralartery disease clopidogrel 300mg loading dose clopidogrel 600mg loading dose bivalirudin unfractionated heparin lowmolecularweight heparin fondaparinux aspirin drugeluting stent baremetal stent balloon angioplasty
baseline_level_2, iv anterior inferior previous congestive heart failure previous pci previous myocardial infarction previous coronaryartery bypass grafting hypertension diabetes symptom onset first medical contact ambulance emergency department symptom onset randomization symptom onset hospital admission randomization arrival catheterization laboratory randomization arterial sheath insertion symptom onset arrival catheterization laboratory symptom onset start reperfusion treatment tenecteplase arterial sheath insertion mean yr 75 yr ii iii
baseline_level_2, insulin 1 2 betablockers calciumchannel blockers longacting nitrates statins antiplatelet agents acel arbs baseline heart rate beats min baseline systolic blood pressure mm hg baseline diastolic blood pressure mm hg age yrs men white hypertension dyslipidemia current smoking prior myocardial infarction prior angioplasty prior bypass graft surgery duration diabetes yrs hbalc antidiabetic medication
baseline_level_2, hawaiian pacific chads score 1 2 3 4 5 6 warfarin naive yes 90 days warfarin 1 yr warfarin experience history cad history diabetes history hypertension age yrs height inches weight lbs sex female male race ethnicity asian black african american caucasian hispanic latino
baseline_level_2, north america south america europe india australia
baseline_level_2, men white systolic blood pressure mm hg diastolic blood pressure mm hg bodymass index kg m2 hba1c fasting plasma glucose mmol l duration type 2 diabetes years range normal 80 mild 50 80 moderate 30 50 yes missing age years
baseline_level_2, bmi kg m2 current smokers history packyears copd duration fev1 l fev1 predicted fvc l fev1 fvc ii iii iv sgrq total score units sabaa labaa saaca laaca icsa ocs theophylline compound age male
baseline_level_2, diabetes duration years current former never hbalc mmol mol glucose mg dl sbp mmhg dbp mmhg map mmhg serum creatinine mg dl triglycerides mg dl total cholesterol mg dl hdl cholesterol mg dl ldl cholesterol mg dl uae p g min n age years sex male n bmi kg m2
baseline_level_2, american indian native alaskan asian black african american multiracial native hawaiian pacific islander white 80 80 90 90 100 100 known duration type 2 diabetes years received oral aha within 8 weeks prior screening
baseline_level_2, number patients male female age years asian white black african american american indian alaska native #1 year 15 years 510 years 10 years body weight kg bmi kg m2 hba1c fpg mmol l mdg mmol l sbp mmhg dbp mmhg egfr ml min 173 m2 mdrdequation
baseline_level_2, ibdq score median interquartile range rectum sigmoid colon left side colon proximal splenic flexure colon glucocorticoids immunosuppressants onlyff glucocorticoids immunosuppressants glucocorticoids immunosuppressants prior antitnf therapy 1 failure inadequate response loss response unacceptable adverse events hemoglobin concentration g liter whitecell count x10_9 liter age yr male sex white race body weight kg current smoker duration disease yr mayo clinic score partial mayo clinic scored
baseline_level_2, women northamerica latin america europe asia pacific white african american asian hba1c fpg mg dl weight kg bmi x30 kg m2 duration diabetes years insulin based sulfonylurea based thiazolidinedione based stage 4 30 stage 3b 30 45 stage 3a 45 60 stage 2 60 urinary albumincreatinine ratioa mg g urinary proteincreatinine ratioa mg mg patients diabetic nephropathy n age years men
baseline_level_2, weight kg median range pancolitis uc duration mean range mayo score mean sd endoscopy subscore rectal bleeding subscore pga subscore stool frequency subscore partial mayo score mean sd crp nmol l median range anemia hypertension gastroesophageal reflux disease hyperlipidemia diabetes asthma oral corticosteroid azathioprine 6mercaptopurine corticosteroid azathioprine 6mercaptopurine corticosteroid azathioprine 6mercaptopurine aminosalicylates prior therapy tnf antagonist n men age median range
baseline_level_2, bmi kg m2 nstemi unstable angina hypertension diabetes mellitus active smoking total cholesterol ecrcl ml min ecrcl 30 ml min ecrcl 60 ml min egfr ml min m2 egfr 60 ml min m2 previous ml previous pci cabg baseline lvef ef 30 ef 45 highrisk clinical features serum creatinine mg dl haemoglobin mg dl ctnl ng ml ckmb ng ml ldl cholesterol mg dl hdl cholesterol mg dl triglycerides mg dl glycemia mg dl symptom onsetto randomizationto within 24 h within 48 h 48 h hospital stay days multivessel disease contrast volume ml contrast volume within 72 h management distribution medical treatment cabg pci multivessel pci contrast volume ml contrast nephropathy risk score score distribution 5 610 1116 16 betablockers ace inhibitors angiotensin receptor nitrates diuretics calcium channel gp llb llla inhibitors calcium channel blockers age yrs age 70 yrs male
baseline_level_2, multivessel disease n stable angina unstable angina nonstsegmentelevation myocardial infarction stsegmentelevation myocardial infarction others aspirin clopidogrel ace inhibitor pblocker calciumchannel blocker statin vessel treated n left anterior descending artery n left circumflex artery n right coronary artery n left main coronary artery n graft n others n multivessel intervention n acc aha lesion class b2 c n bifurcation n calcification n total occlusion n stents per lesion n stent length per lesion mm sirolimus paclitaxel zotarolimus everolimus age male sex n diabetes mellitus n hypertension n current smoker n previous coronary angioplasty n previous myocardial infarction n previous stroke n ejection fraction
baseline_level_2, +ics + laba nz 945 ics + laba n z 597 65 years n z 1761 65 years n z 1330 current n z 1278 former n z 1813 moderate n z 250 severe n z 1932 severe n z 903 north america n z 786 europe n z 1831 rest world n z 474
baseline_level_2, caucasian asian black moderate severe severe 0 exacerbations 1 exacerbations 2 exacerbations exsmoker current smoker
baseline_level_2, white black systolic diastolic total ldl hdl median interquartile range mean ml min 173m2 300449 ml min 173 m2 450599 ml min 173 m2 600 ml min 173 m2 ace inhibitor monotherapy arb monotherapy ace inhibitor arb neither ace inhibitor arb diuretic calciumchannel blocker betablocker alphablocker
baseline_level_2, black angiography duplex ultrasonography computed tomographic angiography magnetic resonance angiography diabetes prior myocardial infarction history heart failure smoking past yr hyperlipidemia stenosis assessed core laboratory stenosis assessed investigator global ischemia bilateral disease jj
baseline_level_2, white asian black otherb north america western europe lebanon eastern europe asia australia new zealand hypertension diabetes hypercholesterolemia present smokerc metabolic syndrome myocardial infarction pci cabg surgery stroke peripheral arterial disease stemi nstemi unstable angina biomarker negative aspirin clopidogrel ticlopidine prasugrel pblocker ace inhibitor arb ldlc hdlc triglycerides 20 40 80
baseline_level_2, white asian african american united states russia mexico ukraine germany argentina poland philippines romania japan australia
baseline_level_2, diskus n handihaler diskus n handihaler n mdi hfa n dpi diskus n
baseline_level_2, age years 65 years 65 years male female asian caucasian chinese indian indian subcontinent duration copd years moderate severe smokers smoking history packyears ics use fevi l fevi predicted fev1 fvc reversibility salbutamol
baseline_level_2, caucasian native american moderate severe 0 exacerbations 1 exacerbation 2 exacerbations exsmoker current smoker
baseline_level_2, male sex white race 9 911 12 13 14 16 16 age age onset age diagnosis duration pd diagnosed total mental adl motor hoehn yahr stage modified seadl scale pdqol scale modified rankin score symbol digit score
baseline_level_2, age years women men 8 years 912 years 12 years white black south asian asian bmi previous cardiovascular disease hypertension present smoker alcohol consumption laser vitrectomy depression hba fasting plasma glucose mmol l mean sd median iqr
baseline_level_2, 0 1 h n 1 2 h n 2 h n anterior n inferior n n ambulance n community hospital n
baseline_level_2, mean age yr 75 yr bmi 30 f 02 36 6 ambulance emergency department ambulance transfer coronary angiography femoral access total radial access total missing data total thromboaspiration pci stentl drugeluting stent baremetal stent without stent cabg pci cabg first loading dose second loading dose maintenance dose use glycoprotein ilb iiia inhibitor pci intravenous anticoagulant hospitalization heparin enoxaparin bivalirudin fondaparinux combination therapy
baseline_level_2, systolic diastolic duration coronary artery disease yr previous myocardial infarction previous coronary revascularization symptoms 1 11 dyslipidemia diabetes mellitus peripheral artery disease current smokerno hypertension left ventricular ejection fraction previous stroke concomitant treatmentno antiplatelet agent anticoagulant aspirin statin betablocker ace inhibitor angiotensin llreceptor blocker dihydropyridine calciumchannel blocker nitrate diltiazem verapamil antidiabetic agent age yr bodymass index heart rate beats min male sex race white asian
baseline_level_2, age yrs female bmi kg m2 waist circumference cm diabetes hypertension coronary disease valvular disease class l heart failure sinus rhythm baseline 12lead ecg heart rate beats min left atrial dimension cm left ventricular hypertrophy echo paroxysmal af persistent af time since first af diagnosis yrs class iii aad use 12 months enrollment betablockers acei arb oral anticoagulant
baseline_level_2, 41 mmol l 41 mmol l apolipoprotein b g l hdl cholesterol mmol l apolipoprotein a1 g l triglycerides mmol l lipoprotein nmol l
baseline_level_2, white racenumber north america south america europe row ra symptom durationyear ra symptom duration 3 monthsnumber rf positivenumber tender joint count 28 joints swollen joint count 28 joints crpmg l patient global assessment 0100 mm vas physician global assessment 0100 mm vas das28 crp haqdi pain 0100 mm vas physical function 0100 short form36 subscale ageyear median weightkg median female sexnumber
baseline_level_2, missingnumber n median 54 number n median 54 number n median 1375 number n median 1375 number n median 037 years number n median 037 years number n 6 monthsnumber n 6 monthsnumber n median 62 number n median 62 number n median 45 number n median 45 number n q1 15 number n q1 15 q2 45 number n q2 45 q3 85 number n q3 85 number n median 05 number n median 05 number n q1 0 number n q1 0 q2 05 number n q2 05 q3 5 number n q3 5 number n q1 2 number n q1 2 q2 45 number n
baseline_level_2, heart rate mean sd range beats min systolic diastolic body mass index mean sd range male sex asian black african american white hispanic latino hawaiian pacific islander mean sd range 1 2 23 congestive heart failure history hypertension age 275 diabetes previous ischemic stroke ortia lv ejection fraction mean sd range paroxysmal persistent permanent unknown 1y 21y estimate united states europe age mean sd range
baseline_level_2, age years female racenon white hispanic latino weight kg bmi kg m2 diabetes mellitus hypertension current cigarette smoker within past year stroke tia congestive heart failure peripheral arterial disease prior pci prior cabg prior mi positive stress test stemi nstemi unstable angina stable angina north america europe australia new zealand clopidogrel prasugrel everolimuseluting paclitaxeleluting zotarolimuseluting sirolimuseluting 1 des type number treated lesions number treated vessels number stents 3 3 3 total stent length lesion characteristics native coronary left main lad rca circumflex venous graft arterial graft modified acc aha lesion class b2 cj
baseline_level_2, 75 years 75 years white nonwhite male female median median diabetes diabetes current tobacco use current tobacco use prior ml prior ml prior pci prior pci prior cabg prior cabg clinical lesion rfs st clinical lesion rf st north america european union australia new zealand 100 mg 100 mg clopiodogrel prasugrel sirolimus zotarolimust paclitaxel everolimus overall
baseline_level_2, age yrs female white race weight 60 kg diabetes mellitus hypertension hyperlipidemia current smoker peripheral artery disease crcl baseline 60 ml min coronary artery bypass grafting prior myocardial infarction prior stemi drugeluting stent aspirin thienopyridine aspirin thienopyridine therapy
baseline_level_2, age years age 65 years caucasian ethnicity current smoking past smoking never smoking alcohol use 1 drink wk peri postmenopausal hormone replacement therapy use body mass index kg m2 high density lipoprotein mg dl total cholesterol mg dl high sensitivity creactive protein mg l systolic blood pressure mmhg blood pressure lowering medication use lipid lowering medication use diabetes mellitus family history premature chd family history cancera history dyspepsia randomized aspirin use major cardiovascular events colorectal cancer noncolorectal cancer major gastrointestinal bleeding
baseline_level_2, bmi kg m2 hypertension diabetes mellitus active smoking total cholesterol 200 mg dl ecrcl ml min egfr ml min m2 previous ml previous pci cabg baseline lvef highrisk clinical features hscrp mg l leukocytes 103 nl neutrophils 103 nl monocytes 103 nl lymphocytes 103 +il glycemia mg dl serum creatinine mg dl hemoglobin mg dl ctnl ng ml ckmb ng ml ldl cholesterol mg dl hdl cholesterol mg dl triglycerides mg dl multivessel disease ciaki risk score pci revascularization symptom onset randomization randomization angiography hospital stay days age yrs age 70 yrs male
baseline_level_2, exsmoker current smoker cardiac vascular change pre fev1 fvc fev1 pred 1 fevi 80 pred 2 fevi 5080 pred 3 fevi 3050 pred 4 fev1 30 pred sama1 lama+ saba laba ics## xanthines11 baseline cardiovascular medication pblockers
baseline_level_2, female n white weight mean sd kg bmi mean sd kg m2 sbp mean sd mmhg dbp mean sd mmhg type 2 diabetes duration mean sd years hba1c mean sd mmol mol fpg mean sd mg dl mmol l prior history cardiovascular disease n thiazide diuretics antihypertensives angiotensin receptor blocker ace age mean sd years
baseline_level_2, mean sd 65 n 65 n male n female n white n black n n tg mg dl median sd diabetes n statin n statin + ezetimibe n statin + fibrate simvastatin n atorvastatin n rosuvastatin n terol hdlc highdensity lipoprotein cholesterol
baseline_level_2, male sex nonwhite white bodymass index kg mj previous diagnosis diabetes coronary heart disease myocardial infarction hypertension statin statin ezetimibe simvastatin 40 mg simvastatin 80 mg atorvastatin 10 mg atorvastatin 20 mg atorvastatin 40 mg atorvastatin 60 mg atorvastatin 80 mg rosuvastatin 5 mg rosuvastatin 10 mg rosuvastatin 20 mg rosuvastatin 30 mg rosuvastatin 40 mg pravastatin 80 mg fluvastatin 80 mg ldlc mmol l hdlc mmol l nonhdlc mmol l apo b g l apo a1 g l lp pmol l triglyceride mmol l age years age 65 years
baseline_level_2, 314 56 327 65 105 78 79 7192 628 541771 793 223 1 662 422 2 886 732 766 194 3 069 779 3 090 784 1 160 294 579 52
baseline_level_2, estimated glomerular filtration rate 60 ml min 173 m2 total median interquartile range stemi nstemi unknown type aspirin dose statin betablocker ace inhibitor arb age yr female sex white race f weight kg hypertension hypercholesterolemia current smoker diabetes mellitus multivessel coronary artery disease total history pci total 1 prior myocardial infarction peripheralartery disease
baseline_level_2, age years female nonwhite race weight kg bmi diabetes mellitus hypertension cigarette smoker stroke tia congestive heart failure peripheral arterial disease prior pci prior cabg prior myocardial infarction myocardial infarction stemi nstemi unstable angina stable angina risk factor stent thrombosis renal insufficiency failure lvef 30 2 vessels stented 2 lesions per vessel lesion length 30 mm bifurcation lesion instent restenosis des vein graft stented unprotected left main stented thrombuscontaining lesion prior brachytherapy clopidogrel prasugrel des sirolimus zotarolimus paclitaxel everolimus 1 type treated lesions treated vessels stents 3 mm 3 mm total stent length mm lesions native coronaryartery lesions left main left anterior descending right circumflex venous graft arterial graft instent restenosis extreme tortuosity heavy calcification modified acc aha lesion class b2 c
baseline_level_2, age median 25th 75th percentiles age 75 years n female n white race n myocardial infarction peripheral artery disease diabetes mellitus hypertension hyperlipidemia current smoker prior coronary revascularization prior pci prior cabg peripheral revascularization established coronary artery disease established peripheral arterial disease estimated glomerular filtration rate 60 ml min per 173 m2 aspirin thienopyridine ace inhibitors arb lipidlowering medications
baseline_level_2, female sex n white black african american asian bw mean sd kg bmi mean sd kg m2 coronary heart disease stroke tia peripheral artery disease reported cv event years 3 years 3and 10 years 10 years seated sbp mean sd mmhg seated dbp mean sd mmhg type 2 diabetes duration years hba1c mean sd mmol mol fpg mean sd mmol l oad oad plus insulin insulin daily insulin dose mean sd iu 0 1 2 2 antihypertensive aceis arbs diuretics loop diuretics lipidlowering medications acetylsalicylic acid age mean sd years subjects 65 years age n subjects 65 years age n
baseline_level_2, female sex white black asian hispanic latino mean body mass index kg m2 systolic blood pressure mmhg diastolic blood pressure mmhg egfr ml min 173 m2 egfr 50 ml min 173 m2 median total cholesterol mg dl ldl cholesterol mg dl hdl cholesterol mg dl triglycerides mg dl prior cardiovascular disease myocardial infarction 50 coronary stenosis prior pci cabg prior cerebrovascular disease prior peripheral arterial disease prior congestive heart failure nyha class 3 higher never smoked prior smoker current smoker metformin sulfonylurea thiazolidinedione insulin beta blocker ace inhibitor arb calcium channel blocker diuretic aspirin antiplatelet statin ezetimibe age years +
baseline_level_2, sex male n caucasian asian duration copd years mild moderate severe gold b gold patients prior copdrelated ics users baseline n current smokers n 0 1 2 postbronchodilator fev1 l postbronchodilator fev1 predicted postbronchodilator fev1 reversibility postbronchodilator fev1 fvc cat score 010 mild 1120 moderate 2130 severe 3140 severe missing bdi focal score sgrq total score 2 3 4 age years
baseline_level_2, white black african american asian
baseline_level_2, female male age yr white black asian american indian alaska native native hawaiian pacific islander hispanic latino ethnic groupf weight kg bodymass index 27299 overweight 30349 obese class 35399 obese class ii 40 obese class iii waist circumference cm glycated hemoglobin fasting glucose mg dl fasting insulin tiu ml systolic diastolic total ldl hdl vldl free fatty acids mmol liter triglycerides mg dl prediabetes 1 dyslipidemia hypertension
baseline_level_2, women white black asian unknown weight kg 0 1 2 3 methotrexate use randomisation systemic glucocorticoid use randomisation psoriasis body surface area 3 pasi 10 pasi score 10 dactylitis dactylitis count enthesitis enthesitis count tender joint count 78 joints swollen joint count 76 joints das28crp pasi physicians global assessment vas haqdi pain vas patients global assessment vas sf36pcs age years
baseline_level_2, 30 30 3050 50 previous cancerc previousdistaldeepveinthrombosisorsuperficialvein thrombosis chronic heart failure chronic respiratory failure highprobability ventilation perfusion lung scanning spiralcomputedtomographyangiography associatedproximaldeepveinthrombosisatdiagnosis residual perfusion defect 10 lung scan residual deepvein thrombosis systolic pulmonary arterial pressure mean sd mm hg ddimer level mean sd ng mld minor major warfarin fluindione acecoumarol duration initial anticoagulation mean sd mo percentage time therapeutic inr range mean sd use compression stockings antiplatelet agent statins low risk factor moderate 1 risk factor high 2 risk factor age mean sd 65y women body mass index mean sd
baseline_level_2, meansd bmi kg m2 mmol mol mmol l mg dl metformin yes basal insulin analogue insulin basal insulin analogue dose coefficient mean sd age years mean sd duration diabetes years women men mean sd weight kg
baseline_level_2, mean sd weight kg usa europe canada latin america rest world mean sd disease duration years mean sd bmi rf+ anticcp+ 60 units mean sd das284 esr mean sd mean sd sdai mean sd cdai mean sd tender joint count mean sd swollen joint count mean sd pain vas mean sd ptga vas mean sd pga vas mean sd crp mg l mean sd esr mm h previously taken methotrexate previously taken dmards methotrexate previously taken tnfi previously taken dmards n abatacept anakinra rituximab tocilizumab tnfi bdmard taken n one tnfi multiple tnfi bdmards tnfi taken n tnfi bdmardst n one tnfi multiple tnfi bdmards caucasian female age years mean sd
baseline_level_2, ii iii iv treated cabg total treated pci total managed medically total
baseline_level_2, age median iqr years female sex n caucasian n others n hispanic latino ethnicity n weight median sd kg bmi median sd kg m2 diabetes duration median iqr years current smoker n hypertension n dyslipidemia n prior myocardial infarction n prior heart failure n prior coronary revascularization n egfr median sd ml min median sd mg mmol hba1c median sd fasting serum glucose median sd mg dl aspirin statins bblockers diuretics ace inhibitors metformin sulfonylurea tzd insulin
baseline_level_2, male white asian black africanamerican missing hispanic latino hispanic latino missing europe north america plus australia new zealand asia latin america africa weight kg body mass index kg m2t cv risk factor coronary artery disease multivessel coronary artery disease history myocardial infarction coronary artery bypass graft history stroke1 peripheral artery disease single vessel coronary artery disease1 cardiac failure glycated hemoglobin 1 years 1 5 years 5 10 years 10 years metformin insulin median daily dose iu sulfonylurea dipeptidyl peptidase4 inhibitor thiazolidinedione glucagonlike peptide1 agonist monotherapy dual therapy antihypertensive therapy angiotensinconverting enzyme inhibitors angiotensin receptor blockers betablockers diuretics calcium channel blockers mineralocorticoid receptor antagonists renin inhibitors lipidlowering therapy statins fibrates ezetimibe niacin anticoagulants acetylsalicylic acid clopidogrel vitamin k antagonists systolic blood pressure mmhg diastolic blood pressure mmhg total cholesterol mg dl low density lipoprotein cholesterol mg dltt high density lipoprotein cholesterol mg dl triglycerides mg dl estimated glomerular filtration rate ml min 173m2tt 90 ml min 173m2 60 90 ml min 173m2 60 ml min 173m2 30 mg g 30 300 mg g 300 mg g age years
baseline_level_2, n median interquartile range female sex n diabetes mellitus current smoker hypertension hyperlipidaemia prior stroke tia prior myocardial infarction prior ptca pci cabg heart failure peripheral artery disease
baseline_level_2, white black asian 0 1 2 psoriasis affecting 3 bodysurface dactylitis enthesitis tenderjoint count 78 joints swollenjoint count 76 joints das28crp pasii physicians global assessment dis modified total sharp score haqdi scoreff psoriatic arthritis pain patients global assessment sf36 physical component summaryjj
baseline_level_2, acr20 response n n acr50 response n n acr70 response n n das28crp ls mean change baseline se das28crp ls mean change baseline se
baseline_level_2, bmi kg m2 mean sd europe eu north america asia pacific latin america europe noneu itt population duration epilepsy years mean sd age first seizure years mean sd baseline pos frequency per 28 days median min max 01 24 5 1 2 3 carbamazepine lamotrigine valproate oxcarbazepine topiramate lacosamide never used lev prior lev use age years mean sd gender female n race white n weight kg mean sd
baseline_level_2, age median iqr female caucasiana bmi median iqr hypertension hyperlipidaemia current smoker diabetes mellitus multivessel cad pci index mi history 1 prior mi egfr baseline 60 ml min b western europe eastern europe north america south america asia pacific months mimedian iqr stemi nstemi mi type unknown
baseline_level_2, duration diabetes 5 510 1015 1520 20 egfr 50 ml min 30 30300 300 metformin sulfonylurea thiazolidinedione insulin aspirin adp antagonist statin ace inhibitor bblocker age male white body mass index kg m2 established cardiovascular disease
baseline_level_2, north america latin america western europe central europe asiapacific 1 ii iii iv hypertension diabetes atrial fibrillation hospitalization heart failure myocardial infarction stroke coronary artery bypass surgery percutaneous coronary intervention diuretic agent digoxin betablocker mineralocorticoid receptor antagonist oral anticoagulant agent antiplatelet agent lipidlowering agent implantable cardioverterdefibrillator cardiac resynchronization therapy black asian
baseline_level_2, male female age 75 n white black african american asian hba1c fpg mg dl mmol l body weight kg bmi kg m2 duration t2dm microvascular complications n egfr ml min 173 m2 60 ml min 173 m2 n use loop diuretics n prior cv history n
baseline_level_2, age years female sex nonwhite raceb hispanic latino ethnic groupb weight kg body mass indexc diabetes mellitus hypertension cigarette smoker stroke tia congestive heart failure peripheral arterial disease renal insufficiency failure prior myocardial infarction prior cancer stemi nstemi unstable anginad stable angina clopidogrel prasugrel drug eluting bare metal
baseline_level_2, female sex mean yr 65 yr 65 yr asia eastern europe latin america north america western europe australia time since diagnosis pah yrf idiopathic heritable associated connective tissue disease associated correctedcongenital shunts associated hiv infection associated drug toxin exposure ii iii iv 6minute walk distance none endothelinreceptor antagonists phosphodiesterase type 5 inhibitors endothelinreceptor antagonists plus phosphodiesterase type 5 inhibitors
baseline_level_2, age years range min max male female weight kg height cm prebronchodilator fev1 l predicted prebronchodilator fev1 postbronchodilator fev1 l absolute reversibility fev1 ml range min max fev1 reversibility baseline fev1 l predicted fev baseline
baseline_level_2, body mass index kg m2 diabetes hypertension current smoker previous mi previous pci previous stroke stemi nstemi symptom onset hospital arrival hours killip class ii anemia creatinine clearance 60 ml min crusade bleeding score 30 age years body mass kg
baseline_level_2, age yr male sex black race total f hispanic ethnic group total j entry previous hypertension total coronary artery disease total atrial fibrillation total bodymass index systolic diastolic score modified minimental state examination median iqr score nih stroke scale median iqr score modified rankin scale median iqr fasting glucose mg dl median fasting insulin iqr pu per milliliter homair index median iqr glycated hemoglobin ldl hdl fasting triglycerides mg dl statin total antiplatelet total oral anticoagulant total ace inhibitor angiotensinreceptor blocker total diuretic total betablocker total days homair testing median iqr days randomization median iqr
baseline_level_2, positive rheumatoid factor 1 2 3 swollenjoint count 66 joints examined tenderjoint count 68 joints examined physicians global assessment patients global assessment patients assessment pain haqdi scored highsensitivity crp mg liter esr mm hr das28crp das28esr simplified disease activity index score age yr female sex duration rheumatoid arthritis yr positive anticyclic citrullinated peptide antibody f
baseline_level_2, age median iqr 260 female body mass index median iqr b white black asian north america eastern europe western europe south america asiapacific hypertension hyperlipidemia diabetes mellitus current smoker prior myocardial infarction prior pci baseline egfr 60 ml min 173 m2c prior heart failure prior coronary artery bypass graft surgery prior peripheralarterialdisease prior ischemic stroke highsensitivitycreactive protein mg l nterminal probrain natriuretic peptide pg ml nonstelevation myocardial infarction stelevation myocardial infarction fibrinolytic qualifying event aspirin p2y12 inhibitor statin pblocker ace inhibitor angiotensin receptor blocker
baseline_level_2, age yrs female race nonwhitet hispanic latino weight kg bmi kg m2 diabetes mellitus insulin oral medications diet controlled hypertension cigarette smoker stroke tia history major bleeding congestive heart failure peripheral artery disease prior pci prior cabg atrial fibrillation history cancer previous mi acute coronary syndrome stemi nstemi unstable anginat stable angina
baseline_level_2, history claudication north america south america western europe including south africa eastern europe asia australia new zealand time qualifying mi yrs unknown stemi nstemi qualifying mi 2 yrs prior time last dose p2y12 inhibitor days aspirin use baseline statin use baseline betablocker use baseline acei arb use baseline age yrs age 75 yrs female body mass index kg m2 caucasian history hypertension history hypercholesterolemia current smoker history copd egfr 60 ml min 173 m2 mdrd history diabetes history chf history stroke tia history second prior mi multivessel coronary artery disease prior angina prior cabg history pci stenting abi #090 peripheral revascularization
baseline_level_2, female n n mean sd europe australia latin north america systemic corticosteroids n das28 esr mean sd moderate disease activity 32 51 n high disease activity 51 n sdai mean sd cdai mean sd haqdi mean sd tjc 28 joints mean sd sjc 28 joints mean sd esr mm h median min max crp mg l median min max months since ra first diagnosed mean sd 4 months mean sd 4 months mean sd months since first ra symptom mean sd f rf positive 14 iu ml n acpa positive 7 iu ml n mtss median min max 4 months median min max 4 months median min max erosion score median min max jsn median min max presence erosions n mean age years sd
baseline_level_2, current smoker group group b group c group postbronchodilator fev1 liters postbronchodilator fev1 predicted value postbronchodilator ratio fev1 fvc total score sgrqc age yr male sex duration copd yr use inhaled glucocorticoids screening
baseline_level_2, female n caucasian black others duration copd years exsmoker current smoker number packyears moderate gold 2 severe gold 3 severe gold 4 missing group b group c group 0 1 2 ics use baseline n grade 1 grade 2 grade 3 grade 4 copd assessment test cat score prebronchodilator fev1 l postbronchodilator fev1 l postbronchodilator fev1 predicted postbronchodilator fev1 reversibility ccv history condition hypertension diabetes mellitus atrial fibrillation flutter hyperlipidemia age years male n
baseline_level_2, diabetes duration years europe north america asia rest world glycated hemoglobin bmi kg m2 body weight kg systolic blood pressure mm hg diastolic blood pressure mm hg heart failurea established cvd age 50 prior myocardial infarction prior stroke transient ischemic attack prior revascularization 50 stenosis coronary carotid lower extremity arteries documented symptomatic chdb documented asymptomatic cardiac ischemiac heart failure nyha ii iii chronic kidney diseased cvd risk factors age 60 microalbuminuria proteinuria hypertension left ventricular hypertrophy left ventricular systolic diastolic dysfunction anklebrachial index 09 normal egfr 90 mild impairment egfr 6089 moderate impairment egfr 3059 severe impairment egfr 30 male sex age years
baseline_level_2, meansd n median q1 q3 range min max female race white asian black hispanic latino diagnosis presentation stable angina nsteacs stemi cardiac biomarker status normal abnormal diabetes mellitus current smoker hypertension hyperlipidemia stroke tia myocardial infarction pci cabg congestive heart failure peripheral artery disease family history cad clopidogrel 300 mg loading dose clopidogrel 600 mg loading dose bivalirudin ufh lmwh fondaparinux aspirin 100 mg 100 mg catheter access site femoral radial brachial number vessels treated index pci 0 1 2 3 4 time hospital admission pci h median q1 q3 drugeluting stent bare metal stent balloon angioplasty
baseline_level_2, mean sd age years exsmoker current smoker fev1 l fev1 predicted fev1 fvc ratio sd ics lama sama laba saba patients n male n
baseline_level_2, female n whitea black asian weight kg mean sd baseline focal seizure frequency 28 days median q1q3 simple partial ia complex partial ib partial evolving secondarily generalized ic 01 24 5 carbamazepine lamotrigine valproate oxcarbazepine topiramate prior lev treatment levnaive mean age sd
baseline_level_2, ntprobnp pg mla iqr ischaemic aetiology hf hospitalization hypertension atrial fibrillation diabetes ckd egfr 60b number patients age years female sex n caucasian n bmi kg m2 heart rate bpm syst bp mmhg egfr ml min 173 m2 lvef nyha class n ii iii iv kccq score
baseline_level_2, female sex white black asian hispanic latino hispanic latino north america latin america western europe eastern europe asia pacific diabetesduration mean sd glycated hemoglobin mean sd 7 27 75 275 egfr mean sd ml min 173 m2 coronary artery disease myocardial infarction cerebrovascular peripheral artery priorheartfailure nyha class nyha class ii nyha class iii nyha class iv nyha class reported systolic diastolic weight mean sd kg body massindex mean sd current former never metformin sulfonylurea thiazolidinedione insulin statin aspirin nonaspirin antiplatelet agent ace inhibitor angiotensin receptor blocker pblocker diuretic calcium channel blocker age mean sd
baseline_level_2, fasting glucose mg dl insulin mu ml homair hba1c 100 mg dl 56 mmol l 110 mg dl 61 mmol l hba1c 57 39 mmol mol hba1c 65 70 4853 mmol mol sbp dbp 130 85 mmhg abdominal obesity hdl 40 50 mg dl 103 129 mmol l men women triglycerides 150 mg dl 169 mmol l 1 2 3 4 5
baseline_level_2, male white asian black bmi kg m2 25 kg m2 25 30 kg m2 30 kg m2 hba1c presence mets 1 year 1 e5 years 5 years homair mean sd mu l mmol l b 40 mu l mmol l 40 55 mu l 55 85 mu l 85 mu l mmol l fasting cpeptide nmol l c none 1 2 age years
baseline_level_2, female n caucasian n mean age years mean disease duration years tjc sjc vdhmtss erosion score haqdi das284 esr hscrp mg dl rf positive acpa positive
baseline_level_2, duration t2dm years mean sd range alone plus metformin 8 8 9 9 10 10 2h pmg mg dl fpg mg dl fasting insulin giu ml homap homair quicki men age years weight kg bmi kg m2
baseline_level_2, female mean sd minmax age white asian multiracial black class class ii class iii biologics user methotrexate user lowdose corticosteroid user dmard user dmard corticosteroid
baseline_level_2, dbp mm hg median iqr history hypertension n hypercholesterolemia n current smoking n diabetes mellitus n egfr 60 n history second prior mi n multivessel cad n history cabg n history pci n qualifying nstemi n history chf n history atrial fibrillation n history tia n history stroke n aspirin n statin n ace inhibitor n arb n age median iqr female n white n weight kg median iqr bmi median iqr sbp mm hg median iqr
baseline_level_2, median iqr 85 female male bodyweight kg bodymass index kg diabetes dyslipidaemia hypertension current smoker previous cancer chronic respiratory failure inflammatory disease heart failure myocardial infarction percutaneous coronary intervention coronary artery bypass grafting peripheral vascular disease aspirin blocker ace inhibitor arb statin mra spironolactone eplerenone calciumchannel blocker protonpump inhibitor ii iii iv left ventricular ejection fraction nstemi unstable angina stemi primary pci secondary pci radial access onevessel disease twovessel disease threevessel disease left main multivessel two vessel three vessel left main stent implanted number stents implanted drugeluting stent implanted least one left main artery left anterior descending coronary artery left circumflex coronary artery right coronary artery coronary bypass graft creatinine clearance admission ml min creatinine clearance 30 ml min haemoglobin g dl
baseline_level_2, age years 12 18 18 75 male female white black african american asian hispanic latino hispanic latino bodymass index kg m2 missing data local eosinophil count cells per pl central eosinophil count cells per pl prebronchodilator fev1 l prebronchodilator fev1 predicted normal fev1 fvc prebronchodilatort reversibility acq6 score time since asthma diagnosis years number exacerbations past 12 months number resulting emergency department visit patients 1 exacerbations resulting emergency department visit number resulting hospital admission patients 1 exacerbations resulting hospital admission total asthma symptom score diagnosis allergic rhinitis nasal polyps atopic based phadiatop test history omalizumab treatment aqlq +12 scorets never current former smoking pack year years fl
baseline_level_2, age years 12 18 18 75 male female white black african american asian hispanic latino hispanic latino bodymass index kg missing data eosinophil count cells per pl central eosinophil count cells per pl prebronchodilator fev1 l predicted normal prebronchodilator fev1 fvc reversibility acq6 scoret time since asthma diagnosis years number exacerbations past 12 months number resulting ed visit patients 1 exacerbations resulting ed visit number resulting hospital admission patients 1 exacerbations resulting hospital admission total asthma symptom score diagnosis allergic rhinitis nasal polyps atopic based phadiatop test history omalizumab treatment aqlq +12 scored smoker nicotine packyears
baseline_level_2, lipidmodifying drug use study entry n high risk moderately high risk moderate risk low risk weight mean sd kg bmi mean sd kg m2 waist circumference mean sd cm sbp mean sd mm hg dbp mean sd mm hg glycaemic parameters hbalc median ql q3 fpg median ql q3 mmol l insulin median ql q3 pmol l cpeptide median ql q3 nmol l homab median ql q3 homair median ql q3 100 lowdensity lipoprotein cholesterol mean sd mmol l lipoprotein median ql q3 nmol l triglycerides median ql q3 mmol l highdensity lipoprotein cholesterol mean sd mmol l apolipoprotein b mean sd g l demographics age years mean sd female sex n race n white black african american coronary artery disease n cerebrovascular peripheral arterial disease n current cigarette use n hypertension n statin use study entry n
baseline_level_2, meansd n range min max median iqr sex male american indian alaska native asian black native hawaiian pacific islander white range min max statin usage diabetes cigarette smoking past year prior ml prior heart failure global ischemia
baseline_level_2, age years sd 35 years 35 50 years 50 65 years 65 years male n white asian black native american alaskan nonhispanic latino hispanic latino 1 year hba1c mean sd b 95 95 fasting plasma glucose mg dl mean sd b 0 bmi kg m2 mean sd normal 90 mild impairment 60 90 moderate impairment 30 60 severe impairment 30 microvascular disease n retinopathy nephropathy neuropathy macrovascular disease n coronary artery disease peripheral artery disease cerebrovascular disease hypertension concomitant medication n aspirin antihypertensive drugs lipidlowering drugs
baseline_level_2, mean age years sd male mean predicted fvc sd mean predicted dlco sd mean 6mwd sd mean ucsdsobq score sd cardiovascular disease chronic renal failure copd hypercholesterolaemia smoker current former hypertension obesity diabetes
baseline_level_2, duration copd years mild moderate severe gold b gold icsusers atbaseline n current smokers n yes 010 mild 1120 moderate 2130 severe 3140 severe 2 3 4 postbronchodilator fev1 l postbronchodilator fev predicted postbronchodilator fev1 reversibility postbronchodilator fev1 fvc age years sex male n
baseline_level_2, diabetes duration years current former never bmi kg m2 systolic blood pressure mmhg diastolic blood pressure mmhg hba1c hba1c mmol mol total cholesterol mg dl ldlcholesterol mg dl egfr ml min 173m2 uacr mg g previous vascular disease myocardial infarction coronary artery disease cerebrovascular disease peripheral arterial disease heart failure metformin sulfonylurea thiazolidinedione insulin statin aspirin thienopyridine acei arb beta blocker calcium channel blocker diuretic age years women white race
baseline_level_2, age yrs female white race bmi kg m2 weight 60 kg smoking status current smoker former smoker never smoker diabetes mellitus hypertension hyperlipidemia coronary artery disease history stroke tia history atrial fibrillation fl utter egfr crcl 60 ml min 173 m2 peripheral artery revascularization without amputation prior amputation prior carotid intervention abi abi 09 abi 14 claudication fontaine class 1 antiplatelet therapy aspirin thienopyridine aspirin thienopyridine therapy cilostazol ace inhibitor arb statin therapy
baseline_level_2, female sex white black asian sbp mean sd mm hg heart rate mean sd beats min bmi mean sd creatinine mean sd mg dl potassium mean sd meq l ischemic cardiomyopathy left ventricular ef mean sd bnp median iqr pg ml ntprobnp median iqr pg ml 1 ii iii iv hypertension diabetes atrial fibrillation hospitalization hf myocardial infarction stroke diuretics digitalis pblocker potassium supplement implantable cardioverterdefibrillator cardiac resynchronization therapy age mean sd
baseline_level_2, men white black african american asian native hawaiian pacific islander american indian alaska native multiple bmi mean sd b hypertension previous pci previous ml smoking diabetes baseline statin usec high moderate low baseline ezetimibe usec antiplatelet therapy pblocker ace inhibitor arb age mean sd
baseline_level_2, sex male american indian alaska native asian black african america multiracial native hawaiian pacific islander white body mass index kg m2 mean sd high risk high risk moderate risk lower risk yes missing diabetes coronary artery disease myocardial infarction hypertension statin statin ezetimibe statin niacin statin fibrate other1 atorvastatin 20 mg atorvastatin 30 mg atorvastatin 40 mg atorvastatin 60 mg atorvastatin 80 mg lovastatin 80 mg pitavastatin 4 mg pravastatin 40 mg pravastatin 80 mg rosuvastatin 5 mg rosuvastatin 10 mg rosuvastatin 15 mg rosuvastatin 20 mg rosuvastatin 40 mg simvastatin 40 mg simvastatin 60 mg simvastatin 80 mg ldlc bq mg dl mean sd hdlc mg dl mean sd nonhdlc mg dl mean sd apo b mg dl mean sd apo al mg dl mean sd age years mean sd age 65 years
baseline_level_2, antitnfnaive n methotrexate sulfasalazine glucocorticoids hscrp median min max mg l elevated hscrp 5 mg l n total basdai mean sd basfi mean sd basmi linear mean sd msasss mean sd syndesmophyte present n total back pain mean sd patients global assessment disease activity mean sd age mean sd years male gender n weight mean sd kg time since diagnosis mean sd years hlab27 positive n current smoker n
baseline_level_2, mean sd age years exsmoker current smoker comorbidities n cardiac history cardiac rhythm disorders ischaemic heart disease vascular disordersb diabetes mellitus 1 80 2 50e80 3 30e50 4 30 sama lama saba laba ics xanthines baseline cardiovascular medication c n bblocker mean sd extent exposure days male n
baseline_level_2, sex male asian white hispanic latino china india korea republic malaysia philippines romania body weighta kg bmi kg m2 duration t2dm years age years
baseline_level_2, weight mean 6 sd kg us americas excluding us western europe australia israel eastern europe asia hispanic latino hispanic latino disease duration median range years mean 6 sd median range score #9 score 10 mucocutaneous musculoskeletal immunologic renal hematologic vascular cardiovascular respiratory constitutional central nervous system least 1 flare least 1 severe flare physicians global assessment mean 6 sd facitfatigue mean 6sd range 052 corticosteroids immunosuppressants antimalarials corticosteroids immunosuppressants corticosteroids antimalarials immunosuppressants antimalarials corticosteroids immunosuppressants antimalarials azathioprine methotrexate mycophenolate mofetil female age mean 6 sd years
baseline_level_2, age years 45 45 65 65 75 75 85 85 male female white black asian unknown bmi kg m2 duration rheumatoid arthritis years anticcp antibody positive rheumatoid factorpositive tender joint count 068 swollen joint count 066 creactive protein mg l das28 creactive protein clinical disease activity index score 076 simplified disease activity index score 086 haqdi score 03 duration morning stiffness min conventional synthetic dmard use baseline none 0 125 mg week 125 mg week
baseline_level_2, age yrs age 75 yrs female caucasian bmi kg m2 diabetes current smoking hypertension heart failure peripheral artery disease previous ml index acs previous pci index acs previous cabg index acs previous stroke lipidlowering agent statin aspirin ml stsegment elevation ml without stsegment elevation unstable angina prerandomization pci total cholesterol mg dl ldlc mg dl nonhdlc mg dl time acs randomization thienopyridine betablocker acei arb hscrp mg l egfr ml min 173 m2 egfr 60 ml min 173 m2
baseline_level_2, 0 male age years white black africanamerican asian american indian alaska native native hawaiian pacific islander hispanic latino ethnic group weight kg bmi kg m2 27299 overweight 30349 obesity class 1 35399 obesity class 2 40 obesity class 3 overall women men glycated haemoglobin fasting glucose mmol l 2h plasma glucose ogtt mmol l fasting insulin pmol l systolic diastolic total ldl cholesterol women n1139 vs 572 men n363 vs 176 vldl cholesterol nonhdl cholesterol free fatty acids mmol l triglycerides mmol l dyslipidaemiat hypertensiont dyslipidaemia hypertensiont
baseline_level_2, age meansd male sex n black race n hispanic ethnic group n stroke entry vs transient ischemic attack prior stroke index event hypertension coronary artery disease myocardial infarction coronary artery bypass graft coronary angioplasty stenting carotid artery intervention atrial fibrillation current cigarette smoking body mass index kg m2 meansd systolic blood pressure mm hg meansd diastolic blood pressure mm hg meansd fasting glucose mmol l meansd insulin iu ml median q1 q3 homair median q1 q3 hba1c meansd ldl cholesterol mmol l meansd hdl cholesterol mmol l men meansd hdl cholesterol mmol l women meansd triglycerides mmol l meansd creactive protein median q1 q3 antihypertensive angiotensinconverting enzyme inhibitor angiotensin receptor blocker pblocker thiazide diuretic antihypertensive lipidlowering agent statin fibrate antiplatelet aspirin alone aspirin antiplatelet nonaspirin antiplatelet anticoagulant coumadin anticoagulant antiarrhythmic loop diuretic
baseline_level_2, age yrs women n bmi kg m2 heart rate beats min systolic blood pressure mmhg diastolic blood pressure mmhg total cholesterol mg dl symptoms nyha ii n nyha iii n nyha iv n former current smoker n hypertension n diabetes n previous hf hospitalization n previous myocardial infarction n previous stroke n previous cabg n previous pci n icd n pm n history atrial arrhythmia n peripheral vascular disease n previous cancer n heart failure cause ischaemic n dilatative n hypertensive n cause n nondetectable unknown n rales n s3 gallop n mitral regurgitation n aortic stenosis n atrial fibrillation flutter n pathologic q waves n lv hypertrophy n qrs duration 120 ms n digoxin n spironolactone n diuretics n ace inhibitors arbs n calcium channel blockers n betablockers n oral anticoagulant n aspirin n antiplatelet agents n nitrates n amiodarone n
baseline_level_2, 2 2 3 3 5 5 150 cells pl 150 300 cells 300 cells pl
baseline_level_2, male sex mean sd median iqr 70 kg 70 90 kg 90 kg 30 30 missing data 30 ml min 30 50 ml min 50 80 ml min 80 ml min isolated deepvein thrombosis isolated pulmonary embolism deepvein thrombosis pulmonary embolism index event asymptomatic unconfirmed provoked unprovoked estrogens progestins known thrombophilia previous venous thromboembolism active cancer median duration studydrug administration 6 mo 9 12 mo 12 mo
baseline_level_2, overall male female 65 years 6575 years 75 years 90 kg 90 kg 30 kg m2 30 kg m2 deep vein thrombosis pulmonary embolism deep vein thrombosis limited intermediate extensive yes unprovoked provoked 9 months 9 months 50 ml min 5080 ml min 80 ml min
baseline_level_2, male female white black african american age years bodymass index kg blood leucocyte concentration 109 cells per l blood eosinophil concentration 109 cells per l blood eosinophil proportion exsmoker current smoker time since first copd diagnosis years fev1 l predicted normal value 30 30 50 fvc l fev1 fvc ratio reversibility inspiratory capacity l chronic bronchitis exacerbation rate previous year range cat total score ics laba ics lama laba lama lama spacer use study patients least one concomitant disease hypertension ischaemic heart disease myocardial ischaemia coronary artery disease angina pectoris ischaemic cardiomyopathy myocardial infarction cardiac failure diabetes mellitus arteriosclerosis coronary artery osteochondrosis cholecystitis chronic obesity
baseline_level_2, age years female patients n duration ra time symptom onset years concomitant corticosteroid use n concomitant mtx use n mean sd mtx dose mg week 1 2 3 0 mtx nonmtx mtx + nonmtx 2 nonmtx swollen joint count 66 tender joint count 68 hscrp mg l esr mm hour das28hscrp sdai cdai health assessment questionnairedisability index patients global assessment disease patients assessment pain 0100 vas functional assessment chronic illness physical component score pcs mental component score mcs health state index score uk algorithm vas 0100
baseline_level_2, age placebo tofacitinib 10 mg twice daily tofacitinib 15 mg twice daily remission maintenancetrial entry median range proctosigmoiditis leftsided colitis extensive colitis pancolitis total mayo score partial mayo score oral glucocorticoid use baseline previous treatment tnf antagonist tnf antagonist glucocorticoid immunosuppressant male sex f
baseline_level_2, age years sex female n race white n body mass index kg m2 south america europe north america rest world psa duration years tjc sjc dip involvement n haqdi patient global assessment disease activity vas 0100 mm physician global assessment disease activity vas 0100 mm patient global assessment pain vas 0100 mm crp mg l elevated crp ulnt n das28 crp psamodified total shs psoriasis covering 3 bsa n pasi score enthesitis n dactylitis n anticcp positive 10 u ml n prior tnfi n 1 2 3 concomitant methotrexate n concomitant csdmards methotrexate n concomitant oral corticosteroids n
baseline_level_2, postbronchodilator percent predicted fev1 sd moderate n severe n b mean number exacerbations previous 12 months sd mean bdi focal score sd mean sgrq total score sd previous treatment laba lama n c baseline ics use n mean age years male n white n current smoker n cigarette smoking mean packyears sd mean fev1 l sd
baseline_level_2, male n asian white black africanamerican hawaiian pacific islander bmi kg m2 weight kg hba1ca mmol mol 1 year 1 5 years 5 10 years 10 years systolic blood pressurea mm hg diastolic blood pressurea mmhg egfr mdrd ml min 173 m2 egfr ckdepi cystatin c ml min 173 m2 90 60 90 30 60 30 uacra mg g gmean gcv 30 300 300 oral antidiabetes monotherapya n metformin oral antidiabetes combination therapy without insulina n insulina n statins antihypertensive therapy n arbs calcium antagonists ace inhibitors diuretics blockers age years
baseline_level_2, age years male female white asian black african american missing data weight kg bmi kg m2 mmol mol 1 year 1 5 years 5 10 years 10 years systolic blood pressure mm hg diastolic blood pressure mm hg mg dl mmol l egfr ml min per 173 m2 90 ml min per 173 m2 60 90 ml per 173 m2 30 60 ml per 173 m2 30 ml min per 173 m2 medical history diabetic retinopathy
baseline_level_2, 0 1 2 2 lama monotherapy laba monotherapy laba + ics free fixeddose combination othersc
baseline_level_2, diastolic blood pressure anterior anterior iiiv low risk 03 moderate risk 46 high risk 714 hemoglobin g l red blood cell counting 1012 l platelet 109 l mean platelet volume fl scr gmol l glucose mmol l total cholesterol mmol l triglyceride mmol l hdlc mmol l ldlc mmol l crp mg l age men body mass index kg m2 weight kg hypertension diabetes mellitus hypercholesterolemia peripheral artery disease previous angina pectoris previous coronary intervention ischemic stroke hemorrhagic stroke family history coronary disease heart rate beats min systolic blood pressure
baseline_level_2, mean yr age group 65 65 70 70 male female coronary heart disease cerebrovascular disease peripheralartery disease diabetes heart failure europe north america china mean mm hg level 125 mm hg 125 140 mm hg 140 mmhg 75 mm hg 75 85 mm hg 85 mm hg mean 25 25 30 30 mean mg dl level 54 mg dl 54 66 mg dl 66 mg dl 85 mg dl 85 101 mg dl 101 mg dl 35 mg dl 35 43 mg dl 43 mg dl mean ml min 173 m2 level 60 ml min 173 m2 60 ml min 173 m2
baseline_level_2, egfr ml min 173 m2 normal egfr 90 mild impairment egfr 6089 moderate impairment egfr 3059 severe impairment egfr 30 microalbuminuria macroalbuminuria antihypertensive therapy beta blockers calcium channel blockers ace inhibitors arb others diuretics loop diuretics lipidlowering drugs statins insulinnaive treated oad insulin treated insulin insulin + oad male sex n age years diabetes duration years hba 1c 2 bmi kg systolic blood pressure mmhg diastolic blood pressure mmhg
baseline_level_2, female sex current smoker former smoker duration copd yr 12 mo screening one requiring hospitalization 12 mo screening 1 gold group fev1 liters percent predicted fev1 fvc liters fev1fvc ratio blood eosinophil count 150 mm3 screening geometric mean blood eosinophil count sd loge scale cells mm3 blood eosinophil count 300 mm3 12 months screening sgrq total score cat scoreff age yr
baseline_level_2, male sex hypertension diabetes mellitus current smoker hypercholesterolemia body mass index 30 f oral contraceptive pills total migraine stroke myocardial infarction deepvein thrombosis pulmonary embolism carotid infarct vertebrobasilar infarct 0 1 2 3 rope score pfo large shunt without atrial septal aneurysm pfo large shunt atrial septal aneurysm pfo mildtomoderate shunt atrial septal aneurysm age yr
baseline_level_2, 20 1619 15 0 1 1 cardiac vascular diabetes
baseline_level_2, male white asian black africanamerican missing hispanic latino hispanic latino missing europe north america plus australia new zealand asia latin america africa weight kg body mass index kg m2 coronary artery disease multivessel coronary artery disease history myocardial infarction coronary artery bypass graft history stroke peripheral artery diseasef single vessel coronary artery disease cardiac failure hba1c 1 years 1 5 years 5 10 years 10 years metformin sulfonylurea thiazolidinedione insulin monotherapy dual therapy angiotensinconverting enzyme inhibitors angiotensin receptor blockers betablockers diuretics calcium channel blockers mineralocorticoid receptor antagonists renin inhibitors statins fibrates ezetimibe niacin acetylsalicylic acid clopidogrel vitamin k antagonists systolic blood pressure mmhg diastolic blood pressure mmhg total cholesterol mg dl low density lipoprotein cholesterol mg dl high density lipoprotein cholesterol mg dl triglycerides mg dl estimated glomerular filtration rate mdrd ml min 173m2 30 mg g 30 300 mg g 300 mg g age years
baseline_level_2, female hispanic latino hispanic latino white black asian indian american alaska native native hawaiian pacific islander hispanic europe north america latin america asia pacific western europe eastern europe diabetes duration years 5 years 5 15 years 15 years prior cv event randomization coronary artery disease cerebrovascular disease peripheral arterial disease history congestive heart failure hba1c min max 8 8 egfr via mdrd ml min 173m2 90 6089 3059 30 body mass index kg m2 30 current former never none oral agents use monotherapy dual therapy 3 oral agents biguanides sulfonylurea thiazolidinedione insulin insulin alone insulin plus 1 oral agent insulin plus 1 oral agent pramlintide nonsulfonylurea secretagogues alphaglucosidase inhibitors glp1 receptor agonist study drug exenatide exenatide lar liraglutide glp1 receptor agonist dpp4 inhibitor therapy sitagliptin vildagliptin allogliptin saxagliptin linagliptin sglt2 inhibitors dapagliflozint sglt2 inhibitor antihyperglycemic agents listed antihypertensive antianginal cardiovascular medications ace inhibitor angiotensin receptor blockers diuretic thiazide beta blockers aldosterone antagonists eg spironolactone hydralazine calcium channel blockers alpha 1 blockers nitrates renin inhibitor eg aliskerin antihypertensive ranolazine digoxin digitalis glycoside antithrombotic anticoagulant medications aspirin low molecular weight heparin vitamin k antagonist eg warfarin coumarol factor xa inhibitor direct thrombin inhibitors antiplatelet agents clopidogrel ticlopidine lipidlowering medications statini ezetimibe fibrate niacini hormone replacement therapy chronic nonsteroidal antiinflammatory drugs chronic cox2 inhibitors fish oil proton pump inhibitors age randomization years 65 years 65 years 75 years
baseline_level_2, male n white asian black african american american indian alaska native multiple hispanic latino north america south america europe asia body weight kg bmi kg m2 duration t2dm years hba1c mmol mol hba1c fpg mmol l fpg mg dl sbp mm hg dbp mm hg biguanides dpp4 inhibitors sulphonylureas two agents three agents one blood pressure medications n ras agents beta blockers calcium channel blockers diuretics antihypertensives egfr ml min 173 m2 cpeptide age years
baseline_level_2, 80 64 mmol mol 80 90 64 75 mmol mol 90 100 75 86 mmol mol 100 86 mmol mol
baseline_level_2, caucasian black asian missing north america latin america western europe central europe asia ischaemic cardiomyopathy nonischaemic cardiomyopathy 1 year 15 years 5 years 30 30 ii iii iv systolic blood pressure mmhg heart rate bpm ntprobnp pg ml q1q3 egfr ml min 173 m2 hypertension atrial fibrillation hospitalization heart failure myocardial infarction stroke coronary artery bypass surgery percutaneous coronary intervention digitalis diuretic betaadrenergic blocker mineralocorticoid receptor antagonists oral anticoagulant antiplatelet drug lipidlowering agent icd crtp crtd
baseline_level_2, duration disease median previous antitnf therapy n concomitant aminosalicylates n concomitant corticosteroids n mayo score mean sd ibdq total score mean sd bowel function systemic symptoms emotional status social function sf36v2 pcs mean sd sf36v2 mcs mean sd physical function role physical bodily pain general health vitality social functioning role emotional mental health age mean years sd gender n male
baseline_level_2, yes male female
baseline_level_2, unprotected left main stented 2 lesions per vessel lesion length 30 mm bifurcation lesion side branch 25 mm stented vein bypass graft stented thrombuscontaining lesion prior brachytherapy stent type sirolimuseluting zotarolimuseluting paclitaxeleluting everolimuseluting 1 des type stent diameter 3 mm stent diameter 3 mm age yrs male hispanic latino nonwhite race body mass index kg m2 diabetes mellitus hypertension current cigarette smoker within past year stroke transient ischemic attack congestive heart failure left ventricular ejection fraction 30 renal insufficiency failure peripheral arterial disease previous percutaneous coronary intervention coronary artery bypass graft atrial fibrillation previous mi history cancer stemi nonstemi stable angina unstable angina number treated vessels per patient 1 2 3 number stents per patient prasugrel clopidogrel
baseline_level_2, age male sex black race hispanic ethnicity ischemic stroke vs tia lacunar large vessel cardioembolic defined uncertain unknown modified rankin scale screening 02 nihss randomization 04 prior stroke index event hypertension coronary artery disease carotid artery intervention atrial fibrillation current cigarette smoking body mass index kg m2 systolic blood pressure mm hg diastolic blood pressure mm hg homair hba1c ldl cholesterol mmol l triglycerides mmol l creactive protein statin antiplatelet anticoagulant
baseline_level_2, male female white black african american asian bmi mean sd 30 60 ml min 173 m2 60 o90 ml min 173 m2 90 ml min 173 m2
baseline_level_2, female male current smoker former smoker diabetes hypertension peripheral artery disease previous myocardial infarction 1 year 12 years 25 years 5 years ace inhibitor arb lipidlowerinq druq calcium channel blocker eblocker north american south american western european includinq australia israel south africa eastern european asia pacific
baseline_level_2, mean age years female male mean bodymass index kg m2 mean systolic blood pressure mm hg mean diastolic blood pressure mm hg current former never median total cholesterol mmol l hypertension diabetes history cad history stroke previous aortafemoral lower extremity bypass surgery pta iliac infrainguinal artery history intermittent claudication abi 090 substantial peripheral arterial stenosis 50 previous limb foot amputation symptomatic pad lower extremities carotid artery diseaset symptomatic padt cad abi 090 normal 090 070090 070 egfr 60 ml min antiplatelet lipid lowering acei arb 3 blocker nonstudy ppi use
baseline_level_2, age years male female current smoking bodymass index kg waist circumference cm hypertension diabetes stemi nonstemi unknown missing history pci history cabg history congestive heart failure lipidlowering therapy reninangiotensin inhibitors antiischaemia agents hscrp mg l interleukin6 ng l total cholesterol mmol l ldl cholesterol mmol l hdl cholesterol mmol l triglycerides mmol l egfr ml min per 173 randomised canakinumab 50 mg randomised canakinumab 150 mg randomised canakinumab 300 mg
baseline_level_2, prior lipidlowering agent use stemi nstemi unstable angina ldlc 100 mg dl ldlc 70 mg dl statin aspirin thienopyridine dual antiplatelet age age 75 hypertension current smoker diabetes mellitus history chf history coronary revascularization history stroke tia peripheral arterial disease cabg egfr 60 ml min 173 m2 bmi kg m2 prior statin use
baseline_level_2, median body mass index kg m2 iqr hyperlipidemia hypertension current smoking myocardial infarction percutaneous coronary intervention coronary artery bypass grafting congestive heart failure peripheral arterial disease aspirin pblocker statin angiotensinconverting enzyme inhibitor angiotensin receptor blocker stsegment elevation myocardial infarction diagnostic angiography lowdensity lipoprotein cholesterol mg dl prior statin use prior statin use highdensity lipoprotein cholesterol mg l triglycerides mg l creatine clearance ml min statin admission statin admission creactive protein mg l mean age sd female white median weight kg iqr
baseline_level_2, age years female n male n american indian asian black african american white multiple body mass index kg m2 former smoker n absolute litres predicted reversibility aqlq score median serum periostin ng mla median feno ppba median blood eosinophil count cells per pla biomarker high periostin 50ng ml blood eosinophils 300cells per pl na biomarker low periostin 50 ng ml blood eosinophils 300 cells per pl na saba puffs per day baseline
baseline_level_2, male female white age years bodymass index kg blood leukocyte count 109 cells per l blood eosinophil count 109 cells per l blood eosinophil exsmoker current smoker time since first copd diagnosis years fev_ l proportion predicted normal fev1 value 30 30 50 fvc l fev1fvc ratio reversibility chronic bronchitis emphysema mixed chronic bronchitis emphysema moderate severe exacerbations previous year range 1 2 copd medication taken least 2 months st ics laba ics lama laba lama lama patients least one concomitant disease hypertension ischaemic heart disease myocardial ischaemia coronary artery disease angina pectoris myocardial infarction ischaemic cardiomyopathy diabetes cardiac failure hypercholesterolaemia dyslipidaemia benign prostatic hyperplasia obesity gastroesophageal reflux disease hyperlipidaemia
baseline_level_2, female gender european black ii iii iv ef bmi kg m2 sbp mmhg dbp mmhg physical exam oedema creatinine mg dl_ ischaemic idiopathic hypertensive previous hf ml angina pectoris cabg pci stroke dm hypertension af pacemaker current smoker icd cancer ace inhibitor betablocker diuretic spironolactone digitalis calcium antagonist vasodilator oral anticoagulant anti arrhythmic aspirin antiplatelet lipidlowering candesartan age years
baseline_level_2, w eight k g height cm ngina 7 day previously infarct ion w ithin previous 7 day infarction 830 days infarction 30 days previously infarction date reported ptca cabg diabetes hypertension current smokers aspirin intravenous heparin nitrates 3blockers calcium antagonists ticlopidin
baseline_level_2, 55 vr 5564 yr 6569 vr 570 yr median vr interquartile range yr male female myocardial infarction unstable angina median interquartile range current smoker former smoker history systemic hypertension antihypertensive treatment diabetes mellitus obesityj claudication stroke transient ischemic attack ptca cabg ptca cabg aspirin betablocker calcium antagonist ace inhibitor nitrate diuretic insulin oral hypoglycemic drug
baseline_level_2, age male female white minority weight kg baseline abi affected limb baseline pfd baseline mwd plasma creatine mg dl hypertension prior myocardial infarction angina pectoris diabetes 3blocker diuretic oral hypoglycemic insulin cholesterol triglycerides hdlc hdl2 hdl3 ldlc apoa1 mg dl apob mg dl lpa mg dl n
other, n 17 n 20 n 11 n 12 n 6 n 8
other, placebo treatment
other, select lipids lipoproteins
other, hope n9297 hope patients coronaryartery disease n7477 europa n122l8 peace n8290
other, pooled simvastatin factorial studies atorvastatin factorial study
other, randomised treatment
other, glyburide
other, patients fistulas baseline
other, study end concentration
other, acute dvt study continued treatment study
other, stratum stratum ii
other, lumbar spine total hip femoral neck distal onethird radius total body
other, study 1 study 2
other, study 2
other, 93 105
other, study 1 study 2
other, serum k+ level drug treatment
other, study 1 study 2
other, study 1 study 2
other, baseline sitosterol
other, n
other, itt population mitt population
other, cohort 1 n 225 f cohort 2 n 521 combined n 746
other, p value
other, hr 95 ci
other, acr20 acr50 acr70 change baseline das28esr mean6 sd das28esr remission lda shs mean 6 sd erosion score mean 6 sd jsn score mean 6 sd
other, fh 1 fh ii
other, radial
other, mtss cfb
other, octave induction 1 octave induction 2 octave sustain
other, week 24 week 44
other, events total
other, metrex modified intentiontotreat population eosinophilic phenotypey metrex overall modified intentiontotreat population metreo modified intentiontotreat population
other, randomization groups 1 2 randomization groups 1 3
other, octave induction 1 octave induction 2 octave sustain
other, octave induction 1 2
other, octave sustain
arms;measures;p-interaction, placebo group warfarin group hazard ratio 95 ci p value interaction
arms;measures;p-interaction, control n9319 epa n9326 hazard ratio 95 cl interaction p
arms;measures;p-interaction, losartan n n placebo n n adjusted3 risk reduction losartan vs placebo 95 cl f
arms;measures;p-interaction, aspirin group placebo group rr 95 ci p inleraclion
arms;measures;p-interaction, placebo n rate 1 rosuvastatin n rate 1 hazard ratio2 95 ci2 subgroup pvalue3 interaction pvalue4
arms;measures;p-interaction, placebo n rate rosuvastatin n rate hr 95 cl p subgroup p interaction
arms;measures;p-interaction, macce abciximab placebo relative risk 95 confidence interval p value interaction
arms;measures;p-interaction, vorapaxar placebo 3yr hazard ratio 95 cl 087 080 094 pvalue interaction
arms;measures;p-interaction, events statin group events control group orc 95 cl p value oradj 95 cl p interaction
arms;measures;p-interaction, ipst ipst 95ci p int
arms;measures;p-interaction, continuation interruption relative risk 95 cl p interaction
arms;measures;p-interaction, continuation interruption relative risk 95 cl p interaction
arms;measures;p-interaction, saxagliptin 5 mg n 6 986 placebo n 6 930 hr 95 ci p saxagliptin 25 mg n 1 122 placebo n 1 118 saxagliptin 25 mg n 172 placebo n 164 p interaction
arms;measures;p-interaction, interaction pvalue patients ticagrelor 90 mg 3 year km ticagrelor 60 mg 3 year km placebo 3 year km hr 95 cl
arms;measures;p-interaction, total vorapaxar placebo 3yr km rate hr 95 ci pvalue interaction
arms;measures;p-interaction, n aiirocumab placebo estimated mean 95 cl interaction pvalue consistency effect
arms;measures;p-interaction, ranolazine vs placebo km failure rate hr 95ci pvalue pfor interaction
arms;measures;p-interaction, pvalue interaction 064 cyclo control odds ratio 95 cl
arms;measures;p-interaction, vora plac hr pvalue pint
arms;measures;p-interaction, cangrelor clopidogrel 95 cl p interaction
arms;measures;p-interaction, saxagliptin placebo hr 95 cl p interaction
arms;measures;p-interaction, saxagliptin placebo hr 95 cl p interaction
arms;measures;p-interaction, n continued thienopyridine placebo hr 95 ci p value interactiont
arms;measures;p-interaction, laa closure warfarin hazard ratio 95 confi dence interval p value p interaction
arms;measures;p-interaction, insulin glargine n x standard care n hazard ratio 95 cl p interaction
arms;measures;p-interaction, n n interaction p value
arms;measures;p-interaction, sitagliptin total placebo total hr 95 ci p value fo interactio
arms;measures;p-interaction, continued thienopyridine n placebo n hr 95 ci log rank pvalue adjusted hr 95 ci p value adjusted hr unadjusted pvalue interaction adjusted pvalue interaction
arms;measures;p-interaction, number patients ticagrelor 90 mg 3 yr km ticagrelor 60 mg 3 yr km placebo 3 yr km ticagrelor 90 mg vs placebo hr 95 ci p interaction ticagrelor 60 mg vs placebo hr 95 ci p interactio n
arms;measures;p-interaction, interaction pvalue pts ularitide n n placebo n n hr 95 cl
arms;measures;p-interaction, p value canagliflozin placebo hazard ratio 95ci
arms;measures;p-interaction, cangrelor clopidogrel 95 ci p value int
arms;measures;p-interaction, rivaroxaban+ aspirin aspirin alone hazard ratio cardiovascular death stroke myocardial infarction 95 ci p value interaction
arms;measures;p-interaction, hdlc nonhdlc anacetrapib n15225 placebo n15224 rate ratio pvalue interaction
arms;measures;p-interaction, enalapril + aliskiren dm 665 nondm 1675 aliskiren dm 627 nondm 1713 enalapril dm 652 nondm 1684 hazard ratio difference3 95 cl pvalue hazard ratio difference1 95 cl pvalue pvalue interaction
arms;measures;p-interaction, pioglitazone placebo hazard ratio 95 cl int p
arms;measures;p-interaction, placebo simvastatin ezetimibe simvastatin p value pin
arms;measures;p-interaction, placebo simvastatin ezetimibe simvastatin p value p interaction
arms;p-interaction, pbo eze 10 mg pvalue
arms;p-interaction, aspirin n 19 934 placebo n 19 942 total n 39 876 p value
arms;p-interaction, valsartan n 836 valsartan hctz n 832 p
arms;p-interaction, valsartan valsartan hctz p
arms;p-interaction, subgroup treatment interaction pvalue placebo
arms;p-interaction, p value interaction irbesartan placebo
arms;p-interaction, valsartan placebo p value interaction
arms;p-interaction, p value heterogeneity fluvastatin n250 placebo n247
arms;p-interaction, pvalue interaction
arms;p-interaction, placebo n3 pufa 95 cl interaction
arms;p-interaction, vorapaxar n 7 223 placebo n 7 268 p value
arms;p-interaction, liraglutide 30 mg ls means n placebo ls means n etd 95 ci
arms;p-interaction, lowdose rivaroxaban + aspirin n n aspirin alone n n hr 95 ci pinteraction
other;outcomes, 45 woscops care postcabg afcaps lipid gissi prevention 1 19945 1996 lips hps prosper allhatllt ascotlla alert cards total
measures;baseline_level_1, baseline history vascular disease
arms;other, events treatment 45002 control 45054 rr cl heterogeneity trend test
arms;other, amlodipine valsartan 5 160 mg n443 amlodipine valsartan 10 160 mg n45i total study population n894
arms;other, placebo n758 n3pufa n758 p value
arms;other, p valuey fibrinolysis n 944 primary pci n 948
arms;other, watchman n 361 control n 186 p value
arms;other, device group warfarin group hr 95 ci
arms;other, statin n 252 control n 252 pvalue
arms;other, complex anatomy n 3 730 noncomplex anatomy n 7 824 p value
arms;other, mvd n 12 558 mvd n 8 600 p value
arms;other;measures, events treatment 45054 control 45002 rr cl heterogeneity trend test
measures;subgroup_level, asian black hispanic white
measures;subgroup_level, mayo 10 n remission n difference placebo 95 ci mayo 10 n difference placebo 95 ci extensive colitis n extensive colitis n corticosteroid without imm n immy without corticosteroid n imm + corticosteroid n corticosteroid + imm n aminosalicylates n aminosalicylates n crp 10 mg l n crp 10 mg l n weight 700 kg n weight 700 kg 820 kg n 820 kg n
measures;subgroup_level, 65 years p value 65 vs 65 years 75 years 75 years p value 75 vs 75 years
subgroup_level;arms, simva 1234 eze simva 1236 female simva 645 female eze simva 645 male simva 589 male eze simva 591 caucasian simva 1055 caucasian eze simva 1082 noncaucasian simva 179 noncaucasian eze simva 154 65 years simva n 948 65 years eze simva n 917 65 years simva 286 65 years eze simva 319 160 mg dl simva n 320 160 mg dl eze simva n 337 160 mg dl simva 0 914 160 mg dl eze simva 0 899 chd simva 0 210 chd eze simva n 240 chd simva n 1023 chd eze simva 0 995
subgroup_level;arms, diabetes mellitus metabolic syndrome neither pbo + statin eze + statin
measures;p-interaction, number patients 4year rates placebo groups interactior 1 p
measures;p-interaction, hr 95ci p value interaction
measures;p-interaction, aggressive n 252 standard n 247 pvalue
measures;p-interaction, epa group events epa group events hr 95 cl p value
measures;p-interaction, value nteraction
measures;p-interaction, number events patients hr 95 ci interaction p value
measures;p-interaction, n3 fatty acids placebo lsm 95 cl interactior pvalue
measures;p-interaction, 1200mg vs placebo 2400mg vs placebo pvalue lnteraction
measures;p-interaction, omega3 fatty acid vs placebo leastsquares mean 95 cl number omega3 number placeb fatty acid p interaction
measures;p-interaction, number unadjusted hr p interaction
measures;p-interaction, endpoint rate pvalue int
measures;p-interaction, 2 yr km n hr 95 cl pvalue interaction
measures;p-interaction, hr 95 cl pvalue interaction
measures;p-interaction, hr 95 ci pvalue interaction
measures;p-interaction, change baseline ls means se interaction pvalue
measures;p-interaction, pvalue interaction hazard ratio 95 ci
measures;p-interaction, pvalue interaction patients event patients analyzed hazard ratio 95 ci
measures;p-interaction, incidence interaction p value
measures;p-interaction, change baseline
measures;p-interaction, events women men ratio hrs 95 ci p sex interaction
measures;p-interaction, events womenmen ratio hrs 95 cl p sex interaction
measures;p-interaction, total events 12wk kaplanmeier rate hazard ratio 95 cl p value interaction
measures;p-interaction, pvalue interaction event rates relative risk 95 ci pvalue variance
measures;p-interaction, number participants p value interaction p value
measures;p-interaction, n ls mean se ls mean difference se vs placebo 95 ci interaction pvalue
measures;p-interaction, n n interaction pvalue
measures;p-interaction, n n interaction pvalue
baseline_level_1;baseline_level_2, age years 65 years 65 75 years 75 years sex female osteoarthritis rheumatoid arthritis cigarette smoker lowdose aspirin use ppi use traditional nsaid use cox2 selective inhibitor use systemic corticosteroid use methotrexate use dmard use history upper
baseline_level_1;baseline_level_2, age median iqr age 75 female sex white race weight median iqr kg body mass index median iqr diabetes mellitus hypertension hyperlipidemia current smoker prior ml prior coronary revascularization prior heart failure estimated creatinine clearance 60 ml mint unstable angina nonstelevation ml stsegment depression 01 mv 02 34 57 time onset pain randomization median iqr h coronary angiography index hospitalization aspirin heparin glycoprotein llb llla receptor inhibitor thienopyridine pblocker ace inhibitor angiotensin ii receptor blocker statin
baseline_level_1;baseline_level_2, age yr 5 yr since menopause 5 yr since menopause years since menopause bodymass index kg m2 lumbar spine bmd tscore serum ctx ng ml serum p1np g liter serum trap5b u liter
baseline_level_1;baseline_level_2, male n age years mean sd race n asian white bmi kg m2 mean + sd sbp mm hg mean + sdc dbp mm hg mean sdc tc mg dl mean + sd ldlc mg dl mean + sd hdlc mg dl mean + sd 10year framingham chd risk 28 mean sd
baseline_level_1;baseline_level_2, age years sex male female race caucasian black asian duration copd years severity copd n gold 2008 moderate severe severea ics use yes exsmoker smoker smoking history packyears fev1 pred postalbuterol fev1 fvc postalbuterol fev1 prealbuterol l fev1 postalbuterol l fev1 reversibility b baseline dyspnea index score baseline sgrq score
baseline_level_1;baseline_level_2, age years male female taiwan indian japanese korean duration copd exsmoker current smoking history ics use fev1 la fev1 predicteda fev1 fvc reversibility copd severity n
baseline_level_1;baseline_level_2, age mean sd male n race n white black african american ethnicity n hispanic latino bmi kg m2 mean sd cv history risk factors n chd history n chd risk equivalents n type 2 diabetes n statin highdose statin use screening llt use ezetimibe use ldlc calculated median q1 q3 minimummaximum ldlc measured nonhdlc apo b lp fasting tgs hdlc
baseline_level_2;measures, mean weight sd kg colon ileum rectum perianal anus gastroduodenal jejunum abdominal perianal fistula baseline n mean cdai score sd mean baseline ibdq score sd crp concentration mg l mean sd median range crp concentration 10 mg l n previous loss response infliximab n previous intolerance infliximab n acute reaction delayed reaction acute delayed reaction previous loss response intolerance infliximab n absent indeterminate present steroids immunosuppressive agent 5aminosalicylates current smoker n men n mean age sd
baseline_level_2;measures, mean sd range male diabetes mellitus hypertension hyperlipidemia history chd history pci history carotid artery disease history peripheral artery disease current smoker
baseline_level_2;measures, 65 normoglycemic3 prediabeticb diabetic0 egfr ml min 173 m2 mean sd hba1c mean sd mean sd median age mean sd
baseline_level_1;measures, age yr mean sd range male sex patients bodymass index duration disease yr mean median current smoker patients cdai score crp mg liter geometric mean disease site patients terminal ileum colon ileocolon previous infliximab therapy patients previous acute hypersensitivity reaction infliximab patients previous bowel resection performed patients concurrent treatment crohns disease study entry patients ff glucocorticoids immunosuppressive agents glucocorticoids plus immunosuppressive agents neither glucocorticoids immunosuppressive agents
measures;other, id genotype p
measures;other, feno placebo lsm omalizumab lsm lsm difference 95 ci p value placebo lsm
measures;other, visits 3e5 visits 9e11 visits 17e19 univariate pvalue multivariate pvalue
measures;other, baseline month 1 month 6 month 12 month 18 month 24 month 25 month12 month18
subgroup_name;subgroup_level, age yrs 51 5160 60 bmi kg m2 30 3035 35 gender male female ldlc mg dl 100 100130 130 nonhdl mg dl 130 130160 160 sbp mmhg 120 120130 ale 7 78 8 crp mg dl 17 1745 45 egfr 78 7896 96 current smoker yes
subgroup_name;subgroup_level, hba1c countries china india korea countries
subgroup_name;subgroup_level, participants mmse 28 mmse 2427 mmse 23
subgroup_name;subgroup_level, age 70 years n960 sex male n1094 country argentina n342 cardiac valve surgery n707 hypertension n368 nyha class 24 nllll serum potassium 418mmol l n729 left atrial diameter 42 mm n480 ejection fraction 50 n288 habitual fish intake 2 servings wk n381 phospholipid omega3 levels 4 n200 study drug loading days actual 0 n34 periop betablockers n456 periop statins n550 periop amiodarone n1295 periop aceinhibitors arbs n655 onpump time l36hrsmin n721 crossdamp time lllhrsmin n724 overall n1516
subgroup_name;subgroup_level, age 65 years age 65 years sex male sex female moderate less airflow limitation severe worse airflow limitation smoking exsmoker smoking current smoker ics use baseline ics use baseline yes reversibility 5 reversibility 5 12 reversibility 12 bmi 300 kg m2 bmi 300 kg m2 overall
subgroup_name;subgroup_level, overall diabetes diabetes age 65 years age 65 years men women depression depression education 8 years education 812 years education 12 years hba median hbakmedian omega3 fatty acid placebo hbak median hbalcmedian
subgroup_name;subgroup_level, overall diabetes diabetes age 65 years age 65 years men women depression depression education 8 years education 812 years education 12 years hbalcmedian hbalcmedian insulin glargine standard care hbalc median
subgroup_name;subgroup_level, patients male female family history diabetes + family history diabetes fbs 100 mg dl fbs 100 mg dl age 65 years old age65 years old bmi 25kg m2 bmi25kg m2 beta blocker without beta blocker acei arb without acei arb
subgroup_name;subgroup_level, total study population women 65 years women 65 years
subgroup_name;subgroup_level, overall age median median sexa male female region latin american asia pacific western europe eastern europe north america racea white black asian ethnicitya hispanic latino hispanic latino diabetes durationa median prior congestive heart failure yes baseline heart failure severity nyha class nyha class ii nyha class reported none prior myocardial infarction yes prior coronary artery disease yes prior hypertensiona yes body mass indexa median 30 30 systolic blood pressure mm hg 140 140 160 160 glycated hemoglobin median renal function 60 egfr ml min 173 m2 60 egfr ml min 173 m2 30 60 egfr ml min 173 m2 60 90 egfr ml min 173 m2 90 egfr ml min 173 m2 insulin yes thiazolidinedione yes ace inhibitor yes angiotensin receptor blocker yes pblocker yes diuretic thiazide
p-interaction;arms, valsartan n n valsartan hctz n n p
outcomes;measures, total cholesterol mg dl ldlcholesterol mg dl hdlcholesterol mg dl triglyceride median mg dl 2575 percentile epa mol fpg mg dl hba c systolic mmhg diastolic fmmhff
outcomes;measures, hdlc baseline mean mg dl final mean mg dl mean change se value tg ldlc nonhdlc apob hscrp baseline median mg l final median mg l median change value1
outcomes;measures, bdi total score baseline tdi total score week 12 locf sgrq total score baseline sgrq total score week 12 locf change baseline
outcomes;measures, cv death first hhf cv death first hhf kccq 12 months death allcause months logtransformed change ntprobnp 12 months logtransformed change sbp 4 months change sbp 8 months change sbp 12 months
subgroup_name;p-interaction, mmse score p value trend
subgroup_name;p-interaction, prior stroke prior stroke p interaction
subgroup_name;p-interaction, baseline bmi 27 35 kg m2 n 1 279 change baseline 56 weeks baseline bmi 35 kg m2 n 2 383 change baseline 56 weeks interaction p value
subgroup_name;p-interaction, baseline bmi 27 35 kg m2 n 273 change baseline 56 weeks baseline bmi 35 kg m2 n 350 change baseline 56 weeks interaction p value
subgroup_name;p-interaction, ef40 ef 4049 ef50 pinteraction
subgroup_level;subgroup_name, age 68 years3 age 68 years3 lvef 33 lvef 33 ischemic aetiology nonischaemic aetiology nyha ii nyha llliv diabetes diabetes history paroxysmal af history paroxysmal af egfr 60 ml min 173 m2 egfr 60 ml min 173 m2 total cholesterol3 194 mg dl total cholesterol3 194 mg dl
subgroup_level;subgroup_name, age 65yrs age 65+yrs female male bl h unilateral bl h bilateral bl updrs low bl updrs high
subgroup_level;subgroup_name, oretal cvd subjects mrf subjects renal function normal mild renal function moderate renal function severe age 75 age 75 sex male sex female race race nonwhite region north america region latin america region asia paafic region europe region europe union
arms;outcomes;measures, arm outcome value
subgroup_level;measures, coenzyme q10 n 1 191 tertile 1 n 400 tertile 2 n 387 tertile 3 n 404 p value trend across tertiles
subgroup_level;measures, metabolic syndrome n 2636 nonmetabolic syndrome n 5196 p value
subgroup_level;measures, dm n3623 dm n13273 p value
subgroup_level;measures, overall median median 65 years 65 years 75 years 75 years male female white black asian latin america asia pacific western europe eastern europe north america 5 years 515 years 15 years yes yes egfr 60 ml min 173m2 egfr 60 ml min 173m2 140 mmhg 140160 mmhg 2160 mmhg 90 mmhg 90100 mmhg 100 mmhg body mass index subgroups median median 30 kg m2 a30 kg m2 current former never
subgroup_level;measures, female subgroup p value
subgroup_level;measures, women n3051 p value cangrelor versus clopidogrel women men n7891 p value cangrelor versus clopidogrel men p value men versus women
subgroup_level;measures, prior mi n 2 456 index mi n 3 576 mi n 5 340 mi n 6 308 pvaluefor mi versus mi
subgroup_level;measures, diabetes n 14 355 diabetes n 6 806 p value
subgroup_level;measures, north america western europe central eastern europe russia latin america asiapacific pvalue
subgroup_level;measures, 3 months 1 kill 36 months fn 1009 612 months n 886 12 months n 1 746 prior hf hospitalization n 3 125 p value
subgroup_level;measures, stable angina n 6 358 acs n 4 584 p value
outcomes;subgroup_level, primary end point tertile 1 tertile 2 tertile 3 randomized allcause mortality randomized coronary end point randomized allcause mortality hospitalization worsening hf randomized
arms;p-interaction;measures, placebo n n czp 400 mg n n odds ratio 95 cl p value
arms;p-interaction;measures, monitoring treatment conventional treatment hazard ratio 95ci p interaction
arms;p-interaction;measures, lowdose rivaroxaban + aspirin group aspirin alone group events total n hr 95 ci pinteraction
p-interaction;other, group n 103 group b n 100 group c n 103 p
arms;p-interaction;other, nito ring treatment conventional treatment r elative risk 95ci p interaction
arms;p-interaction;other, placebo simvastatin ezetimibe simvastatin p value pin
arms;other;p-interaction, nito ring treatment conventional treatment r elative risk 95ci p interaction
